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Abstract 
Metastasis is the leading cause of fatality in 90% of cancers, and approximately 60% of all 
cancer cases will have either regional or distant metastasis at initial diagnosis. Global data 
shows that survival rates drop significantly with the advance of disease stage and metastatic 
activity; therefore, patients with localised disease have a far better prognosis than those with 
disseminated tumours. In this aspect, Leukaemia and oral squamous-cell carcinoma (OSCC) 
are invasive neoplasms. Both cancers are considered the worst prognosis cancers with an 
overall survival rate of 50% or slightly higher.  
 
The accumulating research suggests that inflammation is more likely to act in favour of 
tumour initiation and metastasis. The striking similarity which exists between the out flux of 
tumour mass in the circulation and that of inflammatory exudates in wound healing points to 
the possibility that the same mediators might be utilised for both purposes. Substance P (SP) 
is a primary regulator of neurogenic inflammation mainly acting as a trigger for 
vasodilatation, plasma protein extravasation and leukocyte adhesion to vascular endothelial 
cells. SP has been proposed as a model that can explain the inflammation-tumour 
relationship. Therefore, the link between the role of SP and the extravasation of tumour cells 
into the circulation represents an attractive opportunity for unravelling the metastatic 
mechanisms. 
 
We carried a systematic review which identified nine inflammatory mediators associated with 
metastasis. The 16 articles reported lymph node metastasis and one article reported both 
lymph node and distant metastasis. The inflammatory mediators identified were CXCR4 (six 
studies), CXCL12 (SDF-1), CCR7, IL-6 (two studies each), IL-18, CCL20 (MIP-3), CXCL1 
(GRO-1), CCL3, CXCR2 (one study each). This review systematically summarises the 
evidence of the prognostic role of inflammatory mediators in predicting metastasis/metastatic 
stages in OSCC. Additionally, it compares the available evidence from clinical and 
experimental animal settings.  
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Our experimental results showed that SP increased the adhesion of Jurkat Leukaemia cell 
lines in a time-course treatment with a peak adhesion increase at three-four hours. SP 
increased the adhesion of H157, CAL27, and DOK cells to HUVEC endothelial cells (P < 
0.001), significantly, in a time-dependent treatment with peak adhesion at three hours. It has 
been demonstrated that SP is expressed by several tumours and several roles have been 
proposed for its action in tumour growth and progression. Our study describes a new role for 
SP in stimulating an early onset adhesion of tumour-endothelial adhesion.  
We found that treating endothelial cells with either stimulating factor or inhibitor produces 
more potent levels of adhesion which may 1) explain the organ-specific metastasis of 
cancers; and 2) highlight the active interaction of tumour-endothelial cells during adhesion. 
Moreover, our data suggests that inhibition of adhesion levels – achieved using 
cycloheximide, which blocks translation of messenger RNA on the cytosolic 80S ribosomes 
but does not inhibit the organelle protein synthesis – did not achieve higher levels such as the 
one inflicted with monoclonal antibodies. This might suggest that tumour cells highly express 
adhesion molecules as well as inflammatory receptors. 
Our data also suggests that in Jurkat cells, CAL27 and BICR22, SP 1mcg/ml treatment has 
increased both CD 11 (not significant) and CD 49 (P < 0.05), but not CD15s expression in 1-
48 hour time-scale treatment, as indicated by the FACS analysis. Anti-human monoclonal 
antibodies to VCAM or ICAM significantly inhibited adhesion levels to below the untreated 
baseline levels. The NK-1R antagonist was only effective in inhibiting adhesion molecule 
expression in Jurkat and CAL27. No other effect was noted in the other OSCC cell lines.  
We hypothesised that adhesion molecules were the main requirement of the adhesion process, 
and adhesion molecule expression followed the pattern predicted which increased from no 
expression in the normal oral keratinocytes to the lymph node positive cell line H157 and 
declined in the metastatic cells BICR22, for the three adhesion molecules. The pre-cancer cell 
line DOK had an elevated expression profile which agrees with previous studies, suggesting 
an early invasive/metastatic phenotype in the tumour cycle.  
Our results did not prove any significant effect for SP on the release of MMP-2 in either 
Jurkat cells or OSCC cell lines. This was against the predicted pattern in which we 
hypothesised that SP would trigger up-regulation of MMP enzymes to facilitate the 
transmigration of tumour cells through the endothelium.  
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The resulting model represents a novel approach in cancer treatment where the main target is 
prevention of metastasis. This paradigm shift has a powerful potential to develop effective 
anti-metastatic therapies through interfering with the metastatic cycle. The data resulting 
from the systematic review as well as the experimental findings can be integrated for future 
implementation in two main categories.  
In conclusion, the study identifies a new role for Substance P in mediating an early onset 
adhesion of cancer cells to endothelial cells. The study also highlights the role of the NK-1R 
antagonist as a novel therapy in inhibiting this adhesion in those cell lines. A combined 
therapy of the NK-1R antagonist and monoclonal anti-adhesion molecule would be powerful 
in preventing the onset of metastasis. These primary data warrant further research through 
animal models to confirm this role for Substance P.  
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Cancer remains a major health problem with “17.5 million cancer cases worldwide and 8.7 
million fatalities” reported in 2016 according to GLOBCAN (1). Metastasis is the leading 
cause of fatality in 90 % of cancers, and approximately 60% of all cancer cases will have 
either regional or distant metastasis at initial diagnosis (2). Global data shows that survival 
rates drop significantly with the advance of disease stage and metastatic activity; therefore, 
patients with localised disease have a far better prognosis than those with disseminated 
tumours (2). The advancement of treatment modalities has increased the survival rates. 
Ironically, this has increased the possibility of recurrence (3). It is also estimated that a third 
of cancer survivors (even early-stage patients) will experience recurrence due to treatment 
failure to fully eliminate the disease (4-8).  
 
In this perspective, oral squamous cell carcinoma (OSCC) (90% of all the oral cavity 
tumours) is a locally invasive neoplasm (4, 8). The rate of metastatic spread for OSCC is 
reported to be 65% for regional metastasis, 5-25% for distant metastasis and up to 50% of 
recurrence (9-11). OSCC remains one of the worst prognosis cancers with an overall survival 
rate of OSCC of 50% or slightly higher (12, 21). Patients with positive lymph-node 
involvement have a 50% reduction in the overall survival rate compared with that of their 
negative lymph node peers (13). Metastasis has a great impact on the prognosis of the cancer 
patients not only in terms of survival but also in recurrence which, in turn, reduces chances of 
survival. Even with new combination treatment modalities, those patients are at high risk of 
recurrence (14). Metastasis are not limited to late stages but can occur in patients with 
clinically negative lymph nodes as micro-metastatic foci that are difficult to detect with 
conventional methods and need highly specialised tools such as molecular assessment (15).  
 
The reciprocal relationship between diagnosis, treatment and metastasis is a daunting task for 
clinicians to manage in the clinical settings. As far as the diagnostic methods fail to precisely 
predict metastatic lesions in the early stages, high-risk patients will be liable for more 
aggressive treatment (15). While early detection and prevention programs in most cancers 
prolonged survival time, they are also likely to increase recurrence by prolonging survival 
time (3). Recurrence is the end result of even the most aggressive therapeutic combination, 
and no improvement in loco-regional control has been attained in the recent past (4). 
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Recurrence requires re-treatment and relapsed patients will have the worst prognosis. 
Therefore, there is a need for extensive research to underpin the mechanisms of metastasis to 
explain these relapses and improve this outcome (142).  
 
Metastasis is a precise biological process that consists of several successive stages and 
requires the collaboration of several signalling pathways and molecular components (150). 
Metastasis commences through the invasion of the tumour to the surrounding extracellular 
matrix (ECM) and basement membrane (BM). Then, the detached tumour mass enters the 
circulation, evades the immune response and adheres to the vascular endothelial cells most 
likely through adhesion molecules. Distant metastasis occurs when this mass extravasates 
(steps out of the circulation) and implants in a remote site (153, 158). Although the 
mechanisms behind local invasion have been extensively studied, the stages of distant 
metastasis, particularly extravasation and their mechanisms are poorly understood (154-157).  
 
Cancer does not use novel mechanisms but rather implements existing biological processes in 
favour of its growth and progression (157, 215). With this concept in mind, observations 
from the attraction of the circulating leukocytes to the injured site in inflammation can 
unravel the extravasation process (157, 208). Accumulating research suggests that 
inflammation is more likely to act in favour of tumour initiation and metastasis (215). The 
extravasation of leukocytes in inflammation is well researched and the different stages they 
undertake have been identified (232). The process of extravasation in cancer and 
inflammation requires similar specific components, namely: the adhesion of migrating cells 
to the endothelium through their adhesion molecules; activation of these adhesion molecules; 
and the proteolytic action of matrix metalloproteinase (MMP) (156).  
 
The adherence of leukocytes to endothelial cells is a prerequisite for the inflammatory 
reaction to occur. This adherence occurs mainly through a group of adhesion molecules and 
their receptors on both types of cells (155). There are two categories of these adhesion 
molecules: the endothelial cell adhesion molecules (CAM) and their binding ligands 
expressed on leukocytes (224). The pairing between the two categories causes a different 
degree of adhesion which results in firm adhesion and finally trans-endothelial migration 
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(230-233). The endothelial adhesion binding legends are not expressed in normal cells. They 
are reported as highly expressed in several malignant cell types, specifically highly metastatic 
tumours (208). 
 
MMPs are a group of proteolytic enzymes whose main function is to degrade ECM protein 
(292). Up-regulated expression of MMP members is often associated with the presence of 
inflammation (293). Studies suggest that MMPs are necessary for all stages of the 
inflammation from tissue repair and foreign body elimination to activating cytokines (294). 
In addition, MMP has been implicated in cancer progression and invasion and is highly 
expressed in a variety of cancers including OSCC (297-302).  
 
The striking similarity which exists between the outflux of tumour mass in the circulation and 
that of inflammatory exudates in wound healing points to the possibility that the same 
inflammatory mediators might be utilised in both processes (155). In this respect, Substance 
P (SP) is a primary regulator of neurogenic inflammation mainly as a trigger of 
vasodilatation, plasma protein extravasation and leukocyte adhesion to vascular endothelial 
cells (324-334). SP has been proposed as a model that can explain the inflammation-tumour 
relationship (352), therefore, the link between the role of SP and the extravasation of tumour 
cells into the circulation represents an attractive opportunity to unravel metastatic 
mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
Key Points  
 Metastasis is a major health concern. 
 The complexity of metastatic process. 
 The need to reveal the mechanism of extravasation of tumour 
cells in the circulation. 
 Substance P can provide the link between inflammation and 
cancer. 
 Can cancer cells use the same mechanism to adhere to the 
endothelium to extravasate as in the inflammatory process? 
THE EFFECT OF SUBSTANCE P (SP) ON ADHESION OF JURKAT 
LEUKAEMIA CELLS AND SQUAMOUS CARCINOMA CELLS 
(SCC) TO VASCULAR ENDOTHELIAL CELLS AND ROLE IN 
METASTASIS 
Moustafa Elhousiny Page 5 
 
 
 
 
 
 
 
Chapter 2 Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE EFFECT OF SUBSTANCE P (SP) ON ADHESION OF JURKAT 
LEUKAEMIA CELLS AND SQUAMOUS CARCINOMA CELLS 
(SCC) TO VASCULAR ENDOTHELIAL CELLS AND ROLE IN 
METASTASIS 
Moustafa Elhousiny Page 6 
 
 
2.1 Introduction 
Oral squamous cell carcinoma (OSCC), the most common malignant neoplasms of the oral 
mucosal membrane, together with pharyngeal and laryngeal cancers, are collectively termed 
“head and neck cancers” (16). Oral cancer (ICD10 C00-C06) is considered the 6th most 
common cancer for both sexes, and the 10th most common cancer in males combined with 
oropharyngeal cancer (17-18). Oral cancer is the leading cancer type and accounts for more 
than a third of all cancers in South-East Asian regions such as India and Sri-Lanka (Figure 
2.1-2.2) (19). OSCC, which represents 90% of all oral cavity tumours, is a highly invasive 
lesion with its average survival rate at 50% (18). These figures have remained the same since 
2014 at the commencement of the thesis research.  
 
Figure 2.1: Worldwide estimated cases X 1000 of incidence of oral cancer in, 
Globocan.iarc.fr. Redirect [Internet]. 2018 [25 July 2018]. Available from: 
http://globocan.iarc.fr. 
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Figure 2.2: Worldwide estimated cases X 1000 of mortality of oral cancer in five Continents, 
Globocan.iarc.fr. Redirect [Internet]. 2018 [25 July 2018]. Available from: 
http://globocan.iarc.fr. 
  
2.2 The effect of metastasis of oral cancer 
2.2.1 Metastasis and Prognosis 
More than 60% of oral cancer cases are diagnosed at advanced stages which decreases the 
survival probability significantly (Table 2.1, Figure 2.3-2.4) (20-21). The asymptomatic 
nature of oral cavity tumours and the delay in diagnosis/referral are the main factors 
contributing to the discovery of late-stage tumours that have already metastasised at the time 
of diagnosis (22-24).  
 
 
 
Figure 2.3: Percentage of survival by stage 
of disease SEER. 
THE EFFECT OF SUBSTANCE P (SP) ON ADHESION OF JURKAT 
LEUKAEMIA CELLS AND SQUAMOUS CARCINOMA CELLS 
(SCC) TO VASCULAR ENDOTHELIAL CELLS AND ROLE IN 
METASTASIS 
Moustafa Elhousiny Page 8 
 
 
 
Stage Description 5-year survival 
rate (%) 
I The tumour is relatively small and 
contained within the organ it 
started in. 
80 
II The tumour is larger than in stage 
1 but the cancer has not started to 
spread into the surrounding 
tissues.  
66 
III The cancer have started to spread 
into surrounding tissues and there 
are cancer cells in the lymph nodes 
in the area. 
46 
IV The cancer has spread from where 
it started to another body organ. 
This is also called secondary or 
metastatic cancer. 
38 
Table 2.1: Survival according to the stage of cancer, adapted from the Surveillance, 
Epidemiology, and End Results Program (SEER) National Cancer Institute. 
 
 
 
 
 
Figure 2.4:  Percentage of Cases by Stage at 
Diagnosis; Oral cavity and Pharynx Cancer 
SEER. 
 
 Localised (31%) 
Confined to Primary Site 
 Regional (47%) 
Spread to Regional Lymph Nodes 
 Distant (17%) 
Cancer Has Metastasised 
Unknown (6%) 
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Article 
Country Year Sample 
Size 
5-year survival rate (%) (%) of 
patients 
with 
Stage 
III, IV 
Stage  
     I 
Stage  
  II 
Stage 
   III 
Stage 
  IV 
Chen GS24 China  1996 103 62 80 42 19 62.1 
Y.K Chen25 Taiwan 1999 703 72.7 38.9 26.8 11.8 49.2 
J.A.Woolgar26 UK 1999 200 85 90 82 42 68 
Lo WL27 Taiwan 2003 378 75 65 49 30 47.1 
A. Chandu28 Australia 2004 116 88.7 83.8 83.3 76.5 40 
Goto29 Japan 2004 180 92.7 91.1 65.9 44.7 50 
Garzino-
Demo30 
Italy  2006 245 79 78 48 42 44 
Lisetta Lam31 Australia  2007 212 >50 >50 <40 <40 47 
Katayoun 
Sargeran32 
Iran 2008 470 51 44 13 12 50 
Paolo33 Italy  2008 334 90.7 80 58.9 51.5 31.4 
Table 2.2: Studies comparing survival of oral cancer patients according to stage status at the 
diagnosis. 
 
The accumulating body of evidence is that the involvement of metastasis, whether regional or 
distant, is the most important prognostic factor in OSCC (27, 30, 33, 34-39) (Table 2.2). The 
presence of nodal metastases in oral malignancies significantly decreases both overall and 
disease-specific survival to less than half and increases the risk of recurrence and distant 
metastasis (40, 41). The metastatic potential of oral cancers varies according to the site of the 
primary lesion. In the buccal mucosa, the incidence of cervical metastasis is reportedly 16-
43% (42, 43). On the tongue and the floor of the mouth, this percentage is higher, reaching 
60% of the affected cases (44, 45). The cervical spread occurs in 19-37% of the cases where 
the hard palate, maxilla, or alveolus is the affected sites (46, 47). 
 
The higher the clinical stage of lymph node (N1 “tumour spread to close or fewer lymph 
nodes”; N3 “tumour spread to distant or numerous lymph nodes”), the lower is the survival 
outcome of the patients (Table 2.3) (14, 36, 48-50). In one study of 524 patients with oral 
carcinoma of different sites, the 5-year survival period significantly dropped from a crude 
average of 44% for patients with N0, to 18% and 11% for N2 and N3 stages, respectively 
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(35). The study also demonstrated that despite the treatment modalities in place, the 
difference in survival between N-negative and N-positive group was significantly different, 
65% and 38% respectively. Cervical metastasis affects survival and has a tremendous impact 
on recurrence and therefore the relapse-free survival. Tankéré et al. demonstrated in a study 
of 137 patients with OSCC that recurrence rate increased from 9% in N0 patients to 20% in 
the N-positive patient group and, more importantly, to 29% in N-positive patients with 
extracapsular spread (51). The study also identified that the increase in node stage (N0-N3) 
increased the rate of recurrence (31.2% in the N2 group and 57.1% in the N3 group) as well 
as decreasing the survival rate (44.7% in patients with N0, 37.7% in patients with N1, and 
15.6% in patients with N2; none of the N3 patients survived past the two years).  
 
Study  Country   Year  Study 
Size 
Survival Probability (%) Percentage 
of Lymph 
node 
incidence  
   N0          N1           N2         N3 
Kalnins34 US 1977 340 75 29* 75  
Jones35 UK 1993 524 44 29 18 11 24  
Noguchi36 Japan 1999 136 91  41*  58  
Lo WL27 Taiwan 2003 378 65.8 38 40 20 32  
Garzino-
Demo30 
Italy  2006 245 74 39 34 N/A 29  
Paolo33 Italy  2008 334 87.5 70.4 32 N/A 31.7  
Wang 
Ling37 
China  2013 210 53 41 29  0 42  
Geum38 Korea 2013 37 92 30* 27  
Li39 China  2013 155 47.36 27.48 15.55        0 
  
40   
Table 2.3: Comparison of survival outcomes between node-free and node-positive patients 
and the incidence percentage of lymph node metastases. 
* Denotes average rate for all the node-positive stages. No details about specific stage.  
 
The burden of metastasis in OSCC is magnified by the problem of extracapsular spread 
(ECS), the spread of tumour metastatic deposits outside the lymph node (52). Woolgar et al. 
assessed 200 patients with oral cancer, in which 99 (50%) had metastases subdivided into 
three groups of N0, intra-nodal metastasis and extracapsular metastatic spread. The 5-year 
survival rate was 81%, 64%, and 21%, respectively (26). In a second study, they assessed 173 
patients with confirmed neck metastases, grouped into intra-nodal metastatic group (no ECS), 
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micro ECS, and macro ECS (53). The 1, 2, 3 and 5-year survival rates were 87%, 75%, 72% 
and 70% for Group 1 compared with a mean of 36% for Group 2, falling to 33% for the third 
group. The authors suggested the urgent need for a novel, thorough and reliable method for 
neck staging to detect these micro-metastatic deposits, as currently used routine clinical and 
radiological diagnostic tools usually tend to overlook such lesions. 
 
ECS burden affects survival rate and has a great impact on both recurrence and rate of distant 
metastasis (54, 55). In a study of 400 patients with oral cancers grouped into N0 (n= 221), 
N+ECS- (n= 78) and N+ECS+ (n= 101) (56), the 5-year survival was 65%, 52%, and 23% 
for the three groups, respectively. The 5-year-free period from distant metastases, local 
recurrence, and neck recurrence was two times worse for the ECS+ group than for the other 
two groups. Similar results were obtained by Mayers et al., (57) where they estimated the rate 
of distant metastasis incidence rates to be three times higher for the ECS+ group than for the 
other two groups. 
 
The incidence of cervical metastasis is not confined to late-stage tumours. Metastasis can be 
divided into clinical and subclinical (occult) with the latter reaching up to 30% of early stages 
of oral cancer (stage I, II) (10). These occult metastases can be further divided into micro-
metastatic deposits (0.2-2mm) and isolated tumour cells that can be only detected using 
staining techniques or molecular tools (58). The incidence of occult metastatic deposits can 
be in the range of 11-44% in T1-T2 clinically negative lymph node patients and has a 
deterministic effect on the prognostic outcome of the disease (59-63). Ganly et al. 
demonstrated that patients with occult metastasis in early-stage OSCC have a mortality risk 
five times higher than those who do not (64).  
 
Research suggests that micro metastases significantly decrease the survival rates and 
recurrence rates even when the most aggressive treatment modalities are in place (29, 65-66). 
Jang et al. found that 57% of early-stage oral cancer patients who presented with occult 
metastasis had decreased survival rates (24% compared with 66% for those with no micro-
metastasis) despite receiving radiation treatment and neck dissection (67). Thiele et al. 
retrospectively studied 122 patients with early-stage oral cancer, all of whom underwent neck 
dissection and found 17 (13.9%) patients with occult metastasis (68). Even with neck 
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dissection, the disease-specific survival for those patients was down to 17.8% from 61.9% for 
the occult-free patients. These minimal foci escape treatment and flourish with time into overt 
metastases, which might explain the high recurrence rates of oral cancer especially in early 
stages (69). Despite the importance and effect of these micro-metastases on the prognosis, 
current diagnostic techniques cannot assess the neck nodal stage in patients with early stages 
of oral cancer with a high degree of reliability (70-71), and therefore, most surgeons resort to 
neck dissection procedures which might have a satisfactory advantage (72). 
 
The final form of metastasis in OSCC is distant metastasis (DM) which has been reported in a 
range of 3-30% prevalence among different studies (73-74) and is steadily increasing in 
prevalence, despite the advancement of treatment modalities (21). The rate of distant 
metastasis at initial diagnosis of the oral tumours is estimated to be less than 3% (75-77). 
Moreover, when distant metastasis develops in patients, it usually occurs within two years of 
the discovery of the primary tumour (78-79). The rates of distant metastasis along the course 
of the disease range from 9-30 % (79-80), which might explain the huge fluctuation in the 
rate of metastasis reported by different studies. Another explanation might be that distant 
metastasis develops as a consequence of a regional metastasis in patients who fail to achieve 
loco-regional disease control after treatment (81-83). Shintani et al. found that a 
pathologically positive lymph node group had a threefold incidence of distant metastasis 
compared with their negative peers (50). Lim et al. concluded that patients with positive 
lymph nodes are seven times more likely to develop distant metastasis (84). Shingaki et al. 
divided the patient sample (n= 103) into two groups based on lymph node involvement (69). 
The rate of distant metastasis in the lymph node positive-group was 40% compared with 4% 
in the negative group. 
Regardless of the actual percentage, the incidence of distant metastasis represents the end-
point for the cancer patients with very minimal survival chances. Li et al. (85) reported 1, 3 
and 5-year survival rates of 56.8%, 9.1% and 6.8%, respectively for patients with DMs. Only 
three out of 36 patients with distant metastasis survived to the second year. The most 
common sites for metastasis from OSCC tumours are: lung (>60%) followed by bone, liver, 
and skin (79, 86). 
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2.2.2 Metastasis and treatment 
As discussed earlier, there is a high risk of metastasis in oral cancer, particularly nodal 
metastasis, both in advanced and early stages, due to the inability of conventional diagnostic 
methods in detecting early metastatic signs. This metastatic potential of OSCC is critical in 
the decision-making when choosing treatment, necessitating aggressive therapeutic 
modalities to ensure residual disease-free outcomes (87). The surgical resection of the 
primary tumour remains the mainstream treatment of oral neoplasms (88). Advanced 
malignant lesions (stage III/IV) are often treated with a combination of surgery with chemo 
or radiotherapy or palliative care in the inoperable cases (87). Success in managing oral 
neoplasms depends on treating the neck and ensuring no remaining cervical spread is left by 
performing one of the neck dissection alternatives (89).  
2.2.2.1 Neck dissection for early tumours 
The basis of the decision on whether to conduct a block dissection or “observe and wait” for 
the clinically negative neck is not very clear, although there is some evidence supporting the 
treatment option (90-91). The risk of micro-metastasis is around 30% in early-stage cases, 
which significantly increases the risk of recurrence and reduces the chances of survival (59-
63). It is argued that the “wait-and-see decision” is suitable when the risk is minimal and will 
unnecessarily cause morbidity to significant organs of patients, in comparison to neck 
dissection, which might not provide marked outcomes or advantages on survival (92-94). 
Meanwhile, multiple studies suggest that the benefits of treatment far outweigh the morbidity 
disadvantage and can be utilised to stage the neck pathologically (95-97). The decision to 
treat the neck or the observation policy is mostly made based on the risk of occult metastasis 
(~20%), depending on multi-factors such as the depth, site, and size of the tumour, and 
experience of the physician and institute (98). If current diagnostic methods remain 
unchanged, with no advance in the molecular detection tools, neck dissection with or without 
irradiation will still be the method of choice to treat the clinically negative neck in order to 
ensure the elimination of micro-metastasis and improve outcome. 
 
Radical neck dissection (RND) remained the gold standard in treating regional spread in 
patients with head and neck cancer since its introduction by Crile et al. in the 19th century 
(99). The procedure involved removing major structures of the neck, including accessory 
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spinal nerve, internal jugular vein, and sternocleidomastoid muscle (Figure 2.5). Because of 
the significant morbidity of the procedure and the persistence of recurrence of tumours, 
oncology surgeons have sought alternative ways to dissect the neck that can preserve organs 
and function (100-103).  
 
 
Figure 2.5: Extent of anatomical structures removed by radical neck dissection. 
 
Neck dissection is suggested for elective treatment and staging of the clinically negative 
lymph node patients with stages I and II. However, the indications and advantages of this 
procedure in the head and neck area are under debate (104). Several retrospective studies and 
few RCTs have been conducted to identify the benefits of this invasive procedure (95, 111-
112) (Table 2.4). A recent meta-analysis reported in favour of neck dissection, although 
several issues have been raised regarding the study design, statistical analysis and selection 
criteria, highlighting the need for proper randomised trials (105).  
Careful insights into the studies performed revealed insignificant differences in survival or 
recurrence rates in the overall outcomes (106). Another important factor in the evaluation of 
neck dissection is that some studies reported similar rates of distant metastasis and recurrence 
with very poor salvage results compared with that of the non-treated groups (94, 107-110). 
Neck treatment is currently the only choice available for high-risk patients with some 
prognostic advantages. If the occurrence of micro-metastasis is the main prognostic indicator, 
then its prevention should be the aim of research efforts as it would be of a great benefit to 
cancer patients.  
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Table 2.4: Comparison of studies performed on the outcome of neck treatment through neck 
dissection or observation according to survival.  
Author  Study 
Sample 
Study 
Type 
Recurrence  
Treated 
Vs OBS % 
DSS 
survival 
Overall survival  
Smith92, 2004 171 
 
Retro 20 
7 
96 
92 
same 
Kelner97, 2014 172 Retro  7* 
15 
96* 
85 
87^ 
84 
Feng96 229 
 
Retro 9.6* 
19.2 
79.2* 
61.9 
20* 
41 
Keski-Sa¨ntti 93, 
2006 
80 
 
Retro 44* 
20 
63^ 
66 
82^ 
77 
Liu94, 2011 131 
 
Retro 14.8 
23.2 
NS NS 
Poeschl106, 2012 86 
 
Retro 16.6 
18.4 
NS NA 
D’Cruz110, 2009 359 
 
Retro 5.7* 
47 
74^ 
68 
60^ 
60 
Yuen112, 2009 71 
 
RCT  6 
 37 
89^ 
87 
N/A 
Fakih111, 1989 70 
 
RCT 30 
58 
63 
52 
N/A 
Klingerman95, 
1994 
67 
 
RCT 12 
39 
N/A 72* 
49 
 
Abbreviations 
* Significant results  
NS. Author claimed non-significant 
^ Non-significant    
N/A Data not available 
DSS = disease-specific survival 
Retro = retrospective.  
RCT = randomised control trial  
OBS = observation  
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2.2.2.2 Treatment of advanced oral cancers 
Patients with advanced stages of head and neck tumours were treated with surgery and 
radiotherapy or radiotherapy alone for inoperable tumours, which resulted in poor survival 
and severe morbidity. Therefore, multimodality therapy (surgery, chemo-radiotherapy) was 
introduced to improve the outcome and eliminate the microscopic spread of the disease (113-
114). Loco-regional control, distant metastasis, overall survival and disease-specific survival 
are the end-point measures for studies evaluating the success of these treatments. Clinically, 
these end-points are not practical as patients with these advanced lesions are co-morbid. 
Therefore, tumour response (i.e. tumour shrinkage) has been set as an evaluation measure 
(115-116). Numerous studies have been published claiming significant gains in tumour 
control and survival. However, the results of these studies have to be taken with extreme 
caution (117). First, as mentioned earlier, these studies evaluated tumour response as the 
main outcome but this does not reflect the clinical outcome. Second, population-wide 
epidemiological studies showed a non-significant improvement in the outcome of advanced 
stage patients even with the introduction of these advanced multimodality strategies (21). 
 
While it is out of the scope of this research to evaluate the huge number of studies comparing 
different treatments and outcomes, meta-analysis and systematic reviews have been 
conducted for informed decision-making. In 2000 Pignon et al. (118) performed a meta-
analysis of 70 trials, including 10,741 patients, highlighting only 4% improvement in the 
survival of advanced-stage patients of head and neck cancers in favour of the multimodality 
treatment. Another comparison within the same meta-analysis showed that this humble 
improvement is warranted to some treatment regimens (concurrent chemotherapy with loco-
regional treatment not adjuvant chemotherapy). In 2009, an updated version of the meta-
analysis was been published with 24 new trials with similar results and no difference between 
outcomes in the previous two decades (119). Another meta-analysis claimed that induction 
chemotherapy (i.e. before treatment) resulted in 7% enhancement in the distant metastasis-
free rate compared with loco-regional treatment alone: however, no effect on survival was 
achieved (120).  
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Furness et al. analysed 89 randomised studies on oral and oropharyngeal cancer and found 
that induction or concomitant chemotherapy plus surgery and radiotherapy produced a 10-20 
% survival advantage in patients with advanced-stage neoplasms. However, the study did not 
show any significant improvement in terms of recurrent or metastatic control for these 
treatments (121). A recent study showed an improved outcome for patients with advanced 
oral cancer treated with multimodality in terms of recurrence, metastasis-free and overall 
survival compared with those treated with mono or dual therapies (122). The study revealed 
that 115 patients of 222 (51%) died due to OSCC-related causes with 58% survival advantage 
for surgery chemo-radiotherapy (S-CRT) group. Patients in this group achieved a 22% 
reduction in the recurrence rate, from 39%. The metastasis-free rate for S-CRT group was 
84% but this was a secondary objective of the study and the comparison criteria were not 
clear.  
 
The results confirm the notion that despite a slight improvement in survival, these treatment 
regimens still fail to prove any advantage in recurrent oral cancer. OSCC has a higher rate of 
recurrence even in patients who undergo treatment (8). Patients with recurrent diseases have a 
very poor prognosis, and even with the salvage treatment, the outcome remains unfavourable 
(123-124). The relative success in early detection and prevention of early-stage tumours has 
resulted in prolonged survival periods but with more recurrence and distant metastasis 
incidence rates observed (125).  
 
The choice of treatment is currently determined using diagnostic tools available to identify 
the level of the cervical metastasis. Clinical examination alone is not capable of detecting 
occult metastasis; therefore, adjunctive methods such as imaging should be used to diagnose 
such lesions. The low specificity and sensitivity of these diagnostics compels clinicians to 
deal with the consequences of metastasis after it has occurred. Therefore, the management of 
OSCC patients with metastasis, or those in early stages with high risk of metastasis, requires 
invasive management approaches to ensure the best outcome. The complications of these 
treatment strategies (neck dissection, chemotherapy, radiotherapy) are numerous, resulting in 
morbidity, reduced functionality, and even patient mortality due to treatment complications 
(126). From an evolutionary point of view those treatments impose a selective pressure, 
which kills the weak cancerous cells while preserving the most aggressive clones which have 
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the ability to survive the treatment and further spread into other parts of the body (127). Also, 
the financial burden of such treatment is enormous on the health systems and individuals 
(128). Finally, neither of those modalities have brought significant improvements in patient 
survival or metastatic or recurrence control. The therapeutic approach for treating OSCC 
relies on the stage of the tumour, particularly the nodal status, which in turn defines the 
prognosis and outcome of the disease. Due to incomplete understanding of the metastatic 
process, those treatment modalities fail to establish full recovery and are confined to 
symptomatic relief for cancer patients. 
 
In summary, the focus on exploring the mechanisms of cancer initiation progressed the state 
of knowledge about primary tumours but added only a little to our understanding of how the 
tumour can spread and result in death (146). Information available from this research 
influenced the advent of early detection programs and revolutionised treatment strategies 
leading to prolonged survival across most types of cancer (142). Unfortunately, due to the 
knowledge gap in understanding metastasis, we experience more relapses with cancer 
treatment (144). Metastasis has shifted to become the prime killer of the OSCC patient, not 
the primary tumour itself (125). The presence or risk of metastasis is the single indicator of 
patient outcomes and the most deterministic in electing the method of treatment (14). 
Molecular diagnostics (e.g. PCR, DNA microarray) are revealing higher than ever metastatic 
rates, up to 30%, even in very early stages, with some new opinions that metastasis 
commences as early as the tumour itself (129). This spread makes it hard for any treatment 
regimen to effectively reach and target these disseminated cells, which explains the failure of 
treatments to fully eradicate the disease or establish recurrence-free outcome (130). What’s 
more, the introduction of systematic combination therapies increases morbidity and has 
proven to be highly toxic, and even fatal to the host organism (126-127). Once metastasis has 
occurred, then the treatment of these disseminated tumours is either ineffective or confined to 
palliative treatment providing no clinical benefit to the quality of life of the patient. 
Accordingly, the potential lies in a preventive approach where interference with the critical 
stages in the metastatic process takes place before metastasis occurs. In “the battle against 
cancer”, neoplastic initiatives have been in the lead and clinical oncology is often left to react 
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to the consequences. This approach would represent a paradigm shift, in which medical 
intervention can for the first time gain an advantage over cancer mechanisms.  
If metastasis is of utmost clinical importance, why is this lag in understanding metastasis? 
And how can we interfere with this fierce process?  The answer lies in that metastasis is an 
extremely complex process that results from the interplay between tumour and the host 
microenvironment. Only by understanding the molecular mechanism of the pathogenesis of 
metastasis, can we establish any basis for precise clinical models, which will allow the 
identification of the critical characteristic of those cells and this is a vital requirement for 
development of effective therapeutic modalities. 
2.3 Extravasation in inflammation and metastasis 
2.3.1 Evolutionary stages of metastasis 
Metastasis, according to the progression model, was considered to be an end-point in the 
tumour genesis process (Figure 2.6) (131). Only after the primary tumour has formed then 
mutational changes take place in rare cell populations of the tumour bestowing full metastatic 
potential to those cells (131). Supported by several studies that revealed the existence of 
metastatic cell subpopulations within tumours, this was the prevailing model of metastasis for 
more than three decades (132-135).  
 
Figure 2.6: The diagram is showing the progression model of metastasis and the onset of 
metastatic changes in relation to the diagnosis. 
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However, the model failed to explain the origin of metastatic lesions with unknown primary 
tumour which makes up to 5 % of all metastasis (136). As the model suggests a pattern of 
continuous mutational changes throughout tumour cycle, it would be expected that the 
disseminated cells would have a higher metastatic potential than the primary tumour, which 
proven to be not the case clinically (137). The model prevailed for a long time focusing the 
research on eliminating the primary tumour, which was expected to annihilate the problem of 
metastasis as it is a very late sequela of the cancer formation process. This, once more, was 
clinically proven not to be the case (138). 
The introduction of genome wide profiling techniques has identified a “metastatic signature 
profile” expressed by the bulk of tumour cells which stressed the importance of somatic 
mutations in the cancer evolution, but more importantly, pointed out that the metastatic 
ability is a common trait for most of the tumour cells (139-141). This clearly conflicted with 
the progression model leading to the emergence of an “early genetic model for metastasis” 
which denotes that metastasis is not only an early event in cancer, but might even be caused 
by the same oncogenic alterations that produced the primary tumour (Figure 2.7) (139).  
 
Figure 2.7: The diagram shows the early oncogenic/metastatic model, in which the tumour 
cycle progress from a carcinoma in situ, developing into the tumour. The model hypothesise 
that the oncogenic events that progress the tumour are themselves already establishing a 
metastatic genotype. 
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The current paradigm views metastasis as an evolutionary cycle starting with the initiation of 
the tumour governed by laws of selection and driven by genetic instability (Figure 2.8) (142). 
Cells with better survival advantages such as growth self-sufficient, resistant to inhibitory 
signals and apoptosis will be selected through the neoplastic transformation process to 
become the predominant population and form the primary tumour. These selected clones are 
characterised by a high degree of genetic instability which makes them prone to faster rates 
of genetic and epigenetic alterations, leading to the emergence of different sub-clones with 
different molecular prints and establishing the tumour’s heterogeneous nature (143). 
 
Figure 2.8: Relation of genetic instability, selective pressures, tumour heterogeneity and 
selection of metastatic cells. 
 
Tumour heterogeneity (the presence of different sub clones with different molecular 
characteristics) driven by genetic instability due to loss of DNA repair mechanisms permits 
the early rise of new sub-populations with superior biological advantages (e.g. blood vessel 
formation), alongside an unprecedented ability for invasion and relocation to distant sites 
(143). The tumour is challenged by numerous internal (e.g. telomere attrition) and external 
(e.g. hypoxia) stresses which can potentially limit its growth (144). Selective pressure 
endorsed by these stresses leads to the selection of those metastatic clones with their higher 
survival and proliferation capabilities (145-146). These sub-populations are adapted to lead 
the tumour progression phase of the tumour as well as disseminating to other organs to signal 
the commencement of the malignant stage (147-148). This has been a topic of debate in the 
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oncology field where some argue that the systemic treatment is, in fact, a metastasis trigger in 
which it imparts a selective pressure on the tumour cells, killing only labile tumour cells. This 
allows for the most aggressive subpopulations to escape treatment and stay dormant. They are 
the treatment-resistant clones which will cause the spread of the disease.  
Despite progressing our understanding of some aspects of the metastatic process, all these 
models fail to completely unravel the complexity of tumour dissemination (149). The 
transformation of these hypothetical models into clinical applications will require significant 
efforts through multi-institutional studies to pinpoint the complicated network of factors 
implicated in the process and distinguish suitable markers that can be of clinical value. 
Currently, a more robust approach is needed to improve patient outcome and quality of life. 
A more effective pathway is to review all stages of metastasis, identify the critical ones and 
intervene at this level to prevent the spread of the disease. This can be achieved through 
investigating molecules regulating this stage. 
2.3.2 Clinical Stages of metastasis 
Unlike the evolutionary cycle of metastasis, this phase can be detected clinically with more 
precision and accuracy. It starts with the separation of the cells from the original tumour, then 
colonising a secondary site by disseminating through blood or lymph vessels. For either route 
to produce effective metastasis, cancer cells must survive a marathon of several events where 
each event imposes a challenge to the metastatic process (150). Migrating cells have to 
acquire intrinsic traits as well as deploy extrinsic signals from their environment to direct the 
outcome of this marathon in their favour (151-153). Although all of these steps are necessary 
for the metastatic process, the actual success depends significantly on the rate-limiting step of 
extravasation (154-157). A myriad of molecules control each step but they can overlap to 
regulate the whole process and a clear distinction becomes very hard (158). In this section, 
we provide a review of the stages involved in this process (Figure 2.9) with a focus on the 
extravasation step, its significance and its key regulators.  
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Figure 2.9: Schematic diagram of the clinical stages of metastasis (sequence right to left). 
 
Tumour detachment, invasion and epithelial-mesenchymal transition (EMT): In order 
for tumour cells to commence dissemination, a tumour has to lose its tight adhesion with its 
neighbours and gear into an invasive form, which is more mobile and can degrade any 
hindering structures in its way to access the blood vessels. Cadherin (the intercellular 
adhesion molecules) expression is found to be significantly diminished in several types of 
carcinomas associated with metastatic phenotypes (159). The loss or reduction of E-cadherin, 
which maintains intercellular junctions by adhering to actin cytoskeleton filaments via B-
catenin, causes loss of cell attachment leading to “cadherin-switching” to N-cadherins which 
can trigger EMT (160).  
 
EMT is the process through which the epithelial cell loses its characteristic epithelial 
molecular phenotype (expression of E-cadherins, Actin cytoskeleton, B-catenin) and acquires 
a mesenchymal phenotype (expression of vimentin, N-cadherin) (161-162). The process is 
akin to embryogenesis (e.g. neural crest cell migration) and is driven mainly through 
transforming growth factor (TGF-β) and the transcription factors snail and slug (163-165). 
EMT is a critical process in the metastatic cascade: first, by reversing back into MET, it helps 
the survival of the tumour at the distant site. Second, through EMT, tumour cells acquire a 
mesenchymal mobile phenotype as indicated by in-vivo microscopy, which revealed the 
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ability of tumour cells to migrate across the ECM (166). Finally, the induction of EMT 
promotes the release of MMPs, which can deconstruct and remodel ECM and BM, 
facilitating tumour migration (167). 
Neo-vascularisation and angiogenesis: Neovascularisation involves a de-novo formation of 
blood vessels and occurs in the embryonic development stage (168). Angiogenesis is the 
formation of vascular structures from pre-existing ones and often takes place in the 
physiologic processes of wound healing and pregnancy (169). The increasing demand for 
nutrients and oxygen to fuel tumour growth and its separation from its original blood supply 
by expansion, dictate the adoption of angiogenesis mechanisms to guarantee the survival of 
tumour cells (170). Under normal physiologic conditions, a delicate balance exists between 
several pro/anti angiogenic factors. This balance is tipped in the case of the tumour towards 
“the angiogenic switch” (171-172).  
The angiogenic switch allows a tumour to adopt both neo-vascularisation and angiogenesis to 
maintain its growth (150). In neo-vascularisation, the cancer reactivates the embryonic state 
to recruit endothelial precursors from bone marrow, inducing them to proliferate and 
configure a new vasculature. Tumours can also stimulate angiogenesis by attracting nearby 
endothelial cells, which mobilise towards the tumour bulk influenced by a gradient of 
angiogenic factors secreted by the tumour and its microenvironment, where they can 
reorganise and form new capillaries (173-174). Some tumour cells can form three-
dimensional tubes mimicking blood vessels, with blood flowing into these tubes (175-176). 
Recent microscopic photos demonstrated that the blood vessels formed in the tumour are 
largely different from normal ones in terms of quality of vessel permeability, blood flow, and 
stability (177-178). 
Insights from the physiologic processes where these new blood vessel formations take place 
revealed a set of regulating factors which proved to be the same in the tumour angiogenic 
switch (179-180). Pro-angiogenic factors including vascular endothelial growth factor 
(VEGF), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF) and 
epidermal growth factor (EGF) as well as inflammatory cytokines such as tumour necrosis 
factor-alpha (TNF-α) and interleukin-8 (IL-8) have been demonstrated to be the main 
modulators of angiogenesis. These molecules are triggered by a state of tissue hypoxia 
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endorsed by tumour overgrowth, which induces hypoxia inducible factor (HIF) to initiate the 
angiogenic cascade (181-182).  
Intravasation of metastatic cell foci into lymph or blood vessels follows their detachment 
from the primary tumour. Studies on intravasation show that tumour cells acquire migratory 
behaviour that enables them to mechanically translocate and squeeze through the endothelial 
barrier (183). This includes the ability to orient themselves towards the blood vessels, change 
shape into a more rounded form, and the development of migrating processes that permit 
their locomotion (184-185). Several factors responsible for these mobility transformations 
have been identified, such as insulin-like growth factor and extracellular matrix molecules 
such as laminin and fibronectin (186-187). This process can be active due to the release of 
chemotactic peptide and the movement of cells towards this gradient (188). On the other side, 
a passive mechanism has been postulated, in which the mechanical stress in the tumour 
overgrowth breaks the fragile, immature, newly-formed vessels and pushes the tumour 
through these frail barriers (188). VEGF was shown to accompany tumour-associated 
angiogenesis causing formation of leaky vessels which provide easy access for intravasated 
cells (189). 
Extravasation (the escape of tumour cells from circulation or lymphatic vessels into 
tissue) is a critical step in the metastatic cascade and leads to the implantation of the tumour 
mass at the distant site (156). Insights into the extravasation steps are driven from the studies 
of leukocyte interaction and migration during inflammation (155). The completion of this 
stage requires active adhesion between both tumour and endothelial cells through adhesion 
molecules and is aided by proteolysis enzymes (190, 155). Evidence suggests that the 
adhesion between tumour and endothelial cells during extravasation is mediated by the 
endothelial cell adhesion molecules and their ligands on tumour cells (155, 156). 
Extravasation, itself, is a multistage process encompassing several sub-steps:  
1- Loose attachment of cancer cells to endothelial cells, which triggers rolling movement 
of tumour cells on the endothelium  
2- Cells attach firmly to the endothelium which causes cell structural modifications 
allowing the cells to cross the endothelium in the third step (diapedesis).  
3-  
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Metastasis formation at secondary site: Once metastatic cells exit the vasculature and settle 
into their new microenvironment, they are confronted with a new set of challenges. Most of 
these cells will undergo apoptosis or remain dormant and only a few will have the ability to 
adapt to the new niche (191). This adaptation to create a favourable site for tumour growth 
involves interaction between tumour cells and the host microenvironment (142, 192). The 
implantation of tumours at secondary sites is not merely a random process but is a “seed” and 
“soil” guided event (142).  
Despite an incomplete understanding of the specific molecular mechanisms underlying this 
process, research efforts have suggested a few explanations such as the interaction of the 
tumour with its stromal components, which can trigger cell translocation into the new sites to 
modify the niche to accommodate the new metastasising cells (193). Other studies suggest 
that the different molecular signatures on the endothelium representing the tissue in which 
they reside might attract specific disseminated cells which possess similar signatures (194-
195). 
2.3.3 The significance of extravasation 
The stages of the clinical metastatic cascade are crucial for the successful dissemination and 
implantation of the tumour at the secondary site. Failure of the completion of any stage 
entails the collapse of the overall process (192). However, only the completion of the so-
called “rate-limiting steps”, not all steps, will guarantee the success of metastasis (154). For 
instance, millions of cancer cells can be detected in the circulation of patients (even in 
patients with very small tumours or who have never developed an overt metastasis), yet less 
than 0.01% of these circulating cells can develop clinical metastasis (196-197). When the 
tumour cell is introduced into the circulation, it faces several stresses that diminish its 
survival chances, including the sheer force of blood flow, immune response and apoptosis 
signals induced by loss of cell contact as well as the rocking of cells against the wall of the 
blood vessels (198-199). This highlights the inefficiency of the metastatic process and 
denotes the importance of extravasation and subsequent colonisation as deterministic events 
defining the outcome of the whole process (138). 
The ability of the specific tumour to extravasate determines its metastatic capacity. For 
example, colon cancer cell lines with higher extravasation rates displayed higher colonising 
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potential (200). In a separate study, only 0.05% of lung carcinoma cells injected 
intravenously (IV) were able to survive and colonise the lungs (201). Some tumours display 
higher extravasation rates, which might support the theory that tumour metastasis occurs 
because of mere mechanical entrapment (202-203). These results were challenged with the 
advance in the new intra-vital microscope, which showed that tumour cell arrest occurs in 
capillaries with diameters larger than that of the tumour cells (204). This new data does not 
disprove the importance of extravasation but rather denotes that the steps after extravasation 
are also rate-limiting steps. 
The adhesion of the tumour cells to endothelial cells represents a milestone event in the 
extravasation process (204-205). The interaction of the endothelium with the neoplastic cells 
determines the physical point of cell exit, and hence can explain specific organ metastasis 
(206). In addition, this adhesion is of vital importance to the survival of tumour cells as it 
provides anchorage and, therefore, it prevents cell death and induces proliferation (207). In 
contrast to intravasation, which can be largely passive due to abnormal tumour vasculature, 
adhesion is a highly active and specific event (188, 155-157). The analogy between adhesion 
in inflammation and tumour extravasation provides a powerful tool to understand this process 
(208). These criteria accentuate the promise of the regulators of adhesion mechanism to 
develop therapies that can interfere effectively with the metastatic cycle (207, 209). 
2.3.4 Role of inflammation in cancer and metastasis 
Inflammation is a protective response by which the body can eliminate any harmful irritants 
(physical, chemical, microbial, etc.) (210). In addition, the commencement of inflammation 
triggers the repair process which is vital to restoring the function of organs and the 
homeostasis of the body (210). The strong relationship between cancer and inflammatory 
process has labelled cancer as the “wound that never heals” (211). Population-based studies 
revealed that 25% of all cancers are a result of inflammation, and almost every single cancer 
type is infiltrated or surrounded by inflammatory cells (212-213). The use of anti-
inflammatory drugs to prevent the incidence of several types of cancer highlights the key role 
of inflammation in cancer (214). Hahn et al. identified inflammation as the “seventh hallmark 
of cancer” and recent research indicated that inflammation underlies several aspects of 
tumour growth, survival and, most importantly, metastasis (143). 
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The role of inflammation in several stages of cancer metastasis is supported by several 
studies (215). Research shows that in-vitro co-culturing of tumour cells and tumour-
associated macrophages enhances the invasive capacity of neoplastic cells, which is mainly 
dependent on the secretion of MMPs (216-217). Other studies demonstrated that 
inflammatory cells can induce the expression of both MMP and angiogenic factors, which 
promotes angiogenesis, a crucial requirement in the invasion of tumours (218). Several 
signalling pathways such as nuclear factor kappa-light-chain beta (NF-κβ) and signal 
transducer and activator of transcription (STAT) have been identified to be regulators of both 
metastasis and inflammation (219-220). Inflammatory cytokines can increase the motility of 
metastatic cells through the induction of the EMT program (216, 221). Similarities between 
wound healing and tumour extravasation via identification of the inflammatory mediators that 
can increase the adhesion of either tumour or inflammatory cells to the endothelium provide a 
strong link between inflammation and metastasis (222-223). Advances in exploring these 
common mediators have the potential to be translated into clinical interventions that are more 
efficient in managing patients with metastasis.  
2.3.5 Extravasation in inflammation and metastasis 
The ultimate goal of the inflammatory process is to recruit the leukocytes to the site of 
inflammation so that they can combat the offending stimulus either by ingestion or by the 
appropriate antibody response (210). As mentioned previously, insights into malignant 
extravasation came from the recruitment of leukocytes in the inflammatory process. Initially, 
researchers considered the two processes to be identical (Figure 2.10, 2.11). However, new 
data from different well-documented in-vivo and in-vitro experiments have shown some 
differences (155). The main difference is that tumour cells disrupt the endothelium during its 
migration, unlike inflammatory cells, which preserve its integrity (224). The main similarity 
is that both processes are guided through localisation signals by the tumour, the leukocytes or 
the endothelium, which is an active promoter in both events (225). These localisation signals 
are mainly delivered by neurotransmitters such as Substance P (SP) or cytokines such as 
tumour necrosis factor (TNF-α). Although these mediators have been elaborated extensively 
in inflammation, their action in metastatic extravasation is yet to be identified (225-227). 
Another facet of similarity in both cascades is the use of MMP to ingest the endothelial 
basement membrane and facilitate the movement of cells during diapedesis, though the 
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mechanisms and regulators that induce their expression are not clear (303-304). Finally, a 
definite set of adhesion molecules controls the interaction between the tumour, the leukocytes 
and the vascular endothelium, resulting in the same sequence of adhesion to the endothelium 
leading to extravasation (208). 
  
 
Figure 2.10: Stages involved in extravasation and the adhesion molecules responsible for 
each stage as has been investigated through inflammation research (232). 
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Figure 2.11: Suggested stages of tumour extravasation (206). 
 
 
2.3.6 Adhesion molecules during stages of extravasation 
Adhesion of the leukocyte/tumour cells to the endothelium is the initial critical step in the 
extravasation process. It is a critical requirement for cell migration through the vasculature 
and typically takes place in post-venule capillaries (228-229). The adhesion starts with a 
weak attachment (rolling) of the migrating cells of the endothelium, which in turn triggers 
firmer adhesion and subsequent crossing of the cell through the endothelial barrier (156).  
Every step of the extravasation process is mediated through a group of adhesion molecules 
expressed on the migrating cells and their binding receptors on the endothelial cells (Table 
2.5-2.6) (230-231). The majority of these adhesion molecules have been identified through 
extensive research in inflammation (232). However, their expression and action in tumours is 
not clearly defined. Two large families of molecules, the selectin and integrin, were found to 
be responsible for the adhesive interaction which takes place in extravasation (233). The 
binding of these adhesion molecules to their receptors controls the adhesion and can inflict 
morphological and functional changes on the cells involved in the adhesion.  
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Table 2.5: Endothelial adhesion molecules and their binding receptors. 
Endothelial adhesion 
molecule 
Leukocyte 
receptor 
Major function 
P-selectin Sialyl-Lewis X, 
PSGL-1 
Rolling neutrophils, monocytes and 
lymphocytes 
E-selectin Sialyl-Lewis X Rolling, adhesion of neutrophils, 
monocytes and T cells to activated 
endothelium 
ICAM-1 CD11/CD18 
(integrins) 
LFA-1, Mac-1 
 
Adhesion and transmigration of 
leukocytes 
 
VCAM-1 α4β1 (VLA4) 
(integrins) 
 
Adhesion of eosinophils, monocytes and 
lymphocytes 
GlyCam-1 
CD31 (PECAM) 
L-selectin 
CD31 
Lymphocyte homing and migration 
through endothelium 
 
Table 2.6: Endothelial cells adhesion molecules, their binding receptors in leukocyte and 
counterparts in tumour cells. 
Endothelial cell surface 
molecule 
Leukocyte counter-receptor Cancer cell counter-
receptor 
Selectins 
E-selectin PSGL-1; SLeA-, SLeX-
glycoproteins 
SLeA-, SLeX-
glycoproteins 
Immunoglobulins 
ICAM aLb2 (LFA-1); aMb2 (Mac-1) aLb2 (LFA-1)?? 
VCAM a4b1 (VLA-4) a4b1 (VLA-4) 
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The prediction of this hypothesis proves correct in leukaemias and lymphomas where they 
have the highest metastatic rates (359). Taking into consideration the nature of the cell of 
origin for these neoplasms – as inflammatory cells (i.e. white blood cells and lymphocytes) – 
they are predisposed to express several adhesion molecules to bind with the endothelium in 
inflammatory conditions (360). This facilitates their interaction with the endothelium and 
further dispersion in distant organs. Therefore, these tumours represent an excellent model for 
the study and validation of understanding of the adhesion process in the spread of cancers.  
2.3.6.1 Rolling  
Initial weak interactions between leukocytes and endothelial cells allow rolling on the 
endothelium (EC) and margination of leukocytes from the main blood stream in the blood 
vessels (156, 234). This repeated tethering of the leukocyte retracts the cell from the high-
velocity centre of the blood vessel as well as keeping the migrating cell close to the 
endothelium, which prevents dislodging of the leukocytes (LC) (235). In cancer, research has 
not produced a clear demonstration of this stage, using intra-vital microscopy, unlike the 
distinct rolling motion of neutrophil which has been visualised in-vitro (236-237). Extensive 
experimental models of inflammation revealed that tethering of LC on EC is mainly mediated 
through selectin adhesion molecules. However, tumour cells do not express selectin; instead, 
they express their ligands (238). 
Selectin is a family of vascular adhesion molecules, including E, P and L types that are 
expressed on the endothelium, platelet and leukocyte surfaces respectively (239). The studies 
show that P- and E-selectin are expressed in response to inflammatory mediators and are 
involved in the initial rolling of white blood cells on the surface of the endothelium at the site 
of the inflammation (234). This effect was inhibited in T cells by using anti-P or anti-E 
selectin, which in turn inhibited the migration of leukocytes into endothelial cells (240). 
Genetically engineered mice lacking the genes for P- and E-selectin demonstrated a lack of 
rolling of neutrophils on the endothelium and low extravasation capabilities (241).  
Cancer cell interaction with endothelial cells, mediated via E-selectin, is important for 
metastasis (242-243). E-selectin was shown to be up-regulated in endothelial cells at the site 
of liver metastasis and the media from cancer cell lines induced the expression of E-selectin 
when added to endothelial culture (243, 244-245). Jiang et al. (246) demonstrated that a 
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higher incidence of lung metastasis from breast cancer cell lines was evident in 
inflammation-induced mice, dependent on higher E-selectin production by endothelial cells, 
and anti- E-selectin reduced this metastasis. The high expression of E-selectin in several 
invasive types of tumours such as breast, colon, ovarian and lung cancers suggested that E-
selectin expression by tumours might contribute to the interaction of tumour cells and 
leukocytes during motion of tumour emboli in the circulation (247-250). A study by Ye et al. 
demonstrated that the expression of selectin on EC adjacent to the metastatic tumours was 
higher than that of the EC of the primary tumours (249).  
Selectins can bind to a variety of ligands such as PSGL-1, ESL-1, CD24, sialyl Lewis-a, 
sialyl Lewis-x (SLe-X), CD34 and MAdCAM-1, all of which are expressed by leukocytes 
(238). The most common ligands for P-, L- and E-selectins are PSGL-1, ESL-1, sialyl Lewis-
x, respectively, although binding to other ligands is not uncommon (251-252). PSGL-1, ESL-
1, and sialyl Lewis-x are proteins or lipid cores attached to oligosaccharides epitope that 
works as the functional ligand and requires fucosylation for proper function (251). These 
ligands have been reported to be highly expressed in a variety of cancer types and this 
expression was correlated with a poor prognosis (253-254). In a study of 145 head and neck 
cancer patients by Gunawardena et al., SLe-X was a negative prognostic marker for survival 
in those patients (255). It has been demonstrated that colorectal and gastric cancer cells with 
high expression of the selectin ligands binds more efficiently and extravasate at higher rates 
than those with low expression (256). The use of an anti-SLe-X antibody inhibited the 
formation of metastasising tumour colonies, and the addition of a selectin antagonist to the 
chemotherapy regimen (cisplatin) has a cumulative metastatic inhibitory action (257). 
Cimetidine showed an inhibitory effect on metastasis in gastric cancer and this effect was 
thought to be due, in part, to blocking selectin/SLeX adhesion in those cells (258). These 
results, despite having inconclusive results due to the lack of understanding of the role of 
selectin and its ligand in metastasis, provide some evidence that interference with this 
interaction could be introduced in clinical trials to interfere with metastatic formations.  
 
2.3.6.2 Adhesion  
Firm adhesion to the endothelial cells requires the activation of a group of endothelial cell 
adhesion molecules (CAM) to achieve tight binding with their receptors (integrins) for the 
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successful completion of the extravasation (Figure 2.12) (259). CAM categories that are 
known to participate in the adhesion process are: VCAM and ICAM-1 (related to Ig 
superfamily) (260-261). While VCAM is only expressed in inflammation, ICAM-1 is 
expressed in low-affinity concentrations on the surface of the resting endothelium and 
becomes up-regulated in response to an inflammatory mediator (262-263). Several studies 
have revealed a role for both molecules in leukocyte recruitment during a wide range of 
inflammatory diseases. Antibody blocking of ICAM-1 caused reduced infiltration of 
neutrophils and ICAM-1-deficient mice demonstrated the same signs, whereas VCAM 
knockout mice die during early embryogenesis. (264-265).  
The involvement of these endothelial adhesion molecules is attracting attention recently in 
oncology research. The expression of VCAM and ICAM was shown to be higher in the 
tissues and serum of breast cancer patients (266-268). Other in-vitro studies demonstrated 
that ICAM and VCAM are key mediators of adhesion of endothelial cells and cancer cells 
(269-270). Contrary to this, other findings showed a lack of correlation between specific 
CAMs and the metastatic or adhesion potential of tumour cells (271-272). This conflict of 
results does not void the role of CAMs in the adhesion of cancer to endothelial cells, but 
rather it reflects an incomplete understanding of the adhesion process and different 
modulators and tissue response. Additionally, the type of assay used to assess the adhesion 
greatly influences the outcome and requires the development of more accurate and 
reproducible adhesion models for more validated results (273). 
Integrins are complex molecules that mediate cell-ECM adhesion and control cell 
conformation and several cellular processes such as survival and proliferation through 
interaction with the cytoskeleton (274). There are 18 different alpha and eight beta chains 
which can form 24 heterodimers integrin receptors (274). Integrin molecules which are 
responsible for endothelial adhesion belong to the β1 and β2 sub-families. The αLβ2 
(lymphocyte function associated antigen LFA-1) and αMβ2 (Mac-1) are both ligands for 
ICAM-1/-2 whereas, α4β1 integrin VLA-4 is the ligand of the vascular cell adhesion 
molecule (VCAM-1) (275). 
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Figure 2.12: Molecules involved in the adhesion of tumour and leukocytes to endothelium 
(155). 
 
Studies on melanoma identified VLA-4 integrin as the main molecule involved in binding 
with VCAM and it plays an important role in the endothelial adhesion and trans-endothelial 
migration (TEM) of the tumour cells during metastasis (276-277). Similar results were 
obtained in-vitro in brain metastasis, where metastatic brain cells injected in mice showed 
specific high expression of VLA-4 in the early stages of the tumour seeding (278). VLA-4 
was shown to induce the adhesion with lymphatic endothelium in-vivo and promotes lymph 
node metastasis, therefore, it has been suggested that it can serve as a biomarker in lymph 
node metastasis (279). In oral cancer, few studies have been performed on the expression of 
VLA-4 either in-vivo or in-vitro. Songet et al. showed that Cal 27 oral carcinoma cell line can 
express VLA-4 and demonstrate strong adhesion with TNF-α activated endothelial cells. 
However, the study has not reported the basal expression levels of VLA-4 by OSCC cells 
(280). 
Inhibiting of ICAM-1/LFA-1 axis prevented the formation of micro-metastasis in prostate 
cancer (281). In lung carcinoma, it was shown that the adhesion of tumour cell lines to the 
cultured endothelium was achieved through ICAM-1, both in static and shear flow. The 
monoclonal antibodies to these molecules significantly hindered this adhesion (282). 
However, there is a controversy about the presence of LFA-1 in tumour cells. Jiang et al., in 
their study of adenocarcinoma cell lines, demonstrated that ICAM-1 was expressed on the 
tumour cell proper of all the carcinomas, while its receptor LFA-1 was expressed only in 
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tumour infiltrating lymphocytes. Therefore, they suggested that the actual binding occurs 
between the tumour and the lymphocyte which facilitates the tumour trans-endothelial 
migration and evasion of the immune system (283). These findings were further validated 
with the lack of expression of LFA-1 in melanoma (highly metastatic tumour), however, the 
media of melanoma cell lines promoted tumour-endothelial adhesion and transmigration 
through LFA-1 interaction with its ligand ICAM-1 (284-285). Further studies are required to 
investigate the actual mechanism of LFA-1 in the adhesion of tumour cells. 
The importance of the CAM-integrin adhesion axis is that it can explain site preference of 
metastatic tumours, as studies on metastatic lymphoma and colon cancer cell lines showed 
preferred adhesion to hepatic endothelial cells (286-287). Additionally, the integration 
between different integrin members ensures that after the establishment of adhesion, the 
completion of the TEM will take place (157).  
2.3.6.3 Diapedesis 
After the firm adhesion with endothelium, the migrating cell has to exit the vasculature. In 
the case of inflammation leukocytes leaves the endothelial layer intact, whereas tumour cells 
disrupt their integrity mainly due to their larger size and triggering aptopsis of endothelial 
cells (224). Two routes have been proposed for this step, the first of which is the para-cellular 
route where cells can move between neighbouring endothelial cells. The other route is the 
trans-cellular route in which cells migrate through the endothelial cells themselves (288). 
While both leukocytes and tumour cells can deploy both routes, different subpopulations 
adhere to specific routes and the reasons for this are yet to be identified (288). The adhesion 
step inflicts structural changes in the migrating cells, changing their shape into a drop shape 
as well as arranging the cytoskeleton of those cells (289-290). These changes also occur in 
the endothelial cells where an apparent change of vascular endothelial cadherin has been 
recorded as well as an increase in vascular permeability (289). Adhesion to endothelial cells 
triggers changes that activate PECAM and N-cadherin, which have been demonstrated to 
play a major role in this process (290). Once the migrating cells pass the endothelial layer, 
they are faced with two obstacles; basement membrane of the blood vessel and the 
extracellular matrix of the secondary site (291). Studies have shown that leukocytes utilise 
MMPs to degrade these components to advance to reach the site of inflammation (303-304). 
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On the other side, it is not clear whether cancer cells implement the same mechanism. This 
might seem instinctively mandatory, hence further studies are needed to investigate the role 
of MMP in tumour extravasation. 
 
2.3.7 Action of MMP in extravasation and inflammation 
MMPs are a group of proteolytic enzymes whose main function is to degrade the extracellular 
matrix (ECM) and basement membrane (BM) (292). A recent study suggested that the MMP 
role might not be restricted to matrix digestion, with new evidence demonstrating 
involvement in various processes associated with inflammation and cancer such as 
angiogenesis and phagocytosis (293). MMPs are highly expressed in any disease or condition 
that is associated with inflammation, therefore proteolysis is considered a hallmark of 
inflammatory process (294). Several MMP inhibitors are used as anti-inflammatory drugs in 
periodontal and vascular disease (295-296). Several models of MMP knockout mice have 
been established and each displays a dysregulation of a specific aspect of acquired immunity 
depending on the type of MMP deleted (293). 
In cancer, MMPs are constantly expressed at the invasive front of the tumour, which indicates 
a strong correlation with invasion and metastasis (297-298). It is believed that MMPs can 
also regulate the pre-metastatic niche and play a key role in angiogenesis (298-299). MMPs 
are tightly linked to integrin, which maintains cell-ECM adhesion. Therefore, the interplay 
between both molecules is vital in tumour mass detachment and also in interaction with 
microvasculature and invasion in the distant site (300). Hong et al. (301) showed that high 
levels of MMP-2 and MMP-9 were related to the invasiveness and lymph node metastasis of 
OSCC. Similar results were achieved by Singh et al. (302) who showed a significant 
relationship between MMP-2 expression and tumour stage and differentiation and similar 
results for MMP-9. In addition, multivariate analysis revealed a strong correlation between 
MMP-2 expression and lymph node metastasis.  
 
The contribution of MMP in the extravasation of leukocytes in inflammation has not been 
thoroughly researched, despite a role having been established for these enzymes in 
establishing a chemo-attractant gradient for immune cells which facilitates its migration (303-
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306). Moreover, the relation of the inflammatory mediator’s effect on MMPs as well as the 
relationship between MMPs and integrin adhesion molecules is not fully understood. The 
relationship between MMP and extravasation of tumour cells was suggested when carcinoma 
cells were injected into mice, where this showed invasive protrusions extending between 
endothelial cells in the lung microvasculature, pointing out the disruption of endothelial cells 
by a proteolytic action (307).  Applying a gelatinase inhibitor shortly after the injection of 
melanoma cells in mice inhibited lung colonisation by these tumour cells (308). However, 
applying a broad-range MMP inhibitor did not affect the survival of the colonising cells 
(309). Notably, the survival of the cells was the outcome of the study, and so, the results of 
this study do not effectively evaluate the role of MMP in extravasation. Leroy et al. showed 
that MMP-2 is necessary for the endothelial transmigration of ovarian cancer cells (310). 
Voura et al. developed an in-vitro endothelial transmigration assay, which indicated that the 
proteolysis takes place at the tumour-endothelial interface during migration, mediated by the 
action of MMP-2/9. This was significantly reduced with the application of MMP inhibitors 
(311). Since the regulators of extravasation mechanism are poorly understood, the same will 
apply for MMP role in extravasation, and further studies will be needed to outline whether 
the role of MMP is regulated by the same factors that control the adhesion process.  
2.3.8 Substance P in inflammation 
Substance P (SP), the most potent member of the tachykinin family, was initially identified as 
an active neurotransmitter in primary sensory afferent fibres (312-315). The canonical 
pathway for SP is through binding to the G protein-coupled Neurokinin-1 receptor (NK-1R) 
(316-317), in which the SP/NK-1R ligand-receptor complex is formed, and then SP is 
degraded while NK-1R is recycled to the cell surface (318). The SP/NK-1R complex 
activates a different MAPK signalling cascade such as ERK and P38 MAPK, through 
forming a scaffolding complex with β-arrestin (319). Additionally, the SP/NK-1R complex 
can mediate other pathways such as the NF-kB pathways (320), and transactivates other 
tyrosine kinase receptors such as EGFR (321). SP contributes to the inflammatory process 
possibly through different mechanisms: I) release of inflammatory mediators such as 
cytokines and arachidonic acid derivatives; II) chemo-attractant to the immune cells; III) 
vasodilatation (VD) and leukocyte/endothelial cell adhesion to aid leukocyte recruitment to 
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the injured tissue; and IV) through angiogenesis (322) (for excellent reviews about SP please 
refer to 312-314).   
SP was found to produce vasodilatation and neurogenic plasma extravasation in the rat 
trachea upon infusion or release, due to stimulating of peripheral sensory nerves (323). 
Mashito et al. (324) induced ovalbumin sensitisation in rat trachea, and three weeks later 
assessed bronco-alveolar lavage fluid resulting from the airway allergic response, where they 
found a very high concentration of SP. They concluded that elevated SP caused vascular 
permeability and eosinophils accumulation and was inhibited by using the Nk-1R antagonist 
CP 96,345 (324-325). Upon the injection of nano-concentrations of SP in the skin and 
conjunctiva, similar effects were obtained with concomitant distant flare and wheal formation 
(326-327). Furthermore, non-neuronal injection of SP caused post-venule vascular leakage 
(VL) and plasma extravasation in the gastrointestinal tract and conjunctiva (328-330). Not 
only did SP cause VL and VD, but in most cases this was accompanied by neutrophil or 
eosinophil adhesion or accumulation (324, 331). Hence the main function of the 
inflammatory response is to recruit inflammatory mediators and cells to the injury site. We 
can comprehend that SP can mediate inflammatory reaction via inducing vasodilatation of the 
vessels and plasma extravasation as a result of the sensory nerve stimulation. This is followed 
by leukocyte adhesion and migration through the endothelial barrier (332-334). 
Despite evidence that SP is involved in the adhesion and migration of leukocytes during 
inflammation, the mechanism underlying this process is poorly understood and requires 
further investigation. It is well known that the up-regulation of adhesion molecules on the 
endothelial cells (EC) caused by the release of tumour necrosis factor and interleukin 1 (TNF- 
α, IL-1β), is a prerequisite for slowing of leukocytes (LC) (335-337) and subsequent adhesion 
of LC to EC and their further transmigration (288). SP is a potent and specific stimulus for 
the release of these specific cytokines (338-339). IL-1β and TNF-α were proved to up-
regulate the expression of the selectin adhesion molecules which caused the rolling of 
leukocyte to the EC. It also induces the expression of ICAM and VCAM adhesion molecules, 
which are responsible for the tight binding with leukocyte integrins (340). The most likely 
explanation is that SP triggers the inflammatory pathway NF-KB through p38 MAPK, as the 
inhibitor of this specific pathway blocked the expression of the pro-inflammatory cytokines 
(341-342). Thus, SP can cause vascular permeability by inducing the release of cytokines, 
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which causes the up-regulation of vascular and leukocyte adhesion molecules and eventually 
transmigration of inflammatory cells to the site of injury.   
2.3.9 Substance P in cancer and metastasis 
High expression of SP and NK-1R receptor in various tumours including melanoma(343), 
human malignant glioma (344), retinoblastoma (345) and mammary carcinoma (346), both in 
the primary tumour and their metastatic counterparts, suggests an important role of SP in 
carcinogenesis (347).  SP has been suggested to act as a mitogen for cancer progression (348) 
and even in the early malignant transformation (349). The role of SP in metastasis and 
invasion has not been fully investigated, although initial studies suggested that SP might 
trigger the metastasis of colon cancer (350-351). Taking in consideration the main roles of SP 
in inflammation as vessel permeability, adhesion and migration of leukocyte, it is logical to 
predict similar roles for SP in metastasis (352) via inducing the adhesion between the tumour 
and the endothelium. 
SP was found to be significantly expressed in the tumour cell membrane, cytoplasm and 
nucleus of OSCC as well as the infiltrating lymphocytes of the neoplasms (353). The 
expression of SP was found to be significantly associated with the presence of dysplasia 
(P<0.001) and carcinoma in situ (P=0.021) which strongly suggested a role of SP in the early 
onset of oral oncogenesis (354). Moreover, SP IHC expression was significantly higher in 
kerato-odontogenic tumours and in oral lichen planus than in normal controls (355-356). The 
above evidence points out that SP might be a key player in tumour growth and progression, 
however, the role of SP in metastasis of OSCC has not been well investigated.  
Two points are of concern here. Firstly, in the Brener et al. study the expression of SP was 
58.1% (n= 43) in the peri-tumoural or intra-tumoural blood vessels and these observations 
have not been further studied (353). Secondly, Esteban et al. found that expression of SP was 
higher in 111 out of 114 cases of laryngeal carcinoma with 17 cases of metastases all of 
which expressed SP (+++/++++) (100%) (357).  
The above discussion underscores a number of interesting findings: 1) dissemination of the 
tumour cells requires adhesion of tumour and endothelial cells mediated through their 
adhesion molecules and their legends; 2) SP is an inflammatory mediator that can produce 
vascular adhesion and extravasation of leukocytes through inflammation; 3) SP is highly 
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expressed in metastatic tumours and OSSCC in particular around vascular sites. “Can cancer 
implement the same inflammatory mechanism to adhere and metastasise to other organs of 
the body?” is a question supported by the recent finding that SP enhances breast cancer cell 
adhesion and migration through the blood-brain barrier (358). Furthermore, it constructs a 
hypothetical framework to consider a role for SP in metastases, through affecting the 
adhesion between tumour cells and the vascular endothelium, as a mechanism for 
extravasation of malignant neoplasms, leading to lymph node or distant metastasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key Points  
 Extravasation and adhesion of cancer to endothelial cells is a rate-
limiting step in metastasis. 
 SP is a key mediator of vascular permeability and extravasation. 
 SP is highly expressed in cancer in particular metastatic tumours. 
 Can cancer implement the same inflammatory mechanism to adhere 
and metastasise to other organs of the body via Substance P? 
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Chapter 3 The prognostic role of inflammatory 
mediators in metastasis of oral squamous-cell 
carcinoma, comparison of clinical and experimental 
evidence: Systematic review 
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3.1 Introduction 
Metastasis accounts for up to 90% of cancer fatalities. Ironically, the success in early 
detection and prevention of tumours has resulted in prolonged survival periods, with higher 
metastatic incidence rates observed (17, 361, 3). The rate of metastatic spread for OSCC is 
reported to be 65% for lymph node metastasis, 5-25% for distant metastasis and up to 50% 
rate for local recurrence (20, 362, 18).  
The involvement of metastasis, as the most important prognostic factor (14, 10), significantly 
decreases the survival probability (21). This explains why OSCC remains one of the tumours 
with the worst prognosis, with an overall 5-year survival rate of around 50% (21). Moreover, 
metastasis is not limited to late stages but also can occur in patients with clinically negative 
lymph nodes as “micro-metastatic” foci. This foci can activate primary or secondary 
recurrence in OSCC patients even after they have been treated for the primary tumour (63).  
OSCC patients with metastasis or those in early stages with a high risk of metastasis are 
subjected to invasive management approaches. However, such treatment strategies (neck 
dissection, chemotherapy, radiotherapy) are accompanied by significant morbidity, poor 
quality of life, and even mortality as a result of treatment complications (121). Finally, those 
modalities have not brought significant improvements in patient survival or metastatic or 
recurrence control (118).  
3.2 Clinical stages of metastasis  
For cancer cells to disseminate to a secondary site, they have to go through several stages 
termed the “metastatic cascade” (146, 142). Despite being an ineffective process, it is highly 
regulated by a complex network of mediators. First, the neoplastic cell detaches from its 
neighbouring cells and transforms into a mesenchymal, invasive form that degrades any 
hindering structures to access the blood/lymphatic vessels. This is achieved through structural 
changes of the cytoskeleton of the cells, in particular, the adhesion molecules associated with 
increases in production of matrix degrading enzymes (158). Second, the invading cell turns 
into a migratory pattern termed epithelial-mesenchymal transition (EMT) (163). The 
increasing demand for nutrient and oxygen to fuel tumour growth dictates the induction of 
angiogenesis (formation of new blood vessels) mechanisms by the tumour to guarantee its 
survival (172).  
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Formation of new blood vessels within the tumour provides access for the migrating cells to 
enter the main blood stream in a process termed “intravasation” (183). The escape of the 
tumour cells from the circulation or lymphatic vessels into the tissue (extravasation) is a 
critical step in the metastatic cascade and leads to the implantation of the tumour mass at the 
distant site (127).  
 
3.3 Description of the intervention 
Cancer does not use novel mechanisms but rather implements existing biological process in 
favour of its growth and progression (208). This fundamental concept is supported by insights 
into the different stages of cancer progression and the metastatic cascade (e.g. epithelial 
mesenchymal transition (EMT), angiogenesis, intravasation/extravasation) which reveal that 
most of these stages are identical to some inflammatory processes (215). The link between 
inflammation and cancer has been a topic of research in the recent years since Hahn et al. 
identified inflammation as a main cardinal sign of cancer (363). Although this research has 
revealed several aspects of inflammation in initiating and progressing neoplasms, it has not 
completely highlighted the role of inflammation as a main driver of metastasis (212, 213, 
143). 
 
3.4 Rationale  
Metastasis has become the prime killer of cancer patients, rather than the original tumour 
itself (17, 361, 3). The presence or risk of metastasis is the most important indicator of 
prognosis and the most deterministic in selecting the method of treatment (21). Once 
metastasis has occurred, then the treatment of the primary tumour is either ineffective or 
confined to palliative treatment, providing no clinical benefit in prolonging survival.  
Although there has been progress in understanding the mechanisms of cancer initiation which 
resulted in prolonged survival periods across most types of cancer, relapses are seen clinically 
more often (3). This can be traced to the poor understanding of the key players in the 
interaction between the tumour and its microenvironment which predispose and establish the 
blueprint of the metastatic process.  
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Evidence of the key role of inflammatory mediators in tumour metastasis is paramount. 
However, using this evidence for clinical implementation is challenging, as most of the 
studies focus on other prognostic factors such as survival and treatment response. Systematic 
identification of the role of inflammatory mediators in each stage of metastasis is missing, 
which in turn, reduces the potential of clinical use of these factors as predictors of disease 
progression. Numerous experimental studies reported varying, and even conflicting, findings 
on the role of inflammatory mediators in metastatic development due to different tumour sites 
as well as different experimental conditions. The majority of these studies have not been 
validated by a clinical follow up, indicating a huge gap between the clinical findings and the 
experimental data. This systematic review aims to provide an evidence-based critical analysis 
of the clinical and experimental information. Integrating this vast amount of existing data will 
facilitate the development of more effective prognostic systems which can add clinical value 
to the current inflammation-based grading systems. 
3.5 Methods 
3.5.1 Objectives 
The objectives of this systematic review are: 1) To examine the prognostic value of 
inflammatory mediator expression in relation to the metastatic spread of the tumour in 
clinical patient samples; 2) To assess the association of the expression/inhibition of the 
inflammatory mediator with promoting/inhibiting specific metastatic stages in experimental 
animal studies; 3) To outline the gap in the state of knowledge between clinical and 
experimental data; and 4) To establish a preliminary inflammatory mediator panel that can be 
used for accurate and reliable prediction of the risk of metastasis in cancer patients. 
3.5.2 Search strategy 
To achieve the objectives of the review, the search was designed to include two main groups. 
The first group reports the association of the expression of inflammatory mediators with the 
metastatic progression of OSCC tumours in clinical cases. The second group includes studies 
performed on animal models reporting the effect of over-expression/inhibition of an 
inflammatory mediator on tumour metastasis or one of the specific metastatic stages 
described above. 
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3.5.3 Literature search  
The search strategy was developed according to guidelines outlined in the clinical practice 
guidelines devised by the Australian National Health and Medical Research Council 
(NHMRC). A systematic search was carried out on the PubMed database for articles 
published from January1980 to December 2017. To maximise the identification of relevant 
results, the initial search used truncated forms of the words “Inflammation”, “Cancer” and 
“Metastasis”. The search was further refined by crossing with the terms “prognosis”, “tumour 
progression” and “mediators”. Searches with the inflammatory mediators terms included 
“tumor necrosis factor-alpha”, “neuropeptide”, “chemokine”, “inflammatory cytokines”, 
“inflammatory mediators”, “kinins”, “substance P”, and “interleukin”. Terms were searched 
alone and then crossed with “expression” and the following terms: “tumor progression”, 
“metastatic cascade”, “metastatic stages”, “tumor invasion”, “epithelial-mesenchymal 
transition”, “tumor angiogenesis”, “tumor extravasation” “metastasis formation at secondary” 
(for full description of search strategy and MeSH headings, see Appendix2). The reference 
list of related reviews and potentially relevant articles was checked for further studies. 
Citation lists of relevant articles were screened manually to ensure sensitivity of the search 
strategy. Repeated articles showed on the citation manager were deleted. Relevant journals 
were identified and their index was searched manually to identify further important citations. 
3.5.4 Selection criteria  
The titles and abstracts of all articles identified through the electronic and hand searches were 
scanned independently and grouped into the clinical or the experimental group based on the 
search strategy. The scanned studies were passed through general eligibility criteria before 
being placed into their nominated groups. The general criteria for inclusion of primary studies 
in the clinical or experimental group were: 1) original paper; 2) abstract available; 3) clear 
reporting of association of inflammatory mediator expression with metastasis or role in 
specific metastatic stage; 4) sufficient key information as indicated by the score list; and 5) 
sufficient statistical data. General criteria for exclusion were: 1) duplicate; 2) non-original 
paper; 3) abstract unavailable; 4) missing key information or statistical data; 5) metastasis 
was not reported; and 6) haematological cancer. Articles in every group passed through 
specific inclusion/exclusion criteria as follows; 
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Clinical search: The selection was limited to human studies and included all longitudinal 
studies that presented data for progressing and non-progressing metastatic lesions. Case-
control and cohort studies were included. Potential randomised controlled trials and cross-
sectional studies were included if found.  
Metastatic progression was defined as having a distant disseminated tumour, either nodal or 
distant, as a consequence of the tumour under investigation versus tumour with no spread 
followed over time. The inclusion criteria were as follows: 1) a clinical study on human 
subjects either from biopsy, surgical specimen or bodily fluid (saliva, blood) samples, where 
clear diagnosis and histo-pathological assessment of the case and control group had been 
performed; 2) the inclusion of a control group for comparison; 3) correlation of the 
investigated inflammatory mediator with the metastatic spread of the tumour is reported; 4) 
measurement of inflammatory mediator protein, mRNA or genetic expression; 5) the cancer 
was not associated with another pre-existing condition; 6) TNM was the standard staging 
system used for tumour staging in the patients; and 7) the patient at the time of the biopsy or 
sample had not undergone any chemo or radio therapy. Follow-up period and sample size 
were not a critical factor in inclusion the study. 
Exclusion criteria for primary studies were: 1) duplicate studies; 2) non-human subject; 3) no 
control group; 4) case report studies; 5) review articles were excluded from the primary 
search but categorised for extraction of relevant articles; 6) no follow-up was reported; 7) 
other prognostic outcome (not metastatic progression) was reported; and 8) 
chemo/radiotherapy treatment of the control or the case subjects before the intervention 
(surgical resection was not an exclusion criteria). 
Experimental search: The main criteria for including studies were: 1) experimental animal 
studies reporting the expression/inhibition of specific inflammatory mediators and their 
effects on a specific metastatic stage; 2) evaluating the potential association of the 
measurement of inflammatory mediators with the different stages of disease progression; 3) 
specific inhibition was carried out through the use of antibodies, gene knockdown, miRNA, 
or ablation experiments; and 4) NSAID was included in studies where it was used to inhibit 
the action of a specific inflammatory mediator.  
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Exclusion criteria were: 1) no control group; 2) the inflammatory mediator was expressed as 
a downstream to another molecule; and 3) only the expression was reported with no 
association with disease progression.  
 
3.5.5 Data extraction  
Once finalised, eligible articles were obtained and the data were extracted using a specific 
reporting form for each of the (clinical or experimental) groups. Data extraction forms for the 
clinical research recorded the following information; study title, score, inflammatory 
mediator, number of patients, number of controls, lymph node or distant metastasis, 
correlation with staging, correlation with specific metastatic stage, correlation with other 
prognostic factors, in-vivo validation and remarks. In the experimental search, the form 
contained the following information; article title, score, inflammatory mediator, type of 
animal, method of measurement, downstream pathway, cell of origin, inhibition method and 
remarks. The forms were prepared using Microsoft Access software to facilitate report 
preparation. 
3.5.6 Critical appraisal of studies   
The REMARK Quality Guideline Scale was used to assess the quality of the studies for the 
clinical search (364). The scale was modified to have a score of 16 for the included studies 
(Appendix 3). Animal research: Reporting In-vivo experiments (ARRIVE) guidelines were 
used to assess the quality of the animal studies (365). The original 20-item-checklist 
guideline was modified to meet the specific aims and objectives of the current review (Index 
2). The modified 19-item list scored each item on a scale of [0-1] or [0-1-2].  
 
3.6 Results  
Initially, 5,278,203 articles were found through the general search with the truncated form of 
“Inflammation”, “Cancer”, and “Metastasis”. The search with the specific terms yielded a 
total of 277,974 papers. By scanning through the titles of those articles, 35,111 studies were 
identified as relevant for the review, 19,564 articles were excluded as being irrelevant, 1,345 
systematic reviews and 116 meta-analysis studies were excluded but were further scanned for 
any potential articles, 14,086 research articles were assessed through the abstract, of which 
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3,492 and 3,712 articles were excluded for exclusion criteria and duplication, respectively. 
The remaining articles were divided into 3,103 clinical studies and 3,379 experimental 
studies.  
 
I: Clinical study selection and characteristics: The flow diagram of the retrieved articles for 
the clinical search is shown in Fig. 3.1. In total, 78 articles were obtained for the final 
selection, 50 articles from the clinical search, and 28 from the experimental search.  By 
examining the full text of the articles, 62 articles were excluded due to: full article not 
available; in-vivo study (moved to the experimental group); only the expression of the 
inflammatory mediator with no association to metastasis; not enough data (as per the scoring 
guideline); not statistically significant; outcome other than metastasis was reported; or the 
cases have a pre-operative chemo/radio treatment. Sixteen articles were eligible for the 
review and were scored accordingly (Fig. 3.3). The review identified nine inflammatory 
mediators associated with metastasis. Fifteen articles reported lymph-node metastasis and one 
article reported both lymph node metastasis and distant metastasis. Four articles were clearly 
associated with stages of metastatic cascade and five studies were validated with in-vivo 
studies. The inflammatory mediators identified were CXCR4 (six studies), CXCL12 (SDF-1), 
CCR7, IL-6 (two studies each), IL-18, CCL20 (MIP-3), CXCL1 (GRO-1), CCL3, CXCR2 
(one study each). 
II: Experimental studies selection and characteristics: The flow diagram of the retrieved 
articles for the experimental search is shown in Fig. 3.2. Fifteen articles were identified for 
review. Eleven articles were excluded due to: in-vitro experiments; non-specific inhibition; or 
other outcomes than metastasis. Four articles were included in the final review and have been 
scored (Table 3.1). Three inflammatory mediators have been identified as follows: CXCR4, 
CXCL12 and CXCR7. Three articles reported lymph node metastasis and one reported both 
LN and DM, with all experiments conducted in BALB Nude mice. Finally, two articles 
detailed the downstream pathway of the inflammatory mediator, and all the articles addressed 
specific metastatic stage (adhesion and extravasation).  
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Figure 3.1: Flow diagram of clinical studies search and selection. 
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Figure 3.2: Flow diagram of experimental studies search and selection. 
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3.7 Discussion  
Metastasis remains the major cause of fatality in cancer. Despite extensive research, little is 
known about the precise mechanism of this process (146). The link between metastasis and 
inflammation has been firmly established, however, an understanding of this interaction for 
clinical use remains obscured (366).  
 
This review systematically summarises the evidence of the prognostic role of inflammatory 
mediators in predicting metastasis/metastatic stages in OSCC. Additionally, it compares the 
available evidence from clinical and experimental animal settings. The clinical search of the 
review identified nine inflammatory mediators associated with lymph node metastasis and 
one associated with distant metastasis. The experimental search identified three mediators, all 
of which were included in the clinical search. These inflammatory mediators are discussed 
below. 
 
CXCL12/CXCR4 axis is composed of CXCR4 polypeptide receptor that binds to its conical 
ligand CXCL12 (SDF-1) and is responsible for a variety of physiological processes e.g. 
lymphocyte homing, development, and vascularisation (367). It has been shown to be highly 
expressed by numerous types of tumours with a significant correlation with metastasis (367). 
Several mechanisms have been hypothesised to explain its role in metastasis. First, CXCR4 
acts as a chemotactic factor which is expressed by tumour cells migrating towards an 
increasing CXCL12 gradient in the lymph nodes (368). Further evidence for this role is 
provided by Olivira et al. (369) who showed that non-metastatic lip SCC samples did not 
express either CXCL12 or CXCR4. Uchida et al., (373) – the only study that was validated 
with animal model – showed that CXCR4 has a similar expression both in tumour tissue and 
metastatic lymph node, whereas SDF-1 is higher in metastatic lymph nodes. In the animal 
models, they obtained similar results with heavier staining scores and more numbers of 
lymph node and lung metastases showed autocrine signalling, however, there was no 
comparison with a non-metastatic group. 
 
Second, the activation of CXCR4 due to HIF production, that is induced by the limited 
supply of oxygen to the neoplastic cells, initiates a cascade of downstream pathways leading 
THE EFFECT OF SUBSTANCE P (SP) ON ADHESION OF JURKAT 
LEUKAEMIA CELLS AND SQUAMOUS CARCINOMA CELLS 
(SCC) TO VASCULAR ENDOTHELIAL CELLS AND ROLE IN 
METASTASIS 
Moustafa Elhousiny Page 53 
 
 
to more invasive phenotypes (370). Third, Albert and Lee et al. (371, 372) suggested that 
CXCR4 is responsible for the induction of  
 
Figure 3.3: Articles included in the clinical search. 
 
EMT phenotype as well as MMP2/9 expression. Fourth, Ucida et al. (373-375) suggested the 
CXCR4/SDF-1 axis activates the ERK/AKT/SRC family of kinases. However, the included 
articles (n=7 for clinical, n= 3 experimental) for CXCR4 and CXCL12 did not report the role 
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of these chemokines as a cancer stem cell niche (which has been reported in other studies and 
a role for which has been suggested in the invasive ability of tumours harbouring those 
mediators) and their role in metastasis. Only one experimental study reported the occurrence 
of distant metastasis in the animals. These results suggest a strong role for CXCR4/CXCL12 
for prognosis and predicting lymph node metastasis in OSCC.  
 
A hypothesis can be constructed that CXCR4 is up-regulated in tumour cells due to a hypoxic 
environment. This activates downstream pathways which endow tumours with EMT, invasive 
phenotype and mitogenic signalling. These cell populations mark a new stem cell-like niche 
with growth and migratory advantages, and therefore will be selected to migrate towards 
gradient of CXCL12 displayed by lymph nodes. 
 
Table 3.1: Articles included in the Experimental Search. 
Auth. 
Year 
Score I.M Type 
of 
Animal 
Dowstream  Stage Cell of 
Origin 
Method Remarks 
Xia 
[366]   
2015 
12 CCR7 BALB 
mouse 
NA NA Tumour 
Cell 
Knock-
down  
T. met to LN 
(IM act on 
adhesion) 
Uchida
[377] 
2007 
11 CXCL1
2 
BAL
B 
mouse 
NA NA Tumo
ur 
cells 
Over-
expression 
LN and DM 
met (adhesion 
and 
extravasation) 
Uchida
[380] 
2003 
8 CXCR4 BAL
B 
mouse 
Yes NA Tumour 
cells 
NA LN (adhesion 
extravasation 
and  
downstream 
pathway) 
Uchida
[375] 
2004 
13 CXCR4 BAL
B 
mouse 
Yes  NA Tumour 
cells 
Over-
express
ion  
LN (adhesion 
and 
extravasation 
and pathway) 
* Abbreviations: DM: distant metastasis, IM: inflammatory mediator, LN: lymph node 
metastasis. 
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CCR7 is a trans-membrane receptor that exerts its action by binding to its ligands CCL21/19 
and it is expressed by many immune cells for homing and directional movement of these cells 
(376). CCR7 has been reported to be associated with lymph-node metastasis in several 
tumours (377). Similarly, Xia and Shang et al. described a significant association of this 
receptor with LNM with no distant metastasis (378, 379). Moreover, Adenoid 
cystocarcinoma, which commonly migrates through a hematogenous pathway, did not 
migrate to a gradient concentration of CCL21. The studies suggested an adhesion mechanism 
between CCR7 expressing tumour cells and lymph node cells, explaining the LNM tendency.  
 
IL-6 cytokine can exert either an inflammatory response through autocrine signalling to its 
IL-6R receptor or an anti-inflammatory effect through a paracrine signal via GP130 protein 
(380). Recent studies showed that IL-6 can activate several downstream pathways and it is 
correlated with several types of cancer (381). Due to the complex network activated by IL-6, 
it is difficult to pinpoint its role in metastatic process (381), however, Shinriki et al. showed a 
significant correlation with IL-6 and LNM as well as a correlation with VEGF-C and 
lymphogenesis suggesting a direct effect for IL-6 in the process of metastasis (382). Wang et 
al., was the only study to report an association of an inflammatory mediator with distant 
metastasis, though they did not report specific organ preference (383). More interestingly, 
there is a negative correlation between IL-6 mRNA and the presence of either LNM or DM. 
These conflicting results need further validation to pinpoint the actual role of IL-6. 
 
IL-18 is an IL-1 superfamily cytokine which is reported in the only study in the review to 
report genetic polymorphism (384). The results concluded that G/C heterozygous is a factor 
in increasing OSCC susceptibility though a protective factor against metastasis. 
 
CXCL1 (GRO-1) Shintani et al. (385) found that GRO-1 is significantly correlated with 
LNM, MVD and leukocyte infiltration, which suggests a role for GRO-1 in attracting 
immune cells to the tumour for deploying in new vessel formation.  
 
CCL20 (MIP-3) is a small peptide chemokine with a selective, pleiotropic ligand CCR6 
(389). It has been found to be expressed in liver, mucosa-associated lymph tissue and other 
lymphoid tissue with a main function of recruiting CD34+ (389). CCL20 activates the conical 
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inflammatory pathway NF-kβ and might implement an autocrine manner via activation of 
ERK1/2-MAPK and PI3K pathways (390). This evidence is supported by high expression of 
CCL20 both by highly metastatic colorectal and lung tumours (389, 390). Chang et al. (388) 
showed that MIP-3α was significantly overexpressed by positive lymph node patients 
(P=0.036). This expression was demonstrated to be expressed by the tumour cells versus the 
normal epithelium. They applied in-vitro interfering RNA to CCL20 which inhibited the 
cancer cell migration and proliferation.  
 
CCL3 Macrophage inflammatory protein-1α is a member of the CC inflammatory 
chemokines. They are able to induce chemotactic mobilisation of monocyte-lineage cells and 
lymphocytes into inflammatory tissues as well as the proliferation of haematopoietic 
stem/progenitor cells (391). Only one study reported the expression of the inflammatory 
mediator CCL3 in metastatic lymph nodes and non-metastatic lymph nodes (386). They 
found that CCL3 was significantly higher in metastatic lymph nodes compared with non-
metastatic lymph nodes of the same patients (P=0.013). In contrast, another study showed 
CCL3-secreting tumours resulted in similar increases in CD4+ and CD8+ T cells, resulting in 
immune activation against a murine colon tumour model CT26 (392). Those results might 
indicate a different role for CCL3 in neoplastic progression, depending on the stage of the 
neoplasm as well as the specific tissue microenvironment, which warrants further validation.  
 
CXCR2 is chemokine receptor that binds with high affinity with CXC chemokine ligands 
which contains the ELR positive motif (chemokines responsible for neutrophil chemo-
attractant) (393). CXCR2 has been postulated to play a vital role in the progression of various 
cancers presumably by enhancing angiongenesis, chemoresistant as well as chemo-attractant 
characteristics (394). This is evidenced through the inhibition of CXCR2 either by 
knockdown, deletion, or suppressing its downstream resulted in suppression of metastasis and 
enhancement of chemotherapy efficacy (395). Qian et al. found a significant expression of 
CXCR2 in OSCC patients with cervical metastases. They attributed the role of CXCR2 in 
tumour progression and OSCC LN metastasis was mainly attributed to the ability to invade as 
well as modifying cytoskeleton structure (387). 
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It is well established from several studies that inflammatory processes in cancer can activate 
signalling pathways, which lead to the remodelling of the tumour microenvironment (396). 
This remodelling is accompanied by a profile of inflammatory mediators (e.g. cytokines or 
chemokines) that can be either a driver or an inhibitor of tumour progression. Hence the stage 
of the tumour (progressing or dormant) and the profile of the existing inflammatory 
mediators prognosticate the tumour progression and metastasis. Our review has identified two 
cytokines, three chemokine receptors and four chemokines. This profile was associated with 
cervical metastasis and three of those mediators were further validated through the 
experimental animal models.  
 
It is not surprising that the majority of the panel is chemokines and their receptors with their 
well-known function as chemo-attractant for cell trafficking, homing and upregulating 
endothelial cell adhesion moelcules (397). CXCL12, CXCR4 and CCR7 are known to be of 
the basal (homeostatic) chemokines/receptors produced by different lymphoid organs and the 
receptors displayed by cells supposed to home to those organs. In particular, CCR7 is 
expressed by antigen presenting cells, whereas its ligand is expressed by lymph node (378). 
Meanwhile, CXCL12/CXCR4 is the main axis expressed by bone marrow niche for B-cell 
maturation. CXCR2, CCL3, CXCL1 and CCL20 are inflammatory chemokines that are 
produced in high quantities in inflammatory lesions to attract all types of leukocytes (386). 
Recent experimental investigations are revealing more roles for those mediators in early 
stages of metastasis, such as recruitment of myeloid stem cells for endothelial cell 
proliferation (e.g. CXCL12) (398). Others are suggested to be the regulators of the stem-cell 
nature of those cells (CCL3) or promote angiogenesis directly. IL-6 has been implicated in 
EMT program activation and circulating tumour cell seeding which explains its association 
with distant metastasis (398). 
 
Cancer immunotherapy has achieved some success with some inflammatory mediators being 
used as an adjuvant to increase efficacy metastatic treatment (399). However, the complexity 
of the immunomodulators and their interaction within the tumour domain is challenging and 
will require time to unravel the precise mechanism and role for each tumour. Furthermore, 
the timing of the treatment for metastasis proves to be a critical factor and it has been shown 
that preventing metastasis in animal model was more effective than reversing the process 
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once it has been initiated (400). Therefore, we propose validating this panel with a cohort 
study for prediction of metastatic progression in OSCC high-risk patients such as recently 
diagnosed or precancerous patients.  
 
The review supplemented the clinical data with experimental information which proved 
critical in overcoming the shortcomings of either the clinical or experimental studies. A 
profound disadvantage of the clinical studies is the difficulty in monitoring specific 
metastatic stages as well the uncontrolled experimental condition. While the experimental 
studies do not have such problems, they possess another set of issues such as having an 
immunocompetent model which is technically challenging and time-consuming. On the other 
hand, implementing an immunodeficient model represents a highly biased design. This 
highlights the need for new experimental models which are more robust, representative and 
experimentally reliable. The advent of new molecular biology tools and imaging will 
facilitate such models (e.g. microfluidic metastatic models). 
 
A summary of the findings of the review includes: 1) there was an overwhelming amount of 
information about the involvement of inflammatory mediators in OSCC but this information 
is not in a systemic order to allow for better understanding of their specific role; 2) most of 
the studies did not take metastasis into account as a prognostic outcome but considered other 
prognostic points such as tumour stage or size; 3) there is a clear gap between clinical and 
experimental information, where most of the clinical studies are not supplemented with 
enough experimental data for validation and explaining the biological mechanism; 4) the 
reporting of the association of inflammatory mediators with metastasis lacks precise 
highlighting of their role in specific metastatic stages either in clinical or experimental 
research and some critical metastatic stages such as extravasation could not be detected at all 
in any clinical studies, reflecting the lack of proper experimental tools; and 5) it is more 
likely that a panel of mediators, rather than a single one, orchestrates the metastatic cascade.   
 
Research in such areas is very cumbersome as most of the above-mentioned inflammatory 
mediators have redundant pathways and therefore underpinning their main role is a very 
challenging task. Moreover, most of these mediators have vital physiologic functions and 
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thus interfering with them may result in a catastrophic adverse effect to the cancer patients, 
which may partly explain the slow pace of research in this area.  
 
Some limitation does exist with this review with the small number of studies. Additionally, 
some of the potential articles were difficult to obtain for the final analysis. However, the 
review represents a starting point for a new direction in researching the role of inflammatory 
mediators in the prediction and prevention of OSCC. 
3.8 Conclusion  
Metastasis is a fatal consequence of cancer and so a new paradigm needs to be followed in 
research. Evolutionary insights and experimental evidence are revealing an intricate 
relationship between cancer and its microenvironment with inherent weaknesses and 
strengths on the host and tumour sides. The review revealed a panel of inflammatory 
mediators, each responsible for a pathway/stage in metastasis. Despite requiring further 
validation, this panel can be implemented for the introduction of a new “Metastasis early 
monitoring and prediction” tool similar to cancer early-prevention tutorials. The review 
provides a panel of inflammatory mediators that can be used, after proper validation, in 
clinical settings in high-risk groups of patients and in-vivo to elucidate the specific correlation 
of these mediators with specific stages and their mechanisms. However, such validation will 
require a new and reliable experimental method that can avoid the high technicality of animal 
models, with the ability to detect precisely every stage of metastasis in a way that mimics the 
in-vivo environment. 
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4.1 Concluding remarks from the literature and systematic review  
The previous two chapters discussed the overall picture of metastasis and its underlying 
factors and mechanisms. The findings from the two chapters can be summarised in a few 
points. Metastasis is the main cause of death in cancer patients and even with aggressive 
treatment in place, there is only a slight improvement in survival and patient outcome. 
Models of metastasis on an evolutionary basis fail to improve this outcome mainly due to a 
lack of understanding of the key players in the process. The systematic review pinpoints a 
panel of inflammatory mediators that are shown to be active players in the clinical and 
experimental studies. The literature review highlights these findings by revealing the 
accumulating evidence to understand metastatic mechanisms. Extravasation remains a rate-
limiting step in metastasis, which requires inflammatory mediator, adhesion molecules, and 
proteolytic enzymes (e.g. MMP). The review also shows the inevitable role of inflammation 
as the main driver of metastasis and this is slowly being underpinned. Putting these pieces 
together, metastasis bears a striking similarity with inflammatory processes, in particular the 
extravasation step. Both processes need adhesion molecule expression, adhesion of the 
migrating cell to endothelium, and proteolytic enzymes to cross blood vessels. Moreover, 
inflammatory mediators can drive all these steps in both processes. The logical consequence 
here is to find the common mediators in both metastasis and inflammation, and by blocking 
them, we can interfere with the spread of tumours. That is what the systematic review shows. 
However, a clinical problem appears, in that the extracted inflammatory mediators are critical 
to physiological body functions, hence blocking them will cause more severe side effects than 
the treatment. Therefore, these mediators can be implemented for prognostic purposes but not 
for clinical intervention. With that in mind, the review sets a criterion for an effective 
intervention inflammatory mediator. It can be defined as a substance that mediates 
inflammatory adhesion, expressed in tumours, and, most importantly, its role is mainly 
pathologic. Therefore, antagonists to this mediator can prevent metastasis while not causing 
much harm to normal body functions.  
4.2 Rationale of the study 
Metastasis is the prime cause of mortality in 90% of cancer patients, particularly OSCC. The 
incidence of metastasis significantly reduces the prognostic outcome. More than half of 
neoplasms will have disseminated lesions at the time of primary diagnosis, which render 
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these cases with very poor survival rates. The high risk of cancer metastasis mandates 
aggressive therapeutic modalities in an attempt to prevent their occurrence. However, even 
with the most advanced treatments, little or no improvements have been achieved in the 
outcome of the most advanced-stage cancers. The complications of these treatments outweigh 
their benefits resulting in severe disfigurement, poor psychological wellbeing, poor quality of 
life, toxicity and even death to the patients. Recurrence is the end-result in most of these 
cases (even with multi-modality treatment) signalling the failure of those treatments.  
 
Oral cancer is a highly invasive disease, which is often diagnosed in an advanced stage with a 
relatively poor prognosis. Furthermore, the burden of metastasis is evident even in early 
stages (despite high survival figures), in which the occurrence of occult metastasis 
significantly affects this outcome in terms of survival or recurrence. The current methods of 
detecting metastasis, whether the invasive lymph node biopsy or the traditional histologic 
assessment, fails to detect early metastatic lesions. The inefficacy in exterminating metastasis 
stems from the lag in understanding the complex network of mediators controlling the 
underlying steps. This is reflected in clinical practice with an absence of reliable diagnostic or 
prognostic markers that can be used to accurately predict the presence or absence of micro 
metastases or an effective treatment for a total elimination of metastasis. While the oncology 
researcher’s main target is the early detection of primary tumours, longer survival periods are 
seen with more chances of metastasis and recurrence for those patients. In order to reduce the 
high mortality and morbidity rate of cancer patients, a better understanding is needed of 
molecular modulators, leading to metastatic seeding of the tumour cells and their homing in 
distant sites or lymph nodes.  
 
Tumour cell extravasation is an important, rate-limiting step in the process of metastatic 
spread. This study investigates the mechanisms of extravasation, and examines the action of 
one potential mediator of this process, SP. The effects of antagonising the actions of SP, 
through treatment with a selective NK1 receptor antagonist, are examined at Jurkat leukaemia 
cells as well as different stages of oral cancer and pre-cancer cell cultures, and the effect of 
this treatment on the adhesion of each cell line to endothelial cells is monitored. This will add 
to the current state of knowledge about the unknown “rate-limiting” extravasation stage as 
THE EFFECT OF SUBSTANCE P (SP) ON ADHESION OF JURKAT 
LEUKAEMIA CELLS AND SQUAMOUS CARCINOMA CELLS 
(SCC) TO VASCULAR ENDOTHELIAL CELLS AND ROLE IN 
METASTASIS 
Moustafa Elhousiny Page 63 
 
 
well as to an understanding of the role of inflammatory mediators and adhesion molecules in 
oral cancer metastasis. The study at this cellular level has the advantage of examining the 
relevant factors, thus, providing the raw data that can be integrated into a complex model that 
can be applied to in-vivo trials. The resulting model represents a novel approach in cancer 
treatment where the main target is prevention of metastasis incidence. This paradigm shift has 
a powerful potential to develop effective anti-metastatic therapies through interfering with the 
metastatic cycle. 
4.2 Study hypothesis 
  
 
 
 
 
 
 
 
 
 
 
 
 
4.3 Aims of the study 
The study’s overall objective is to examine the role of SP and the adhesion molecules in the 
adhesion of oral cancer cells to endothelial cells and the subsequent effect on metastasis of 
the tumour. To obtain the information that can establish the model to answer the main study 
question, the study has six main aims. 
Aim 1. To examine the adhesion of Jurkat cell lines to endothelial cells and to determine the 
effect of SP on this adhesion.  
SP increases the expression of adhesion molecules of leukaemia, 
oral squamous cell carcinoma cells and vascular endothelial cells 
so it facilitates the adhesion of invading tumour cells to the 
endothelial lining of the blood vessels which in turn enhances 
the metastatic potential of the tumour. 
 
STUDY QUESTION 
What is the effect of Substance P on the adhesion of 
leuakaemia and oral squamous cell carcinoma cells to 
vascular endothelial cells? 
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Aim 2. To examine the expression of adhesion molecules in Jurkat cell lines and to determine 
the effect of SP on this process. 
Aim 3. To examine the effect of the SP on the release of MMP-2 in Jurkat leukaemia cell 
lines. 
Aim 4. To examine the adhesion of different oral cell lines to endothelial cells and to 
determine the effect of SP on this expression.  
Aim 5. To examine the expression of adhesion molecules in different oral cell lines and to 
determine the effect of SP on this process. 
Aim 6.  To examine the effect of SP on the release of MMP-2 in oral cell lines.  
4.3.1 Study: To examine the effect of SP on the adhesion of Jurkat cell lines to the 
endothelial cells lines HUVEC.  
Study Question  
What is the optimal dose of Substance P required to produce early-response significant 
change in the adhesion of Jurkat cell and endothelial cell lines? 
This main question can be subdivided into the following sub-questions: 
a: What is the adhesion basal level of Jurkat cell lines to endothelial cells? 
b: Do different SP doses cause a change in the level of adhesion? 
c: Is this change of adhesion level between Jurkat cell lines and endothelial cells significant? 
Hypothesis  
Substance P treatment of Jurkat cancer cell lines does change the level of its adhesion to 
endothelial cells. 
Null hypothesis: Substance P treatment of Jurkat cancer cell lines does not change the level 
of its adhesion to endothelial cells. 
Aim 
1: Determine the basal level of adhesion of Jurkat cancer cell lines to the HUVEC cell lines.  
2: Determine the effect of SP treatment on this basal level of adhesion. 
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Materials and Method:  
1: Endothelial Cell Adhesion Assay Kit (Cat. No. ECM645, Millipore) are used as per 
manufacturer’s protocol to measure the basal adhesion level of Jurkat cell lines to HUVEC 
endothelial cells. 
2: This is repeated following the treatment of these cells with different doses of substance P. 
3: The experiments are divided into two groups. The first group will have only the cancer 
cells treated according to the protocol. The second group will have only the endothelial cells 
treated according to the protocol.  
4: Results are measured using a microplate reader and confirmed with the fluorescent 
microscope.  
5: Determine whether there is a significant difference between the results before and after 
treatment using ANOVA with P value=0.05 considered statistically significant. 
6: Optimise the assay procedures and controls. 
 
4.3.2 Study: To examine the expression of cell adhesion molecules in Jurkat cell lines and to 
determine the effect of SP on this adhesion 
Study Question  
What is the optimal dose of Substance P required to produce an early-response significant 
change in the adhesion molecules of Jurkat cell lines? 
This main question can be subdivided into the following sub-questions: 
a: What is the basal expression level of Jurkat cell lines? 
b: Do the different SP doses cause a change in the level of expression of adhesion molecules? 
c: Do the timings of SP treatment affect the level of adhesion molecule expression? 
d: Is there a change in the expression of adhesion molecules before and after treatment? Is it 
significant? 
Hypothesis  
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Substance P treatment of Jurkat cell lines does change the expression of the adhesion 
molecules. 
Null Hypothesis: Substance P treatment of Jurkat cell lines does not change the expression of 
cell adhesion molecules. 
Aim 
1: Determine the basal level of expression of cell adhesion molecule (VLA-4, LFA, SLeX) in 
Jurkat E-6 cell line.  
2: Determine the effect of SP treatment on this basal level of expression. 
Materials and Method:  
1: Use flow cytometry to measure the expression of these adhesion molecules in the Jurkat 
cell line before and after the treatment of these cells with different doses of SP. 
2: Mean fluorescence intensity for each replicate with reference supplied by the antibody 
manufacturer which will be used for statistical calculation before and after treatment.  
3: Determine whether there is a significant difference between the results before and after 
treatment using ANOVA with P value=0.05 with CI= 95% considered statistically 
significant. 
4.3.3 Study: To examine the effect of SP on the release of MMP-2 in Jurkat cell lines. 
 Study Question  
What is the optimal dose of Substance P required to produce an early-response significant 
change in the expression of MMP-2 in Jurkat cell lines? 
This main question can be subdivided into the following sub-questions: 
a: What is the MMP-2 basal expression level of Jurkat cell lines? 
b: Do different SP doses cause a change in the level of expression of MMP-2? 
c: Do the timings of SP treatment affect the level of MMP expression? 
d: Is there a change in the expression of MMP-2 before and after treatment? Is it significant? 
Hypothesis  
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Substance P treatment of Jurkat cancer cell lines does change the expression of MMP-2. 
Null hypothesis: Substance P treatment of Jurkat cancer cell lines does not change the 
expression of MMP-2. 
Aim 
1: Determine the basal level of expression of MMP-2 in Jurkat cell lines.  
2: Determine the effect of SP treatment on this basal level of expression. 
Materials and Method:  
1: Total MMP-2 ELISA (Enzyme linked immunosorbent assay), to measure the basal 
expression of MMP-2 in Jurkat cell lines. 
2: Using ELISA, to measure the expression of MMP-2 in these cell lines after the treatment 
of these cells with different doses of Substance P. 
4: Determine whether there is a significant difference between the results before and after 
treatment using ANOVA with P value=0.05 considered statistically significant. 
 
4.3.4 Study: To examine the effect of SP on the adhesion of different oral cell lines and 
endothelial cells.  
Study Question  
What is the optimal dose of Substance P required to produce significant change in the 
adhesion of OSCC and endothelial cell lines cell lines? 
This main question can be subdivided into the following sub-questions: 
a: What is the basal adhesion level of each cancer cell line to endothelial cells? 
b: Do different SP doses cause a change in the level of adhesion? 
c: Is this change of adhesion level between cancer cell lines and endothelial cells significant? 
Hypothesis  
Substance P treatment of oral cancer cell lines does change the level of its adhesion to 
endothelial cells. 
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Null hypothesis: Substance P treatment of oral cancer cell lines does not change the level of 
its adhesion to endothelial cells. 
 Aim 
1: Determine the basal level of adhesion of each (CAL 27, SCC 25, H157) oral cancer cell 
line, and BICR22 oral metastatic cell line to the HUVEC cell lines.  
2: Determine the effect of SP treatment on this basal level of adhesion. 
Materials and Method:  
1: Endothelial Cell Adhesion Assay Kit (Cat. No. ECM645, Millipore) is used as per 
manufacturer’s protocol to measure the adhesion level of CAL 27, SCC 25, H157 oral cancer 
cell lines, and BICR 22 oral metastatic cell line to HUVEC endothelial cells. 
2: The same assay is performed following the treatment of these cells with different doses of 
Substance P. 
3: The experiments are divided into two groups. The first group has only the cancer cells 
treated according to the protocol. The second group has only the endothelial cells treated 
according to the protocol.  
4: Results are measured using a microplate reader and confirmed with the fluorescent 
microscope.  
5: Determine whether there is a significant difference between the results before and after 
treatment using ANOVA with P value=0.05 considered statistically significant. 
6: Optimise the assay procedures and controls. 
4.3.5 Study: To examine the expression of cell adhesion molecules in different stages of oral 
cancer cell lines and to determine the effect of SP on this adhesion 
Study Question  
What is the optimal dose of Substance P required to produce an early-response significant 
change in the adhesion molecules of oral cancer cell lines? 
This main question can be subdivided into the following sub-questions: 
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a: What is the basal expression level of each oral cell line? Is there any difference between 
the expression of the adhesion molecules in normal and malignant cell lines? 
b: Do the different SP doses cause a change in the level of expression of adhesion molecules? 
c: Do the timings of SP treatments affect the level of adhesion molecule expression? 
d: Is there a change in the expression of adhesion molecules before and after treatment? Is it 
significant? 
Hypothesis  
Substance P treatment of oral cell lines does change the expression of the adhesion 
molecules. 
Null Hypothesis: Substance P treatment of oral cell lines does not change the expression of 
cell adhesion molecules. 
Aim 
1: Determine the basal level of expression of cell adhesion molecules (VLA-4, LFA, SLeX) 
in  normal oral keratinocytes, DOK, (CAL 27, SCC 25, H157) oral cancer cell lines, and 
BICR22 oral metastatic cell lines.  
2: Determine the effect of SP treatment on this basal level of expression. 
Materials and Method:  
1: Use flow cytometry to measure the expression of these adhesion molecules in the normal 
oral keratinocytes, DOK, (CAL 27, SCC 25, H157) oral cancer cell lines, and BICR22 oral 
metastatic cell lines before and after the treatment of these cells with different doses of SP. 
2: Mean fluorescence intensity for each replicate with reference supplied by the antibody 
manufacturer which will be used for statistical calculation before and after treatment.  
3: Determine whether there is a significant difference between the results before and after 
treatment using ANOVA with P value=0.05 with CI= 95% considered statistically significant 
4.3.6 Study: examine the effect of SP on the release of MMP-2 in oral cell lines. 
Study Question  
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What is the optimal dose of Substance P required to produce an early-response significant 
change in the expression of MMP-2 in OSCC and pre-cancer cell lines? 
This main question can be subdivided into the following sub-questions: 
a: What is the basal expression level of each cell line? 
b-: Do different SP doses cause a change in the level of expression of MMP-2? 
c: Do the timings of SP treatments affect the level of MMP-2 expression? 
d: Is there a change in the expression of MMP-2 before and after treatment? Is it significant? 
Hypothesis  
Hypothesis: Substance P treatment of oral cancer cell lines does change the expression of 
MMP-2 molecules. 
Null hypothesis: Substance P treatment of oral cancer cell lines does not change the 
expression of MMP molecules. 
Aim 
1: Determine the basal level of expression of MMP-2 in each of CAL 27, SCC 25, H157 oral 
cancer cell lines, and BICR22 oral metastatic cell lines.  
2: Determine the effect of SP treatment on this basal level of expression. 
Materials and Method:  
1: Total MMP-2 ELISA (Enzyme linked immunosorbent assay), to measure the basal 
expression of MMP-2 in the (CAL 27, SCC 25, H157) oral cancer cell lines, and BICR 22 
oral metastatic cell lines. 
2: Use ELISA (section 5.9) to measure the change in expression level of MMP-2 in these cell 
lines after the treatment of these cells with different doses of Substance P. 
4: Determine whether there is a significant difference between the results before and after 
treatment, using ANOVA with P value=.05 considered statistically significant. 
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4.4 Definitions of terminology  
Early-response: defined as the response to treatment in time scale from 1- 48 hours. 
Level of adhesion/expression of adhesion molecules: the quantitative measurement of these 
levels as shown by fluorescent methods such as plate reader for adhesion levels and flow 
cytometry as mean of events for cell population.    
Basal level of adhesion: the expression or the level of adhesion in untreated cell lines (also 
defined as the control adhesion level). 
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5.1 Cell lines  
Cell culture technique is a tool that involves removal of cells from human or animal tissues 
and propagating them to obtain a continuous cell culture that can be utilised for research 
purposes. The majority of cells used in this thesis are continuous cell lines derived from 
tumours that are illustrated for each cell culture. Cell culture is one of the major tools used in 
molecular biology research, providing excellent model systems for studying the normal 
physiology and biochemistry of cells (e.g., metabolic studies, ageing), the effects of drugs 
and toxic compounds in the cells, mutagenesis and carcinogenesis. It is also used in drug 
screening and development, and large-scale manufacturing of biological compounds (e.g., 
vaccines, therapeutic proteins). The major advantage of using cell culture for any of these 
applications is the consistency and reproducibility of results that can be obtained from using a 
batch of clonal cells. Another advantage with using cell culture is the ability to control 
experimental conditions and therefore to manipulate one specific experimental variable at one 
time. A major drawback is that cell culture does not measure the effect of microenvironments 
on the biological system and other tissue components. Nonetheless, it provides an 
inexpensive, quantitative tool to assess the initial effects of a drug or treatment before further 
proceeding with other expensive animal models or clinical trials. 
Cells were selected to present the progressive stages of oral cancer as follows: HOK primary 
oral keratinocyte isolated from human oral mucosa was purchased from Sciencell®. CAL 27 
(ATCC CRL- 2095) was obtained from tissue taken prior to treatment from a 56-year-old 
Caucasian male with a lesion in the middle of the tongue. SCC25 (ATCC CRL- 1628) tongue 
squamous carcinoma cell line is from a tongue carcinoma. Both were purchased from 
ATCC® cell lines and they are from negative lymph-node patients. DOK cell line was 
isolated from a piece of a dorsal tongue from a 57-year-old man with mild to moderate 
dysplasia. An H-157 cell line from oral squamous-cell carcinoma from a positive lymph node 
patient and BICR-22 cell line from OSCC lymph node metastases were purchased from 
Sigma-Aldrich®. The selection of the cells to represent the progressive stages of OSCC was 
intended as discussed earlier as this choice can monitor every stage within the tumour cycle. 
For example, the adhesion molecule expression as well as the adhesion of the tumour to the 
endothelial cells can be measured in every stage of the tumour development so as to identify 
how early those events are likely to occur in the tumour cycle. HUV-EC-C (ATCC CRL-
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1730) human vascular endothelium, Jurkat Clone E6-1(ATCC TIB-152TM) human acute cell 
leukaemia cell line lines were purchased from ATCC®.  
5.2 Culture Media  
Dulbecco modified eagle (DMEM) culture media, fetal bovine serum (FBS), endothelial cell 
growth supplement (ECG), L-glutamine, hydrocortisone, heparin sodium, and trypsin-EDTA 
were obtained from Sigma-Aldrich®. Eagles minimum essential medium (EMEM), F-12k 
medium, ATCC DMEM/F12 medium, vascular basal media, endothelial cell growth kit BBE, 
I-1640 media, and antibiotics were purchased from ATCC® cell lines. The oral keratinocyte 
medium was purchased from SciencellR. 
5.3 Treatment  
Substance P acetate salt hydrate (SP) and [succinyl-ASP6,ME-PHE8] Senktide Substance P 
analogue were purchased from Sigma-Aldrich®. Tumour necrosis factor (TNF-α) was 
purchased from Sigma-Aldrich. The selective NK1 antagonist, CH123001 (N-(3,5-bis-
trifluoromethyl-benzyl-N-methyl-6-4-methylpiperazin-1,4-(o-tolyl-nicotinamide), was 
provided by CH Biotech Pty Ltd, Sydney, Australia. 
5.4 Cell culture  
For SCC25 A 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 medium 
containing 1.2 g/L sodium bicarbonate, 2.5 mM L-glutamine, 15 mM HEPES and 0.5 mM 
sodium pyruvate and supplemented with 400 ng/ml hydrocortisone and 10% FBS was used 
for culture. 
CAL27 was cultured in Dulbecco’s Modified Eagle’s Medium with FBS to a final 
concentration of 10%.  
DOK cells were cultured in DMEM + 2mM Glutamine + 5μg/ml Hydrocortisone + 10% 
FBS. 
For HOK, OKM consists of 500ml of basal medium, 5ml of oral keratinocyte growth 
supplement and 5ml of penicillin/streptomycin solution.  
Jurkat cells Clone E6.1 was cultured in RPMI 1640 + 2mM Glutamine + 10% FBS. 
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HUVEC-EC was cultured in F-12K Medium, with 0.1mg/ml heparin; 0.03-0.05mg/ml 
endothelial cell growth supplement (ECGS) adjusted to a final concentration of 10% FBS.  
 
5.5 Culture method  
All culture procedures were carried out under sterile conditions within a laminar flow hood, 
with all equipment sterilised in an autoclave and all solutions were either sterile filtered, 
autoclaved or obtained sterile. Cultures were incubated in a 37°C incubator with 5% CO2 in 
air atmosphere. Most of the experimental procedures used cells in passage 3-9.  
5.5.1 Resuscitation of frozen cells.  
Upon receiving frozen cell ampoules, the cap of the ampoule was wiped with 70% alcohol 
immersed tissue in the laminar flow cabinet. The ampoule was quickly transferred into a 
water bath at 37C for 1-2 minutes. The ampoule was then wiped with 70% alcohol. The 
content of the ampoule was pipetted into a pre-warmed appropriate complete media in the 
culture flask. The cell density was adjusted according to the supplier data sheet. Cells were 
incubated in incubator at 37C and 5% CO2 level. Media was changed the next day. 
5.5.2 Subculturing Cells.  
Once the cells achieved 70-80% confluence, they were split at a ratio recommended by the 
manufacturer. The culture medium was discarded and the cells were briefly rinsed with 
trypsin 0.25% / EDTA 0.2% for the specified time on the data sheet. Cells were observed 
under the light microscope until they became round in shape and detached. Once the majority 
of the cells detached from the culture vessel, growth media with trypsin inhibitor was added 
rapidly to stop the enzymatic actions. The contents of the flask were pipetted to a 15ml tube 
and centrifuged at 1000RPM for 5 minutes and the cells were resuspended in 5ml of fresh 
growth media. Cells were counted and then seeded in culture plates for subculturing or used 
for experimental procedures or aliquot and frozen at -80C. Every cell line has a cell record 
and log to describe each procedure and the number of passages and special requirements for 
this cell type. Cells were used in passage 3-9 for the experimental purposes.   
THE EFFECT OF SUBSTANCE P (SP) ON ADHESION OF JURKAT 
LEUKAEMIA CELLS AND SQUAMOUS CARCINOMA CELLS 
(SCC) TO VASCULAR ENDOTHELIAL CELLS AND ROLE IN 
METASTASIS 
Moustafa Elhousiny Page 76 
 
 
5.6 Flowcytometry Antibodies Anti-integrin alpha 4 antibody CD49d PE (12-0499), 
Mouse IgG1 K isotype control (124714), Anti- CD11a antibody FITC (BMS102FI) were 
purchased from affymetrix eBioscience®. Anti CD15S Mouse anti human Alexa Flour 647 
(563526), Alexa Flour 647 Mouse IgM isotype control was purchased from BDR.  
5.7 Adhesion molecule expression by flow cytometry 
Flow cytometry measures single cells “flowing” through a detector system. The process 
begins with the selection of fluorescent-labelled antibodies specific to cell-surface markers 
used to characterise the cell population of interest. These cell surface markers are usually 
called cluster of differentiation (CD) markers. In our study, we used CD markers that 
represented antibodies to the adhesion molecules expressed by the cell.  
The sample is processed with enzymatic degradation, centrifugation, and/or filtration to 
isolate the cells of interest, and the resulting cellular suspension is “stained” with fluorescent 
antibodies. The single cell suspension is then introduced into the flow cytometer into a cell-
free buffer solution, called the sheath fluid, which flows towards a laser aimed at the 
solution’s path (optic part of the flow cytometry). Because the flow of the liquid through the 
tubing is laminar, or sheet-like, and the diameter of the tubing narrows along its path, the 
cells are forced to line up single-file as they approach the laser. The fluorescent chemical 
bound to the antibody, called a fluorophore, is chosen based on the specific wavelength of 
laser present in each flow cytometer. If cells have the selected marker on the surface, the 
bound antibody-fluorophore will absorb the laser energy and subsequently release it in the 
form of a specific wavelength of light as the cells pass through the laser. The emitted light is 
detected by an optical system that is sensitive to various wavelengths, allowing for 
information on multiple surface markers to be read simultaneously and collected by an 
adjoined computer. Specialised software then can graphically represent the distribution of the 
labelled cell populations in one-, two- or three-dimensional formats. A variety of 
fluorochromes are available that individually emit light of specific, different wavelengths 
while absorbing light of the same wavelength. This is the basis for polychromatic flow 
cytometry, and it allows for a flow cytometry sample labelled with different fluorochrome–
antibody complexes to be read simultaneously with one pass through the laser. This is the 
technique that was implemented in this study to enable the analysis of multiple cell adhesion 
molecules at once. Flow cytometry offers a powerful analytic tool that can provide precise 
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information about the expression of specific molecules on the cell. It also provides a high-
throughput, quantitative technique that is less time-consuming and has more productivity. 
Some limitations exist with flow cytometry. Extensive data production makes analysis hard 
and time-consuming. Also, no information is available about the tissue structure. But for the 
purpose of this study, these limitations were of no great concern.  
In general, cells were harvested after serum starvation with serum-free media for 12 hours 
before the beginning of treatment and washed as a single-cell suspension in 96-well round-
bottomed microtiter plates. Density was adjusted to a concentration of >50,000 cells/ml then 
the media was discarded and the cells were twice washed and centrifuged in an ice-cold 
FACS Buffer. 
An antibody cocktail was made at a 1:20 concentration with the FACS buffer with 50μL for 
each sample; 50μL of antibody cocktail was added and the sample was incubated for at least 
30 minutes at room temperature or 4°C in the dark. The cells were washed with FACS buffer 
three times by centrifugation at 1500RPM for 5 minutes and resuspended in 200μl to 1ml of 
ice-cold FACS buffer. The cells were kept in the dark on the ice or at 4°C in a fridge until 
analysis. 
  
 
Figure 5.1: High and low density of HUVEC endothelial cell lines with permission of 
ATCC®. 
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Figure 5.2: High and low density of SCC 25 oral squamous tongue cell lines grown in 
culture with permission of ATCC®. 
 
5.8 Cell adhesion assay  
The CHEMICON® Endothelial Cell Adhesion Assay kit (ECM645) is designed to test a 
variety of cell types that interact with activated or inactivated endothelial cell layers. The 
CHEMICON® Endothelial Cell Adhesion Assay kit includes a 96-well tissue culture treated 
fluorescence microtiter plate and reagents that allow for large-scale screening and 
quantitative comparison of multiple samples/cell line adhesion to an endothelial monolayer. 
Once endothelial cells are seeded in the tissue culture plate, they can be treated with 
cytokines, chemokines, transcription regulators or selective adhesion inhibitors. The protein 
synthesis inhibitor Cycloheximide and the RNA synthesis inhibitor Actinomycin D are 
provided as controls for adhesion protein expression studies.  
 
The viable cell fluorescent compound Calcein-AM® is provided for labelling test cells and 
quantifying their adhesion by comparing bound versus unbound cells. The kit includes three 
Mouse anti-human monoclonal mAbs for adhesion blocking studies of ICAM-1, VCAM and 
E-selectin endothelial cell surface markers. These may be used to verify changes in 
expression levels of adhesion molecules, or effects of integrins upon endothelium activation.  
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This simple and high-throughput kit format allows for the monitoring of the effects of a 
variety of conditions and compounds on endothelial adhesion. CHEMICON® also offers a 
variety of antibodies to leukocyte adhesion molecules and surface antigens.  
ECM645 was obtained from Merckmillipore®. Briefly, HUVEC cells were grown as normal 
to 80% confluent. Cells were then harvested (see subculture methods 5.5.2) after serum 
starvation, then seeded at a density of 50,000 in a 96-well plate or 10,000 in a 384-well plate. 
The plate was incubated for 48 hours at 37C in a CO2 incubator and cells were verified 
microscopically to ensure cell viability. In all the experiments of adhesion, half of the 
endothelial cells were treated or inhibited where the media and the dose were adjusted to the 
desired concentration and time. Tumour cell lines were grown to 80% confluent, harvested 
and viability determined. Cells were seeded in plates at 200,000 cells/ml for a 96-well plate 
and 50,000 for a 384-well plate and the appropriate treatment was applied to each well. After 
treatment, both the endothelial cells and tumour cell media were discarded and tumour cells 
were treated with Calcein-AM to a final concentration of 2.5μM. Cells were then incubated 
for 30 minutes and centrifuged at 400Xg for 5 minutes. Cells were washed three times in PBS 
buffer until all the remnant solution was removed. Cells were suspended in 1-5ml of assay 
buffer. Tumour cells from each well were pipetted with the media to the corresponding well 
of endothelial on the fluorescent plate. Cells were covered and incubated for 30 minutes. The 
majority of the solution was then aspirated and discarded. Nonspecific binding was removed 
by washing each well 2-3 times with the assay buffer. After washing, the plate was read with 
a fluorescence plate reader using 485/530nm excitation/emission filter sets. Experiments 
were done in four replicates or duplicates and repeat. 
The experimental design was divided into two groups as in the following diagram; 
Group/Experiment 
Sample size n=20 
Tumour treated group 
When incubating the 
tumour and endothelial 
cells only the treatment has 
been applied to the tumour 
cells 
 
Endothelial treated group 
The same protocol but in this 
group the treatment has been 
applied to the endothelial cells. 
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Negative control Untreated 
endothelium/untreated 
cancer cells 
Untreated endothelium/untreated 
cancer cells 
Experimental 
group 
(stimulation) 
Untreated 
endothelium/treated cancer 
cells with SP 
Endothelium treated with 
SP/untreated cancer cells  
Experimental 
group (inhibition) 
Untreated 
endothelium/treated cancer 
cells with NK-1R inhibitor 
Endothelium treated with NK-1R 
inhibitor/untreated cancer cells  
Experimental 
group (inhibition) 
Untreated 
endothelium/treated cancer 
cells with (monoclonal 
antibody) 
Endothelium treated with 
monoclonal antibody/untreated 
cancer cells  
Positive control Untreated 
endothelium/treated cancer 
cells with TNF 
Endothelium treated with 
TNF/untreated cancer cells 
 
Cell adhesion was measured as a percentage of the basal adhesion according to the following: 
Particular cell adhesion plate reader value                                       
Basal value plate value (non-treated cell adhesion value) 
 
5.9 Quantikine total MMP-2 ELISA kit  
Description of the procedure: The kit utilises an enzyme-linked immunoassay sandwich 
technique. The antibody used is a monoclonal epitope highly specific to MMP-2 which has 
been coated on the microplate. The proper samples and controls are added to the wells of the 
plate and washed after binding to MMP-2 and then a secondary antibody is added and then 
washed. Finally, the substrate is added for colour development. The ELISA assay has a very 
high sensitivity to detect very low concentrations of the antigen represented in the biological 
    X 100 
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system. It also plots those concentrations against a standard curve of serial dilutions of a 
conjugate protein supplied by the manufacturer. This data is plotted with the log of the total 
antigen concentration versus the optical density reading of the plate reader for the sample. 
The kit was obtained from R&D® Systems. Media from treated and untreated cells are 
collected and stored at -20C. 50 μL of assay diluents R1-116 is added to each well. A 50 μL 
of standard, control or sample is added to each well and incubated on an orbital microplate 
shaker (0.12”) orbit at 500RPM. After incubation, each well is washed with wash buffer three 
times using a squeeze bottle. A 200 μL of Total MMP-2 conjugate is added to each well and 
incubated for another two hours. The washing procedure is repeated after incubation. A 200 
μL of substrate solution is added to each well and incubated for 30 minutes at room 
temperature in the dark. A 50 μL of stop solution is added to each well until the colour 
changes to yellow. Immediately the optical density of each well is determined using a 
microplate reader set to 450 nm and wavelength correction to 540-570 nm. Cells are either 
untreated, treated with SP or TNF-α for three hours. Samples were run in duplicates and 
repeated. 
Experiment Design  
Standard 
curve 
(MMP-2 
recombinant 
protein) 
X 2 rows 
32 ng/ml 16 ng/ml 8ng/ml 4ng/ml 2ng/ml 1ng/ml 0.5ng/ml 
Experiment  -ve CNT 
Clear 
media  
X2 and 
repeat 
EXP  
Media of 
untreated 
cells  
X2 and 
repeat 
EXP  
Media of 
untreated 
cells 
X2 and 
repeat 
EXP  
Media of 
cells 
treated 
with SP 
for 3 hrs  
X2 and 
EXP  
Media of 
cells 
treated 
with SP 
for 3 hrs 
X2 and 
EXP  
Media of 
cells 
treated 
with 
TNF for 
3 hrs  
EXP  
Media of 
cells 
treated 
with 
TNF for 
3 hrs X2 
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repeat repeat X2 and 
repeat 
and 
repeat 
 
5.10 Fluorescent microscope. The technique of fluorescence microscopy is an essential 
tool in biology and the biomedical sciences, as well as in materials science due to attributes 
that are not readily available in other contrast modes with traditional optical microscopy. The 
application of an array of fluorochromes has made it possible to identify cells and sub-
microscopic cellular components with a high degree of specificity amid non-fluorescing 
material. The fluorescence microscope is capable of revealing the presence of a single 
molecule. Through the use of multiple fluorochromes, labelling different probes can 
simultaneously identify several target molecules simultaneously. Although the fluorescence 
microscope cannot provide resolution below the diffraction limit of specific specimen 
features, the detection of fluorescing molecules for a single molecule is achieved with a 
satisfactory degree with the fluorescent microscope. The fluorescent microscope used is Zeiss 
Axio Imager M1 and the imaging system (camera) is a CRI Nuance multispectral imaging 
system. The experimental design and protocol was similar to section 5.8. Cell adhesion assay 
was performed on an 8-well glass chamber for visualising the cell adhesion under the 
fluorescent microscope. 
5.11 Statistical analysis 
Student t-test was employed to determine the significance of the mean of two groups. 
ANOVA was used to determine the mean of more than two groups. The SPSS software 
package was used as the statistical analysis software. P<0.05 was considered statistically 
significant. 
5.12 Research highlight  
The research was carried out in two main studies which represent chapters 6 and 7. The first 
study (chapter 6) investigated: 
1. The effect of SP and the NK-1R antagonist on the adhesion between Jurkat and endothelial 
cells.  
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2. The effect of SP and the NK-1R antagonist on the expression of the adhesion molecules 
(VLA-4 integrin, SLeX and LFA) in Jurkat cell line. 
3. The effect of SP and NK-1R antagonist on the expression of MMP-2 in Jurkat cells. 
The study in chapter 7 investigated the same effects of SP and its antagonist in different cell 
lines representing different stages of tumour development (section 5.1). In each study the 
effect of the treatment or the antagonist was assessed through time-dependent manner and 
dose-dependent manner. For the adhesion assays, early response was defined as 1-4 hours of 
treatment, while in FAC analysis the time of treatment was assessed at 1-48 hours. In the 
adhesion experiments, there were two groups where the treatment/antagonist was allocated to 
either tumour cells (group 1) or the endothelial cells (group 2) as mentioned in the 
experimental design. Finally, chapter 8 is the discussion and the synthesis of all the 
experimental research data as well as the systematic review and position the results of the 
thesis in the current literature to outline the potential and future significance.   
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Chapter 6  Substance P (SP) increases the 
adhesion of Jurkat cell line to human umbilical vein 
endothelial cells (HUVEC) through upregulating 
adhesion molecules; implication for metastasis 
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Background  
Leukaemia is a highly metastatic neoplasm with the lowest prognosis among all cancers, 
which can drop to 27% survival rate. Despite decades of research into the biophysics of this 
process, little insight has been obtained into the actual key players of metastasis. Metastasis is 
a multi-step process where the tumour cell has to detach from the primary neoplasm, invade 
the surrounding tissues, enter the circulation, exit the circulatory system and finally implant 
in the new site. The whole metastatic success depends on the ability of neoplastic cells to 
interact and cross the endothelial barrier in the rate-limiting step (extravasation). The 
remarkable similarity between outflux of cells in inflammation and cancer points to the 
possibility of a common inflammatory mediator driving both processes.  
Aims 
The study examines the effects of SP on tumour-endothelial adhesion between Jurkat cells 
and HUVEC cell line. In addition it examines the role of SP in upregulating the expression of 
the adhesion molecules in Jurkat cell line. The study also examines the effect of SP on the 
expression of MMP-2 in these cells. 
Methods 
Flow cytometry was used to measure the level of expression of the adhesion molecules. 
Adhesion assay 645 ECM was used to measure the adhesion of Jurkat cell line to HUVEC 
cells. The MMP-2 ELISA kit was used to measure the expression level of MMP-2 in Jurkat 
cell line.  
Results 
Our results showed that: 1) SP and TNF-α increased the adhesion of Jurkat cells in a time-
course treatment with a peak adhesion at 3 hours; 2) this adhesion was proportional to the log 
concentration of SP from 100 ng/ml (10-8) M to 1 mcg/ml (10-7) M; 3) NK-1R inhibitor 
reduced the adhesion in a time and dose-dependent manner; 4) the HUVEC treated group had 
a higher values of adhesion as well as lower values of adhesion inhibition than the Jurkat 
treated group; 5) SP 1mcg/ml (10-7) M or TNF-α 100 ng/ml (10-9) M treatment has increased 
both CD 11 (not significant) and CD 49 (significant), but not CD15s expression in 1-48 hour 
timescale treatment, as indicated by the FACS analysis; 6) NK-1R inhibited CD49 expression 
stimulation in Jurkat cell lines at a dose-dependent curve with concentrations of 100 ng/ml, 
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300 ng/ml, 750 ng/ml and 1 mcg/ml (10-6-10-7) M, respectively; 7) Anti-human monoclonal 
antibodies to VCAM or ICAM significantly inhibited the adhesion levels to below the 
untreated baseline levels; 8) The treatment of Jurkat cell lines with SP or TNF-α for 3 hours 
did not significantly affect expression of MMP-2. However, the treatment of the Jurkat cell 
line with SP treatment for 1 hour significantly decreased this expression significantly P= 
0.003. 
 
Introduction  
Metastasis is the main cause of death of cancer patients. A systematic review of the global 
burden of cancer shows 17.5 million cancer cases worldwide and 8.7 million deaths, annually 
(401). Approximately 90% of cancer mortality rates are due to metastasis. Leukaemia is a 
highly metastatic neoplasm with the worst prognosis among all cancers, which can drop to 
27% survival rate (359). Despite decades of research into the biophysics of this process, little 
insight has been obtained into the actual key players of metastasis (402).  
Metastasis is a multi-step process where the tumour cell has to detach from the primary 
neoplasm, invade the surrounding tissues, enter the circulation, exit the circulatory system 
and finally implant in the new site (403). The migrating tumour cells face critical events (e.g. 
immune attacks in the blood vessels) leading to the death of most of them (403). The whole 
metastatic success depends on the ability of neoplastic cells to interact and cross the 
endothelial barrier in the rate-limiting step (extravasation) (404). Several studies elucidated 
variety of molecules – mainly adhesion molecules – as effectors of the tumour-endothelial 
interaction; however, the exact drivers and their role in the interaction remain poorly 
understood (233).  
The extravasation step requires active interaction between the migrating cell and the 
endothelium through changes in the expression of the adhesion molecules on both cells (208). 
This is most likely mediated by an inflammatory mediator expressed in the area where 
extravasation takes place. Finally, proteolytic enzymes such as MMPs facilitate the physical 
invasion of the cell across the endothelial barrier (405). This remains the main scheme for 
cellular extravasation, however, the drivers and the exact mechanisms requires further 
investigations. Recent research points to the same inflammatory mediators controlling the 
extravasation events in both metastasis and inflammation (215).   
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Substance P was initially identified as a neurotransmitter in primary sensory afferent fibres, 
and the most potent member of the tachykinin family (312-315). The canonical pathway for 
SP is through binding to the G protein-coupled NK-1 receptor (316-317) in which the 
SP/NK-1R ligand-receptor complex is formed, then SP is degraded while NK-1R is recycled 
to the cell surface (318). SP contributes to the inflammatory process possibly through 
different mechanisms: 1) release of inflammatory mediators such as cytokines and 
arachidonic acid derivatives; 2) as a chemo-attractant to the immune cells; 3) vasodilatation 
(VD) and leukocyte/endothelial cell adhesion to aid the facilitation of leukocyte recruitment 
to the injured tissue through angiogenesis (322) (for excellent reviews about SP please refer 
to 312-314).   
The high expression levels of SP and the NK-1R receptor in various tumours including 
melanoma (343), human malignant glioma (344), retinoblastoma (345) and mammary 
carcinoma (346), both in the primary tumour and their metastatic counterparts, imply an 
important role of SP in carcinogenesis (347). SP has been suggested to act as a mitogen for 
cancer progression (348) and even in the early malignant transformation (349). The role of 
SP in metastasis and invasion has not been fully investigated, although initial studies 
suggested that SP might trigger metastasis of colon cancer (350-351). Taking into 
consideration the main roles of SP in inflammation (vessel permeability, adhesion and 
migration of leukocyte) it is logical to predict similar roles for SP in metastasis (352). This 
study examines the role of SP in upregulating the expression of the adhesion molecules in 
both Jurkat cells and HUVEC endothelial cells, in addition to examining the effect of SP on 
tumour-endothelial cell adhesion. The effect of SP on the expression of MMP-2 in those cells 
is also investigated. 
 
Materials and Methods 
Cell lines: HUV-EC-C (ATCC CRL-1730) human vascular endothelium, Jurkat Clone E6-1 
(ATCC TIB-152TM) human acute leukaemia cell lines were purchased from ATCC®.  
Culture Media: Dulbecco modified eagle (DMEM) culture media, foetal Bovine serum 
(FBS), endothelial cell growth supplement (ECGS), L-glutamine, hydrocortisone, heparin 
sodium, and trypsin-EDTA were obtained from Sigma-Aldrich®. Eagles Minimum Essential 
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Medium (EMEM), F-12k medium, ATCC DMEM/F12 medium, vascular basal media, 
endothelial cell growth kit BBE, RPMI-1640 media and antibiotics were purchased from 
ATCCR cell lines.  
Treatment: Substance P acetate salt hydrate (SP) and [succinyl-ASP6, ME-PHE8] Senktide 
substance P analogue were purchased from Sigma-Aldrich®. Tumour necrosis factor-α 
(TNF-α) was purchased from Sigma-Aldrich. A selective NK1 receptor antagonist, 
CH123001 (N-(3,5-bis(trifluoromethyl)benzyl)-N-methyl-6-(4-methylpiperazin-1-yl)-4-(o-
tolyl)nicotinamide) was a gift from CH Biotech Pty Ltd, Sydney, Australia. 
Cell culture Jurkat cells Clone E6.1 was cultured in RPMI 1640 + 2 mM Glutamine + 10% 
FBS. 
HUVEC-EC was cultured in F-12K Medium, with 0.1 mg/ml heparin; 0.03-0.05 mg/ml 
adjusted to a final concentration of 10% FBS. 
Flow cytometry Antibodies: Anti-integrin alpha 4 antibody CD49d PE (12-0499), Mouse 
IgG1 K isotype control (124714), Anti-CD11a antibody FITC (BMS102FI) were purchased 
from Affymetrix Bioscience®. Anti-CD15S Mouse anti-human Alexa Flour 647 (563526), 
Alexa Flour 647 Mouse IgM isotype control purchased from BD®.  
Adhesion molecule expression by flow cytometry: In general, cells were harvested after 
treatment and washed as a single cell suspension in a 96-well, round-bottomed microtiter 
plates and adjusted to a concentration of >50,000 cells/ml, then the media was discarded and 
the cells were washed twice and centrifuged on ice-cold FACS Buffer. 
An antibody cocktail was made at 1:20 concentration with the FACS buffer with 50 μL for 
each sample. 50 μL of antibody cocktail was added and the sample was incubated for at least 
30 minutes at room temperature or 4°C in the dark. The cells were washed three times with 
FACS buffer by centrifugation at 1500 RPM for 5 minutes and resuspended in 200 μl to 1ml 
of ice-cold FACS buffer. Cells were kept in the dark on ice or at 4°C in a fridge until analysis 
(n=3).  
Cell adhesion assay: ECM645 was obtained from Merckmillipore®. Briefly, HUVEC cells 
were grown as normal to 80% confluent. Cells were then harvested (see subculture methods) 
then seeded at a density of 50,000 in a 96 well-plate or 10,000 in a 384-well plate. In all, half 
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the endothelial cells were treated or inhibited where the media and the dose were adjusted to 
the desired concentration and time. Cancer cells were seeded at 200,000 cells/ml for the 96 
well-plate and 50,000 for the 384-well plate. The appropriate treatment was applied to either 
the endothelial or the tumour cells according to the experimental protcol. After treatment, 
tumour cells were treated with Calcein-AM to a final concentration of 2.5 μM. Cells were 
then incubated for 30 minutes and centrifuged at 400X g for 5 minutes. After washing the 
plate was read with a fluorescence plate reader using 485/530 nm excitation/emission filter 
sets. Sample size (n= 20). 
Quantikine total MMP-2 ELISA Kit was obtained from R&D Systems®. Cells were either 
untreated, treated with SP or TNF-α for 3 hours. Samples were run in duplicates and 
repeated. Media from different treated and untreated cells were collected and stored at -20C. 
A 50 μL of standard, control or sample were added to each well and incubated on orbital 
microplate shaker (0.12”) orbit at 500 RPM. A 200 μL of Total MMP-2 conjugate was added 
to each well and incubated for another 2 hours. A 200 μL of substrate solution was added to 
each well and incubated for 30 minutes at room temperature in the dark. Immediately the 
optical density of each well was determined using a microplate reader set to 450 nm and 
wavelength correction to 540-570 nm.  
Fluorescent microscope: The same protocol for the adhesion assay was followed for 
validation of adhesion results with the fluorescent microscope with the use of an 8-well 
chamber slide (n=20). The microscope used was a Zeiss Axio Imager M1 with an imaging 
system (camera) CRI Nuance multispectral imaging system. 
Statistical analysis: Student t-test was employed to determine the significance of the mean 
of two groups. ANOVA was used to determine the mean of more than two groups. The SPSS 
software package was used as the statistical analysis software. P<0.05 was considered 
statistically significant. 
Results  
Effect of SP on the adhesion of Jurkat-HUVEC 
The effect of SP on the adhesion of Jurkat cells to HUVEC cells was evaluated through the 
adhesion assay by co-incubating the two cell lines. The experimental design involved two 
groups wherein the first group, tumour cells, were treated with SP, while in the second group; 
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the endothelial cells were treated with SP. Both groups were treated with a time course from 
1-4 hours (SP peak threshold activity is 60-180 minutes) (Figure 6.1- 6.2). Data are presented 
as per cent of adhesion, calculated as follows: Sample adhesion value/ control adhesion value 
X 100, where control adhesion was measured in the absence of any treatment of the tumour 
or endothelial cells. Two concentrations of SP were utilised 1 mcg/ml (10--6) M and 100 
ng/ml (10-8) M. Both concentrations of SP significantly increased the adhesion of Jurkat cells 
to HUVEC as measured by the mean fluorescence intensity of the well compared with the 
baseline adhesion level of the untreated cells. In the first group, Jurkat cells that were treated 
with 100 ng/ml (10-8) M of SP for 1, 2, 3 and 4 hours reached a maximum of adhesion at 3 
hours while treatment with 1 mcg/ml (10-6) M reached a maximum at 2 hours. The second 
experimental group, where the HUVEC cells were treated with 1 mcg/ml or 100 ng/ml of SP 
for the same time course, had similar time-dependent curves. In both groups, HUVEC treated 
groups had slightly higher adhesion values. Both treatment concentrations significantly 
increased the adhesion of Jurkat cells to HUVEC endothelial cells (P<0.001). These values 
were significant for both treatment groups; the tumour treated and the HUVEC treated group. 
 
Figure 6.1: Effects of SP on Jurkat cells adhesion to HUVEC. Two experimental groups in 
which Jurkat cells were treated with 100 ng/ml (10-8) M, where the other group had HUVEC 
cells treated the same. Treatment time was 1-4 hours and then both cells were incubated 
according to the assay protocol. Data are expressed as per cent of adhesion. Statistical 
analysis established the following significance: P<0.001 vs control for all the time points for 
either group, however, the group in which HUVEC cells were treated had slightly higher 
values of adhesion levels. 
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Figure 6.2: Figure 6.2: Effects of SP on Jurkat cells adhesion to HUVEC. Two experimental 
groups in which Jurkat cells were treated with 1 mcg/ml (10-6) M, where the other group had 
HUVEC cells treated with the same treatment. Treatment time was 1-4 hours and then both 
cells were incubated according to the assay protocol. Data are expressed as per cent of 
adhesion. Statistical analysis established the following significance: P<0.001 vs control for 
all the time points for either group, except of the 1-hour time point in the Jurkat treated 
group. 
 
Comparison of the effect of SP and TNF-α on Jurkat-HUVEC adhesion  
Next, we compared the effect of TNF-α 100 ng (10-9) M, as a positive control, on the 
adhesion of Jurkat to HUVEC cells at the time points 3 and 4 hours of treatment with 1 mcg 
(10-6) M. All of the treatments increased the adhesion levels of Jurkat cells to HUVEC 
(Figure 6.3).  
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Figure 6.3: Comparison of the effect of SP and TNF-α as a positive control on the adhesion 
of Jurkat cells to HUVEC. The first two groups were treated with SP (10-6) M, where the 
other two groups were treated with TNF-α (10-9) M at time points 3 and 4 hours. All values 
are significant at (P<0.001), except for Jurkat cells treated with TNF at 3 hours and HUVEC 
cells treated with TNF-α at 4 hours. 
 
 
Effect of SP receptor (NK-1R) antagonist  
A time-course inhibition assay was performed with the same time points 1-4 hours, where 
cell adhesion was inhibited with NK-1R antagonist. The NK-1R antagonist significantly 
reduced the adhesion level, where this adhesion followed a dose-dependent curve through the 
two concentrations of inhibitor which mirrored the concentration of SP used for the 
treatment. In each group, Jurkat or HUVEC cells were incubated with NK-1R inhibitor 100 
ng/ml or 1 mcg/ml for 1, 2, 3 or 4 hours and then incubated with the corresponding SP 
concentration for the same time point. In the Jurkat cells treated group (Figure 6.4), the use of 
NK-1R antagonist (1 mcg/ml and 100 ng/ml) was significant in inhibiting the adhesion of 
Jurkat cells to HUVEC cells significantly (P<0.001) at 2 hours. In the HUVEC treated group 
(Figure 6.5) with NK-1R antagonist (same concentrations), the inhibition effect was 
significant (P<0.001) in all the time points except at 3 and 4 hours with 100 ng/ml of NK-1R. 
SP inhibition of the HUVEC had a higher effect of inhibiting the tumour-endothelial 
adhesion.  
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Figure 6.4: Effect of the NK1 receptor antagonist on the adhesion effects evoked by SP 
treatment. Jurkat cells were incubated for one time point from 1-4 hours with the antagonist 
(10−6, 10-8) M, then was incubated with the same SP concentration for the same time point. 
Asterisks mark statistically significant inhibition values (*P<0.01). 
 
  
 
Figure 6.5: Effect of the NK1 receptor antagonist on the adhesion effects evoked by SP 
treatment. HUVEC cells were incubated for one time point from 1-4 hours with the 
antagonist (10−6, 10-8) M, then was incubated with the same SP concentration for the same 
time point.  
 
* 
* 
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Effect of adhesion molecule Monoclonal Antibodies on the adhesion 
Finally, we performed an anti-human monoclonal antibody inhibition assay. Briefly, either 
tumour or HUVEC cells was treated with SP 1 mcg (10-6) M or TNF-α 100 ng (10-9) M for 3 
hours and then co-incubated with mouse anti-human monoclonal antibodies VCAM 50 
μg/ml, ICAM 50 μg/ml, or cycloheximide 50 μg/ml for 30 minutes as per assay protocol. 
Cycloheximide treated cells (tumour or endothelial) had significantly reduced adhesion levels 
triggered by SP treatment. However, they remained higher than the untreated basal adhesion 
levels. Monoclonal antibody to VCAM and ICAM significantly reduced the adhesion to 
levels beyond the basal adhesion levels of the untreated cells (Figure 6.6). 
 
Figure 6.6: Inhibition of the adhesion triggered with SP treatment. Jurkat (left) or HUVEC 
(Endo) (right) cells were incubated with monoclonal antibodies or cycloheximide then 
incubated with SP 100 ng/ml for 3 hours. All the treatments significantly inhibited the 
adhesion as compared to the treated levels or the control (basal levels) (P<0.001). Note: All 
columns have error bars; however, due to the small ratio of some error bars in relation to 
column, they do not appear on the graph.  
 
 
Effect of SP treatment on the adhesion molecule expression 
Next, we tested the effect of SP and TNF-α on the expression of the adhesion molecules, 
using flow cytometry: CD11 (LFA), CD49 (VLA-4) and CD15S (Sialy Lewis) both on a 
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time-course at 1, 2, 3, 4, 24 and 48 hours as well as a dose-response curve for NK-1R 
inhibitor at 100, 300, 750 ng/ml, 1mcg/ml and 10 mcg/ml (10-5-10-8) M. 
CD11: Both SP and TNF-α increased the CD 11 expression. However, it was not significant. 
The optimal increase in the expression was at 3-hour treatment of SP and 24-hour treatment 
of TNF-α. The NK-1R antagonist at 1mcg concentration at 4 hours reversed the expression 
back close to the untreated levels (Table 6.1, Figure 6.7). 
 
Table 6.1: The effect of SP 1 mcg/ml and TNF 100 ng/ml on the expression of CD 11 in 
Jurkat cells. Data are represented as measured by the fluorescence intensity of the treated 
samples against the untreated levels of expression n=3.  
 
CD11 JURKAT_SP 1 mcg  P-Value CD11 Jurkat 
TNF 100 ng 
P-Value 
JURKAT_SP_1 Hr 0.925 1 Hr 1.00 
JURKAT_SP_2Hr 0.996 2 Hr 0.85 
JURKAT_SP_3Hr 0.459 3 Hr 0.71 
JURKAT_SP_4Hr 0.544 4 Hr 0.44 
JURKAT _SP_24Hr 0.897 24 Hr 1.00 
JURKAT_SP_48Hr 0.896 48 Hr 0.21 
 
Figure 6.7: The effect of SP 1mcg or TNF-α 100 ng/ml on the expression of CD11 (LFA) on 
a time-course treatment from 1-48 hours. Data are represented as mean of fluorescence 
intensity. 
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CD15s (Sialyl Lewis x): Neither SP or TNF-α treatment affected the expression of CD15s 
expression. The untreated expression of CD15s molecule was relatively low at a mean value 
of 64.9 (Table 6.2). 
Table 6.2: Flow cytometry mean expression levels of CD15s in Jurkat cells treated with SP 
1mcg/ml for different time points in comparison to untreated Jurkat cells expression of 
CD15s. 
 
CD15s_JURKAT_ P-Value 
CD15s_JURKAT_SP_2Hr 0.05 
CD15s_JURKAT_SP_3Hr 0.58 
CD15s_JURKAT_SP_4Hr 0.89 
CD15s_JURKAT_SP_48Hr 0.48 
 
CD49 (VLA-4 integrin): SP treatment has significantly increased the expression of VLA-4 
in a time-course treatment at 1, 2, 3, 4, 24, 48 hours (Figure 6.8). The peak of the expression 
increase was at 3-4 hours with (P = 0.02, 0.03) respectively, and the expression assumed a 
plateau curve after this time point (Table 6.3). Next, inhibition of CD49 expression using 
NK-1R inhibitor at doses of 1mcg, 750 ng, 300 ng, and 100 ng produced a dose-response 
curve (Figure 6.9). Jurkat cells were incubated with NK-1R antagonist for 1, 2, 3, 4, 24 hours 
then cells were incubated with the 1 mcg/ml then analysed for FACS expression of CD49.  
 
Figure 6.8: The effect of SP 1mcg or TNF-α 100 ng/ml on the expression of CD49 (LFA) on 
a time-course treatment from 1-48 hours. Data are represented as a mean of fluorescence 
intensity. 
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Table 6.3: CD49 FAC expression SP treatment values. 
CD49_JURKAT_Untreated P-Value 
CD49_JURKAT_SP_1Hr 0.03 
CD49_JURKAT_SP_2Hr 0.01 
CD49_JURKAT_SP_3Hr 0.02 
CD49_JURKAT_SP_4Hr 0.03 
CD49_JURKAT_SP_12Hr 0.04 
CD49_JURKAT_SP_48Hr 0.05 
 
 
 
Figure 6.9: Effect of the NK1 receptor antagonist on the expression of the adhesion molecule 
CD49. Jurkat cells were incubated with each concentration of the antagonist for 1, 2, 3, 4, 24 
hours, then incubated with the corresponding concentration of SP. Data are expressed as a 
mean of the fluorescence intensity. 
 
 
Table 6.4: Comparison of the effect of the inhibitor NK-1R on the expression of CD49 at 
time points 1-4 hours in a dose-dependent manner with 1 mcg/ml, 750 ng/ml, 300 ng/ml, 100 
ng/ml. Data are represented as a mean of the fluorescence intensity of the inhibitor sample 
versus the SP treatment at that time point. * denotes significant <0.05. 
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NK-1R 
antagonist P-
Value 
1 mcg/ml 750 ng/ml 300 ng/ml 100 ng/ml  
1-Hour 0.96 0.58 0.66 0.34 
2-Hour 0.43 0.81 0.52 0.48 
3-Hour *0.002 0.13 0.74 0.11 
4-Hour <*0,001 *0.002 0.08 
 
0.56 
 
Fluorescence Microscope 
Using the same protocol, we investigated the effect that adhesion of human Jurkat cells to 
HUVECs with SP activation on a chamber glass with the fluorescence microscope. The result 
showed that the adhesion of Jurkat cells increased significantly with SP stimulation for 3 
hours (Figure 6.10). In contrast, when cells were treated with NK-1R inhibitor for 3 hours, 
they showed significant reduction of Jurkat cells adhering to ECs. 
 
Figure 6.10: Fluorescence microscope image for Jurkat cell adhesion to HUVEC with SP 
treatment and SP inhibitor effect on the adhesion: (right to left) A: Untreated Jurkat adhesion 
to HUVEC; B: Jurkat SP-activated 3-hour adhesion to HUVEC; C: Inhibition of Jurkat 
adhesion HUVEC by NK-1R. 
 
Figure 6.11: Flow cytometric 
analysis of SP-induced expression of 
cell-surface VLA-4. For FACS 
experiments, a PE-conjugated anti-
VLA-4 antibody binding to HUVEC 
suspensions was detected. 
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Effect of SP treatment on MMP-2 expression 
Finally, the effect of SP and TNF-α treatment on the release of MMP-2 was measured using 
an ELISA technique, comparing untreated Jurkat cells MMP-2 levels to those of the same 
cell line treated with SP 1 mcg for 1 and 3 hours. The basal (untreated) expression of MMP-2 
was positive at1.87 ng/ml. Neither of SP 1 mcg/ml or TNF 100 ng/ml treatment at 3 hours 
significantly affected the expression with P= 0.87, 0.50, respectively. However, SP treatment 
for 1 hour was significant P= 0.003.    
Discussion  
Blood cancers remain a challenge to the current therapeutic modalities because of their 
inherent capacity to metastasise (359). Recent studies have supported an important role for 
inflammation in cancer initiation, progression and metastasis. In addition, emerging studies 
highlight inflammation as a driver of the different stages of metastasis, such as tumour-
endothelial cell adhesion (215). However, the current literature has not identified the 
particular mechanism of the relationship of inflammation and metastasis or the precise effect 
of inflammatory mediators on the adhesion and extravasation of tumour cells. Therefore, our 
study aimed at: 1) exploring the effect of the inflammatory mediator SP on the adhesion of 
Jurkat leukaemia cells to HUVEC cells; 2) the effect of SP on the expression of adhesion 
molecules in Jurkat cells; and 3) investigating the effect of SP on MMP-2 release by tumour 
cells.  
Metastasis starts with the tumour cell loosely adhering to neighbouring cells, invading the 
surrounding tissues, gaining access to blood vessels, and finally adhering and exiting the 
blood vessels to implant in secondary sites (208). The success of metastasis is dependent on 
the rate-limiting step of extravasation. Leukaemias and lymphomas, being already in the 
blood, bypass the need for the rest of the steps before extravasation, as well as expressing a 
variety of adhesion molecules and inflammatory mediator receptors for normal function. This 
facilitates the migration of such cells and may account for the high metastatic potential of 
blood malignancies (359).  
The extravasation stage is crucially important not only for the migration of the tumour but 
also for the survival of the migrating cell. Adhesion of tumour cells to the endothelium 
withdraws the cell from the mainstream in the blood vessel and provides protection against 
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immune attack (208). Therefore, this adhesion and subsequent exiting has to happen in an 
acute phase similar to an inflammatory process. Dianzani et al. reported that SP increased the 
adhesion of neutrophils to HUVEC cells in a time/dose-dependent curve at 5-40 minutes 
(331). In line with these data, our results (to the best of our knowledge) showed that: 1) SP 
and TNF-α  increased the adhesion of Jurkat cells to HUVEC cells in a time-course treatment 
with a maximum adhesion at 3 hours (Figure 6.1, 6.2); 2) this adhesion was proportional to 
the log concentration of SP from 100 ng to 1 mcg; 3) treatment with NK-1R inhibitor reduced 
the adhesion in a time and dose-dependent manner; 4) the HUVEC-treated group  had higher 
values of adhesion as well as lower values of adhesion inhibition than the Jurkat-treated 
group (treating the Jurkat with SP before mixing with HUVECs).   
Stucki et al. reported a static quantitative adhesion assay of leukaemic cells to endothelial 
cells at 0-24 hours, where they found that the significant increase in adhesion occurred by 
three times at 3 hours up to 24 hours (360). The authors suggested a similar mechanism for 
leukaemic cells to produce inflammatory stimulating factors that can accumulate more 
tumour cell adhesion to the endothelium. We did not found any studies have reported less 
than 48-72 hours tumour-endothelial adhesion except for inflammation studies in the 
literature. It is logical to consider that a cancer cell with multiple genetic aberrations and high 
mutation levels could acquire a mutated phenotype that allows these cells to mimic an acute 
adhesion onset similar to that of inflammatory reaction (bearing in mind that cells of origin 
for blood malignancies are inflammatory cells).  
Continuing the previous list, our study showed that: 5) SP 1 mcg or TNF-α  100 ng treatment 
has increased both CD11 (not significant) and CD49 (significant) but  not CD15s expression 
in 1-48 hour timescale treatment, as indicated by the FACS analysis; 6) NK-1R inhibited 
CD49 expression stimulation in Jurkat cell lines at a dose-dependent curve with 
concentrations of 100 ng, 300 ng, 750 ng and 1 mcg; 7) Anti-human monoclonal antibodies 
to VCAM or ICAM significantly inhibited adhesion levels to below the untreated baseline 
levels.  Zepeda-Moreno et al. reported that SDF-1 increased the expression of LFA-1 in 
Jurkat cells (406). Similarly, Stucki (360) reported that adhesion to TNF-α activated 
endothelium was dependent on members of the immunoglobulin superfamily ICAM-1 and 
VCAM-1 in a manner similar to normal leukocyte trafficking. However, they postulated that 
the adhesion was mainly dependent on the selectin family (406). This does not contradict our 
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results as it might be due to tissue specific factors (authors used different cell line), as well as 
the authors having concluded that while the selectin family mediates rolling activity on the 
endothelium, the main adhesion drivers are the ICAM-β1 integrin.  
Interestingly, we found that treating endothelial cell with either stimulating factor or inhibitor 
produces more potent levels of adhesion which may explain the organ-specific metastasis of 
cancers. It also highlights the active interaction of tumour-endothelial cell during adhesion 
(404, 208). Moreover, our data showed that inhibition of adhesion levels achieved using 
cycloheximide, which blocks translation of messenger RNA on cytosolic 80S ribosomes, but 
does not inhibit organelle protein synthesis, did not achieve higher levels such as the ones 
inflicted with monoclonal antibodies which might suggest that tumour cells highly express 
adhesion molecules as well as inflammatory receptors. 
Together with these findings, our results, provided a link of inflammation with metastasis, 
and suggested that SP and TNF-α may serve as an inflammatory mediators triggering early 
onset of cancer–endothelial cell adhesion. 
Adhesion of tumour cells to endothelial cells requires subsequent steps to promote tumour 
cell migration and implantation in the secondary site. MMP group of enzymes have been 
implicated for facilitating the tumour cell migration and invasion of the endothelial barrier 
(405). In our study Jurkat cell line had a high basal level of expression of MMP-2, however, 
the treatment of SP or TNF-α for 3 hours did not significantly affect this expression. More 
importantly, the treatment of the cell line with SP treatment for 1 hour significantly decreased 
this expression significantly (P= 0.003). Li et al., reported a significant effect of SP on the 
expression of MMP-2 on mRNA level (407). These results are counterintuitive as if the 
adhesion is to peak at 2 to 3 hours, then MMP-2 release should be following this adhesion. 
This conflict may be due to either tissue factors or multiple functions for MMP-2 in tumour 
environment which will require further study to validate those results. 
 
Our study showed that SP has the ability to mediate the adhesion between Jurkat cell lines 
and HUVEC cell lines and that integrin activation seems crucial for this adhesion. Despite the 
static and in-vitro nature of the study, this requires further validation with in-vivo models; 
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these observations increase our understanding of cancer cell biology. Importantly, they also 
suggest a new therapeutic potential for SP antagonists against leukaemic cell adhesion. 
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Chapter 7 Substance P (SP) increases the adhesion 
of oral cancer cell lines (OSCC) to human umbilical 
vein endothelial cells (HUVEC) through 
upregulating adhesion molecules; implication for 
metastasis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE EFFECT OF SUBSTANCE P (SP) ON ADHESION OF JURKAT 
LEUKAEMIA CELLS AND SQUAMOUS CARCINOMA CELLS 
(SCC) TO VASCULAR ENDOTHELIAL CELLS AND ROLE IN 
METASTASIS 
Moustafa Elhousiny Page 104 
 
 
Background  
OSCC is a locally invasive lesion with a best survival rate of 50%. Interaction of cancer cells 
with endothelial cells plays an important role in both tumour angiogenesis and metastasis. 
The similarity between tumour and leukocyte extravasation indicates similar localisation 
signals through common mediators of inflammation and cancer. These localisation signals are 
mainly delivered by neurotransmitters such as SP or cytokines such as TNF-α, and although 
these mediators have been elaborated extensively in inflammation, their actions in metastatic 
extravasation is yet to be identified. Taking in consideration the main role of SP in 
inflammation (vessel permeability, adhesion and migration of leukocytes) and the up-
regulated expression in OSCC, our study hypothesised that SP might play a role in the 
adhesion of OSCC cells to HUVEC cells. 
Methods  
HOK primary oral keratinocytes, CAL 27, SCC25, DOK, H157 and BICR22 OSCC cell lines 
were used for the experiments as well as HUVEC endothelial cell lines. Adhesion molecule 
expression was measured by flow cytometry. The ECM645 adhesion assay was obtained 
from Merckmillipore® for quantification of tumour-endothelial cell adhesion. A Quantikine 
total MMP-2 ELISA kit was obtained from R&DSystems® for measurement of MMP-2 
expression in OSCC cell lines.  
Results  
Our results showed that: 1) treatment with SP and TNF-α increased the adhesion of H157, 
CAL27 and DOK cells to HUVEC endothelial cells in a time-dependent manner with a 
maximum adhesion at 3 hours; 2) the endothelial-treated group had more adhesion values 
than the tumour-treated groups; 3) NK-1R inhibitor reduced the adhesion in a time and dose-
dependent manner from 1-4 hours with a peak suppression of 3 hours in H157 and DOK, 
while the peak of inhibition in CAL27 cell was at 2 hours treatment; 4) monoclonal anti-
adhesion antibodies inhibited the adhesion between OSCC and HUVEC; 5) the expression of 
each adhesion molecule assumed an increasing expression according to malignant potential; 
6) SP time treatment increased CD49 adhesion molecule with a peak of 3 hours as well as 
CD11 and CD49 in both SCC25 and BICR22, respectively; 7) SP treatment increased MMP-
2 release at 3 hours in each cell line; however, this increase was not significant. 
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The burden of metastasis in OSCC  
The metastatic potential of OSCC has shaped the extent of treatment strategies necessitating 
aggressive therapeutic modalities to eliminate metastasis and ensure residual disease-free 
outcome (16, 18, 146, 408). The increasing rates of metastatic spread seen in clinical settings 
and detected by molecular diagnostics necessitates a new paradigm of cancer treatment 
approaches (125, 129).  Furthermore, the scientific literature showing a failure of 
combination systematic therapies to produce any significant improvement of patient outcome 
or quality of life (126-127, 130).  
The initial success of cancer immunotherapy highlights the efficacy of a novel approach to 
replace the traditional therapies as well as provide better understanding of the disease (215). 
This approach is based on looking into critical biologic mechanisms hijacked by cancer for 
the favour of its growth (225). By identifying those process, interfering with them will 
provide potential targets for metastatic therapies. A major critical as well as common 
mechanism, is inflammation and the role of its mediator in different aspect of cancer stages 
(409).  
SP was found to be significantly expressed in the tumour cell membrane, cytoplasm and 
nucleus of OSCC as well as the infiltrating lymphocytes of the neoplasms (353). The 
expression of SP was found to be significantly associated with the presence of dysplasia and 
carcinoma in situ, which strongly suggested a role for SP in the early onset of oral 
oncogenesis (354). Taking into consideration the main role of SP in inflammation (vessel 
permeability, adhesion and migration of leukocyte) and the up-regulated expression in 
OSCC, our study hypothesised that SP might play a role in the adhesion of OSCC cells to 
HUVEC cells. Therefore, our study aimed to examine the role of SP in stimulating OSCC-
HUVEC adhesion as well as investigating the role of SP in upregulating the adhesion 
molecule expression of OSCC cell lines. The study also examined the effect of SP on tumour-
endothelial adhesion and the effect of SP on the expression of MMP-2. 
Materials and Methods 
Cell lines: Cells were selected to represent the progressive stages of oral cancer as follows: 
HOK primary oral keratinocyte isolated from human oral mucosa was purchased from 
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Sciencell®. CAL 27 (ATCC CRL- 2095), SCC25 (ATCC CRL- 1628), DOK, H-157 and a 
BICR-22 were used. A HUV-EC-C (ATCC CRL-1730) human vascular endothelium was 
purchased from ATCC®.  
Culture Media: Dulbecco modified eagle (DMEM) culture media, foetal bovine serum 
(FBS), endothelial cell growth supplement (ECG), L-glutamine, hydrocortisone, heparin 
sodium, and trypsin-EDTA were obtained from Sigma-Aldrich®. Eagle’s minimum essential 
medium (EMEM), F-12K medium, ATCC DMEM/F12 medium, vascular basal media, 
endothelial cell growth kit BBE, RPMI-1640 media, and antibiotics were purchased from 
ATCC® cell lines. Oral keratinocyte medium was purchased from Sciencell®. 
Treatment: Substance P acetate salt hydrate (SP) and [succinyl-ASP6, ME-PHE8] Senktide 
Substance P analogue were purchased from Sigma-AldrichR. Tumour necrosis factor (TNF-α) 
was purchased from Sigma-Aldrich®. A selective NK1 receptor antagonist, CH123001 (N-
(3,5-bis(trifluoromethyl)benzyl)-N-methyl-6-(4-methylpiperazin-1-yl)-4(otolyl)nicotinamide) 
was a gift from CH Biotech Pty Ltd, Sydney, Australia. 
Flow cytometry antibodies: Anti-integrin alpha 4 antibody CD49d PE (12-0499), Mouse 
IgG1, K isotype control (124714), Anti-CD11a antibody FITC (BMS102FI) were purchased 
from Affymetrix eBioscience®. Anti-CD15S Mouse anti-human Alexa Flour 647 (563526), 
Alexa Flour 647 Mouse IgM isotype control was purchased from BD®. 
For a full description of experimental design and methodology, please refer to chapter 5. 
Results  
 
Effect of Substance P on OSCC/HUVEC adhesion 
We examined the effect of SP on the adhesion of OSCC to HUVEC using the Tumour-
Endothelial Adhesion Assay 645 (Merckmillipore®). The protocol used is listed in the 
Material and Methods chapter (section 5.8). Briefly, the experimental design was established 
to use cells representing the different stages of cancer progression. Therefore, the cells used 
were DOK (pre-cancer), CAL 27 and SCC25 (negative lymph node OSCC cell lines), H157 
(positive lymph node OSCC), and BICR22 (lymph node metastases). All the treatments were 
done in two main groups. The first group had the treatment applied to the cancer cells, 
whereas the second group had HUVEC cells treated with the experimental reagents. The 
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results showed that SP treatment increased the adhesion in H157, DOK and CAL27, whereas 
no effect was observed in either SCC25 or BICR22 (Table 7.1). SP treatment 1 mcg/ml (10-6) 
M significantly increased the adhesion of OSCC cell lines in a time-course treatment from 1 
to 4 hours (Figure 7.1-7.4). In both H157 and CAL 27 cells, the adhesion levels were higher 
for the HUVEC treated group. Both groups had (P = 0.001). 
 
Figure 7.1: Effects of SP 1 mcg/ml (10-6) M on H157 cells adhesion to HUVEC. Treatment 
time was 1-4 hours and then both cells were incubated according to the assay protocol. Data 
are expressed as per cent of adhesion. Statistical analysis established the following 
significance: P<0.001 vs control (untreated adhesion levels) for all the time points. 
 
 
 
Figure 7.2: Effects of SP on H157 cells adhesion to HUVEC. Two experimental groups in 
which H157 cells were treated with 1 mcg/ml (10-6) M, where the other group had HUVEC 
cells treated with the same treatment. Treatment time was 1-4 hours and then both cells were 
incubated according to the assay protocol. Data are expressed as per cent of adhesion. 
Statistical analysis established the following significance: P<0.001 vs control for all the time 
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points for either group, however, the group in which HUVEC cells were treated had higher 
values of adhesion levels. 
 
 
 
 
Figure 7.3: Effects of SP on CAL27 cells adhesion to HUVEC. Two experimental groups in 
which CAL27 cells were treated with 1 mcg/ml (10-6) M, where the other group had HUVEC 
cells treated with the same treatment. Treatment time was 1-4 hours and then both cells were 
incubated according to the assay protocol. Data are expressed as per cent of adhesion. 
Statistical analysis established the following significance: P<0.001 vs control for all the time 
points for either group, however, the group in which HUVEC cells were treated had higher 
values of adhesion levels. 
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Figure 7.4: Effects of SP treatment 1 mcg/ml (10-6) M on DOK cells adhesion to HUVEC. 
Treatment time was 1-4 hours and then both cells were incubated according to the assay 
protocol. Data are expressed as per cent of adhesion levels. Statistical analysis established the 
following significance: P<0.001 vs control for all the time points. 
 
 
Table 7.1: Shows the P- value for adhesion levels of SCC 25 and BICR22 OSCC cell lines to 
HUVEC endothelial cells at 1, 2, 3 and 4 hour-time when treated with SP 1 mcg/ml. 
Cell Line Time of Treatment/P Value for adhesion 
1-Hour 2-Hour 3-Hour 4-Hour 
SCC25 0.84 0.21 0.59 0.95 
BICR22 0.44 0.95 0.95 0.33 
 
Comparing SP and TNF-α effect on Jurkat adhesion to HUVEC 
Next, we compared the effect of SP and TNF-α treatment (as a positive control) on the levels 
of adhesion in OSCC lines to HUVEC. The results showed that both SP 1mcg (10-6) M and 
TNF-α 100 ng (10-9) M stimulation for 3 hours significantly increased the adhesion levels of 
H157 and CAL 27 to HUVEC (Figure 7.5).  
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Figure 7.5: H157 (top) and CAL 27 (bottom) treated with SP 1mcg (10-6) M or TNF-α 100 
ng (10-9) M at 1-4 hours adhesion levels to HUVEC. Data are represented as per cent of 
adhesion levels vs control adhesion (untreated adhesion levels). P= 0.001 for all treatments. 
Error bars might be smaller than some data points.  
 
Effect of SP receptor (NK-1R) antagonist 
To investigate the effect of NK-1R on inhibiting the adhesion levels triggered by SP 
stimulation, we applied NK-1R antagonist to either the tumour cells or HUVEC. The data 
showed that the NK-1R antagonist significantly inhibited adhesion levels, reversing back to 
untreated baseline adhesion levels. Treating of H157 cells with SP treatment 1 mcg/ml for 1, 
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2, 3 or 4 hours then treating the cells with 1 mcg/ml of the NK-1R antagonist for the same 
time point significantly inhibited (P=0.001) the adhesion levels with HUVEC cells at all the 
time points 1-4 hours (Figure 7.6 top). Additionally, treating the HUVEC cells with SP 1 
mcg/ml at 1, 2, 3 or 4 hours, then adding NK-1R, inhibited adhesion levels compared with the 
HUVEC treated with SP only (P=0.001) for all time points (Figure 7.6 bottom). The 
adhesion levels suppression induced by treating the HUVEC cells with NK-1R inhibitor had 
lower values of expression than H157 cells treated with NK-1R at 1, 2 and 3 hours. In 
CAL27 cells, application of NK-1R to the cells significantly inhibited the adhesion levels 
compared with the same cells treated with SP only, with a maximum value of suppression at 
the 2-hour time point (Figure 7.7). Also, the HUVEC cells treated with inhibitor suppressed 
adhesion significantly as compared to HUVEC cells treated with SP only, reaching a 
maximum at 3 hours (P=0.001) (Figure 7.8). The suppression of those adhesion levels 
brought back the adhesion levels triggered by the SP treatment to values below the untreated 
adhesion threshold. Similarly, adhesion of DOK cells to HUVEC was significantly 
suppressed by the application of NK-1R to DOK cells with a maximum at 3 hours (Figure 
7.9).  
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Figure 7.6: Effect of NK-1R antagonist on the inhibition of adhesion in H157 to HUVEC 
cells. Top figure compares the effect of SP 1 mcg/ ml treated H157 with the effect of the NK-
1R 1 mcg/ml inhibitor applied to either H157 or HUVEC. The bottom figure compares the 
same inhibitor treatment in both groups with SP 1 mcg/ml HUVEC treated cells. Data 
represented as per cent of adhesion levels vs control adhesion (untreated). P=0.001 for all the 
time points (as a mean difference between SP treated and NK-1R inhibited). 
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Figure 7.7: Effect of NK-1R antagonist on the inhibition of adhesion in CAL27 to HUVEC 
cells. The figure compares the effect of SP 1 mcg/ ml treated H157 with the effect of the NK-
1R 1 mcg/ml inhibitor applied to CAL27.  Data represented as per cent of adhesion levels vs 
control adhesion (untreated). P=0.001 for all the time points (as a mean difference between 
SP treated and NK-1R inhibited).  
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Figure 7.8: Effect of NK-1R antagonist on the inhibition of adhesion in CAL27 to HUVEC 
cells. The figure compares the effect of SP 1 mcg/ ml treated HUVEC cells with the effect of 
the NK-1R 1 mcg/ml inhibitor applied to HUVEC. Data represented as per cent of adhesion 
levels vs control adhesion (untreated). P=0.001 for all the time points (as a mean difference 
between SP treated and NK-1R inhibited). 
 
Figure 7.9: Effect of NK-1R antagonist on the inhibition of adhesion in DOK to HUVEC 
cells. The figure compares the effect of SP 1 mcg/ ml treated DOK with the effect of the NK-
1R 1 mcg/ml inhibitor applied to the same cells. Data represented as per cent of adhesion 
levels vs control adhesion (untreated). P=0.001 for all the time points (as a mean difference 
between SP treated and NK-1R inhibited). Some error bars are smaller than the 
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corresponding data points and therefore they might not appear on the graph (All data points 
are represented as “Mean, SEM”). 
 
Next, we performed a dose-response curve to investigate the effect of different concentrations 
of the NK-1R antagonist of the level of the adhesion. The NK-1R antagonist was used at 
concentrations of 100 ng, 300 ng, 750 ng and 1 mcg at time point 3-hour treatment (as this 
point was the average maximum for adhesion and inhibition for H157 and DOK). Application 
of increasing doses of NK-1R inhibitor to H157 cells produces a significant suppression of 
the adhesion which assumed a bell-shaped curve, with the maximum inhibitory point at 750 
ng/ml and then the curve assumed a plateau (Figure 7.10 top). A similar curve was observed 
in DOK cells (Figure 7.10 bottom).  
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Figure 7.10: Dose-response curve of NK-1R antagonist at concentration 100 ng, 300 ng, 750 
ng and 1mcg. Top: H157 cells adhesion levels at 3 hours showing SP stimulation levels 
above the untreated levels and the different concentration inhibition of adhesion by NK-1R, 
reversing the adhesion back to untreated basal levels. Bottom: DOK cells adhesion levels at 3 
hours showing SP stimulation levels above the untreated levels and the different 
concentration inhibition of adhesion by NK-1R, reversing the adhesion back to untreated 
basal levels. Data are represented as per cent of adhesion levels versus control adhesion 
(untreated levels).  
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Effect of adhesion molecule anti-Human Monoclonal Antibodies on the adhesion 
To investigate whether the monoclonal antibodies to the adhesion molecules had an effect on 
the adhesion levels stimulated by SP treatment, we used the adhesion monoclonal antibodies 
to E-selectin, VCAM and ICAM to test whether they can block the adhesion initiated with 
SP. Our data showed that in general, monoclonal antibodies to adhesion molecules 
suppressed the adhesion levels back to the untreated levels. However, the results were 
different for each cell line. In H157 cells, the maximum inhibitory effect was achieved with 
anti-E selectin followed by anti-ICAM which produced adhesion levels much lower than the 
threshold of the basal adhesion levels, while similar levels was observed for NK-1R inhibitor 
750ng as well as anti-VCAM antibody at levels close to the basal untreated adhesion levels 
(Figure 7.11). In DOK precancer cells, the situation was completely reversed with the most 
potent adhesion suppressors NK-1R and anti-VCAM Mab. 
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Figure 7.11: Comparing the effect of adhesion molecule monoclonal antibodies on the 
adhesion levels triggered by SP treatment to the NK-1R antagonist at time point 3 hours. Top: 
H157 cell line. Bottom: DOK cell lines. 
 
 
Effect of SP treatment on the adhesion molecule expression 
We hypothesised that surface adhesion molecules should be the main player in the adhesion 
event and that the increase in cell adhesion is attributable to induction of adhesion molecule 
expression on stimulated cells by either SP or TNF-α treatment. We used flow cytometry to 
analyse the expression of adhesion ligands (CD49, CD15s, CD11) for HUVEC adhesion 
receptors VCAM, E-selectin and ICAM, respectively in each cell line. 
Basal levels of adhesion molecule expression in OSCC 
First, we investigated the initial levels of those expression molecules in each cell line, 
according to the malignant potential, form normal, precancer, primary tumour (with/without 
lymph node metastases) to metastases. The untreated levels of adhesion molecule expression 
were plotted according to the mean value of the experimental samples for CD49, CD15s and 
CD11, respectively (Figure 7.12-7.14). Our results showed that each adhesion molecule 
expression increased significantly with the increase in the malignant potential of the cell line, 
ranging from a negligible expression in the normal oral keratinocyte to the more aggressive 
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H157 cell line with positive lymph node, and then declined in the metastases cell line 
BICR22. 
 
Figure 7.12: Untreated CD49 adhesion molecule expression levels in different stages of 
OSCC cell lines as illustrated by mean intensity using FACS analysis. 
 
 
Figure 7.13: Untreated CD15s adhesion molecule expression levels in different stages of 
OSCC cell lines as illustrated by mean intensity using FACS analysis. 
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Figure 7.14: Untreated CD11 adhesion molecule expression levels in different stages of 
OSCC cell lines as illustrated by mean intensity using FACS analysis. 
Effect of SP treatment on the expression of adhesion molecules  
Our hypothesis was that if SP increased adhesion levels and, given the trend of the expression 
of adhesion molecules in the different cell lines, SP treatment may trigger expression of these 
adhesion molecules. Therefore, we performed a time-course treatment of SP 1mcg at 1-36 
hours in each cell line and analysed the expression of each adhesion molecule in each cell 
line using the FACS cell sorter. Our results showed that SP treatment increased the 
expression of CD49 in CAL27 in a time-course treatment (Figure 7.15). 
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Figure 7.15: SP time-treatment for CAL27 cell line, showing the untreated expression level 
of CD49 (VLA-4). 
 
The peak of expression increase was at 3 hours treatment and then the expression reverted to 
untreated levels. The 3-hour treatment significantly increased the expression of both CD11 
FITC and CD49 molecules as indicated by FACS analysis in both SCC25 and BICR22, 
respectively (Figure 7.16). 
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Figure 7.16: SP treatment effect on OSCC cell lines adhesion molecule expression; Top: 
FACS histogram showing CD11 FITC in SCC25 before and after treatment. Bottom: 
Treatment effect of SP at 3 hours on the expression of adhesion molecules CD11 and CD49 
in both SCC25 and BICR22 OSCC cell lines, indicating the untreated levels. 
 
Comparing SP and TNF-α effect on the expression of adhesion molecules 
We performed a comparison of the effects of SP (1mcg) and TNF-α (100ng) on the 
expression of adhesion molecules in different cell lines (Figure 7.17).  
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The effect of the NK-1R antagonist on the expression of adhesion molecules stimulated by SP 
treatment 
Finally, we investigated the effect of the NK-1R antagonist on the expression of adhesion 
molecules in OSCC cell lines, as we predicted that it would negate the stimulation caused by 
SP treatment 1 mcg. The inhibitor produced an inhibitory effect on CD49 (VLA-4) integrin in 
CAL27 at 3 hours adhesion in which it reverted the expression levels back to untreated levels 
(Figure 7.18). The NK-1R antagonist inhibited the effect of TNF-α stimulation to CD49 in 
the BICR22 cell line (P=0.002).  
Figure 7.17: Comparison of SP and TNF effect on expression of different OSCC 
cell lines at 3-hour treatment. 
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Figure 7.18: The figure shows the expression of CD49 in CAL27 cells (untreated levels, 
treated for three hours, and inhibited with NK-1R antagonist) as shown by the FACS 
analysis. 
Fluorescence microscope 
Using the same protocol as the endothelial adhesion assay, we investigated the effect of SP 
and its inhibitor NK-1R antagonist on the adhesion of DOK and H157 OSCC cell lines to 
HUVECs on a chamber glass with the fluorescent microscope. The result showed that the 
adhesion of both cell lines to HUVEC increased significantly with SP stimulation at 3 hours 
(Figure 7.19-7.21). By contrast, when cells were treated with NK-1R inhibitor for 3 hours, it 
showed significant reduction of this adhesion to ECs (n=20). 
 
Figure 7.19:  Untreated basal 
adhesion levels of H157 to 
HUVEC cell lines  
 
Figure 7.20: SP treatment at 3 
hours adhesion levels of H157 
to HUVEC  
 
Figure 7.21: Inhibition of 
adhesion of H157 to 
HUVEC by NK-1R 
antagonist  
Effect of SP and TNF-α on the release of MMP-2  
Finally, we investigated the effect of SP and TNF-α treatment on the release of MMP-2 in 
OSCC cell lines. The experimental design involved measuring MMP-2 levels at basal 
(untreated levels) as well as after treatment at the 3-hour time point using the ELISA 
technique. Neither SP nor TNF-α treatment significantly affected the expression (results 
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shown in table 9). However, some interesting findings have been obtained. Firstly, the 
untreated expression of OSCC cell lines assumed an increasing expression of MMP-2 with 
the exception of DOK premalignant cells, which remarkably showed higher baseline 
expression of MMP-2 at a mean 1.76 ng/ml. This expression was proportional to the 
malignant potential of the corresponding cell lines. Secondly, SP treatment significantly 
decreased the expression of MMP-2 in BICR22 metastatic cell line P= 0.003.   
 
Table 7.2: MMP-2 ELISA measurement in OSCC cell lines. 
Cell Line Basal Expression Treatment/P Value 
DOK ++ 
1.76 ng/ml 
SP          0.36 
TNF       0.82 
 
CAL27 + 
1.91 ng/ml 
SP          0.45 
TNF       0.12 
 
SCC25 ++ 
1.51 ng/ml 
SP           0.92 
TNF        0.98 
 
H157  +++ 
2.23. ng/ml 
SP           0.32 
TNF        0.23 
 
BICR22 +++ 
1.85 ng/ml 
SP          0.04* 
TNF      0.78 
 
 
Discussion 
Metastasis, the main cause of cancer patient deaths, starts with the tumour cell losing 
adhesion with its neighbouring cells, invading the surrounding tissues, gaining access to 
blood vessels, and finally adhering to and exiting the blood vessels to implant in secondary 
sites (402). Interaction of cancer cells with endothelial cells plays an important role in both 
tumour angiogenesis and metastasis (410). Recent studies support an important role for 
inflammation in cancer initiation, progression and metastasis. In addition, emerging studies 
highlight inflammation as a main driver of the different stages of metastasis, such as tumour-
endothelial cell adhesion (416). However, the current literature has not identified the 
particular mechanism of the relationship of inflammation of metastasis or the precise effect of 
inflammatory mediators on adhesion and extravasation of tumour cells.  
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Our results showed that: 1) SP and TNF-α increased the adhesion of H157, CAL27 and DOK 
cells to HUVEC endothelial cells in a time-course treatment with a peak adhesion at 3 hours; 
2) the endothelial treated group had higher adhesion values than the tumour treated groups; 3) 
NK-1R inhibitor reduced adhesion in a time and dose-dependent manner; and 4) Monoclonal 
anti-adhesion antibodies inhibited adhesion between OSCC and HUVEC.  
These observations demonstrate a new observation of cancer-endothelial cell adhesion, 
occurring in the acute phase, which may be of fundamental importance to the process of 
metastasis. Firstly, early tumour-endothelial cell adhesion may contribute to enhanced tumour 
cell survival via bypassing immune attack and loss of attachment (233, 261). Secondly, it 
provides tumour cells with an early seeding capacity. In fact, early adhesion has been found 
to increase the metastatic capability of cancer cells (403). Cancer-endothelial cell adhesion 
has been speculated to be related to cancer progression and metastasis via a number of 
studies. However, the mechanisms of adhesion between cancer cells and endothelial cells and 
its main drivers remain unclear.  
There has been a lack of research into the triggers and mechanisms underlying cancer-
endothelial adhesion in an acute phase. Inflammation is the main characteristic of the tumour 
microenvironment and plays multifaceted and critical roles in every aspect of tumour 
development and progression (411). In the present study, we demonstrated for the first time 
that the inflammatory mediators, SP 1 mcg/ml and TNF-α -α 100 ng/ml were involved in oral 
cancer-endothelial cell adhesion in acute phase manner with a peak of 3 hours in-vitro.  
It is well established that SP acts as a mitogenic stimulator for tumour growth and 
proliferation of tumour cells (20-22). Brener et al. described SP expression in infiltrating 
lymphocytes in 81.6% (n=71) and in peritumoural or intratumoural blood vessels in 58.1% 
(n=43), where they proposed a diffusion mechanism for SP from lymphocytes to the 
parenchyma of the tumour (353). Similarly, Munoz et al. identified NK-1R receptors in 
smooth muscle of the blood vessels surrounding the primary malignant melanoma (412). 
Similar results were obtained in leukaemia cell lines (349). In all those studies, the NK-1R 
antagonist inhibited the growth of tumour cells, suggesting a potent mitogenic action for 
SP/NK1R complex interaction, where several mechanisms have been proposed. The SP/NK-
1R complex activates different MAPK signalling cascades such as ERK and P38 MAPK, 
through forming a scaffolding complex with β-arrestin (319). Additionally, the SP/NK-1R 
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complex can mediate other pathways such as the NF-kB pathways (413), and transactivates 
other tyrosine kinase receptors such as EGFR. In one recent study, Carotid artery injection of 
Walker 256 cells (for experimental metastasis induction) increased SP reactivity in 
coincidence with the primary tumour invasion of brain microvessels (414). These results can 
be explained in the context of SP acts as a mitogenic inducer of a mutant phenotype that 
selects for more invasive subpopulations of tumour cells with enhanced growth and migratory 
abilities that follow a concentration gradient, providing a pathway for these cells’ invasion.  
Based on previous observation that the close contact and adhesion of cells is a prerequisite 
for cell transmigration (261), we hypothesised that adhesion molecules are the main 
requirement of the adhesion process. Firstly, the adhesion molecule expression followed a 
predicted pattern which increased from no expression in the normal oral keratinocytes to the 
lymph node positive cell line H157 and declined in the metastatic cell lines (for the three 
adhesion molecules). The precancer cell line DOK had an elevated expression profile which 
agrees with previous studies, suggesting an early invasive/metastatic phenotype in the tumour 
cycle (415).  
Although SP treatment increased a specific adhesion molecule as observed by FACS, the 
VLA-4 (α4β1 integrin) pathway was the main molecule affected with the SP treatment and 
may mediate the enhanced oral cancer-endothelial cell adhesion in this study. Rebhun et al. 
reported that B16α4+ tumours generated lymph node metastases in 80% of mice and that 
melanoma cells that were deficient in α4 integrins (B16α4−) were nontumorigenic (279). 
Okahara et al. showed that interaction between VLA-4 on tumour cells and VCAM-1 on 
endothelial cells is implicated in progression of metastasis in-vivo (416). Collectively, these 
data show that the α4 integrin expressed by cancer cells contributes to tumorigenesis and may 
also facilitate metastasis to regional lymph nodes by promoting stable adhesion of tumour 
cells to the lymphatic vasculature. It has been reported that cancer cell-endothelial adhesion is 
thought to be regulated by the mechanical properties of the cancer cells and also by the 
specific expression of various adhesion molecules and/or ligands to adhesion molecules on 
the surface of cancer cells and endothelial cells induced by inflammatory mediators (417-
419). Thus, these results provided preliminary evidence for the adhesion of oral cancer cells 
to endothelial cells, suggesting a role for VLA-4 in this adhesion. 
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Our study reports a number of interesting findings; firstly that DOK precancer cells treatment 
with SP has produced adhesion results comparable with H157 positive lymph node cells. This 
indicates an early invasive phenotype in the tumour life cycle predisposing to an early 
metastatic potential. Secondly, although NK-1R inhibitor suppressed the adhesion, it was not 
as effective in suppressing the adhesion molecule expression, except in CAL 27 and BICR22. 
In addition, the monoclonal human antibodies to adhesion molecules had a profound 
inhibitory effect on the adhesion. Those results will require further investigation to underpin 
the exact mechanism of the tumour-cell interaction. Thirdly, the endothelial treated group 
with either SP or NK-1R inhibitor had more significant values of adhesion stimulation or 
adhesion suppression than the tumour-treated group in most cases. We suggest that this may 
be explained in the context of organ-specific metastasis. Finally, the NK-1R antagonist 
inhibited not only SP treatment but also TNF-α treatment which might be due to 
transactivation or for the suppression of downstream pathways, as SP and TNF-α are known 
to activate downstream NF-Kβ pathway (413). 
Adhesion of tumour cells to endothelial cells requires subsequent steps to promote tumour 
cell migration and implantation in the secondary site. The MMP group of enzymes has been 
implicated in facilitating the tumour cell migration and invasion of the endothelial barrier 
(405). In our study, OSCC cell lines had a varying basal level of expression of MMP-2, 
which was directly proportional to its malignant potential.  However, the treatment of SP or 
TNF-α did not significantly affect this expression. More importantly, the treatment of the 
BICR 22 cell line with SP treatment for 3 hours significantly decreased this expression 
significantly P= 0.04. Additionally, the DOK premalignant cell line had a high expression of 
MMP-2 which again suggests an early metastatic potential in tumour cycle (415). Li et al. 
reported a significant effect of SP on the expression of MMP-2 on mRNA level (407). This 
data will require further investigation to validate those results. 
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Limitations 
The current study was performed in-vitro, using OSCC cell lines and this approach, despite 
providing an easy experimental approach, neglects the tumour microenvironment. Also, there 
is a limitation in the small sample size but the study provides a preliminary dataset that can 
be used for further validation in either animal or clinical studies. 
In conclusion, the present study inflammatory mediator SP could promote oral cancer-
endothelial cell adhesion. The SP enhanced oral cancer-endothelial cell adhesion can occur in 
an early onset and might be mediated through the VCAM-1/VLA-4 pathway. This adhesion 
was significantly suppressed with monoclonal antibodies to adhesion molecule as well as the 
NK-1R antagonist. These findings may provide insights into tumour microenvironment 
interaction and reveal new therapeutic targets for cancer prevention and treatment. 
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Background 
The last decade witnessed a revolution in the treatment of tumours. The information gained 
from the sheer effort of researchers worldwide led to the introduction of new therapeutics (2). 
However, the burden of metastasis assumed an increasing pattern alongside with a failure of 
treatment to provide a complete remission or control over the spread of the tumours (2). This 
metastatic potential is variable for different neoplasms, and some types of cancers (e.g. oral 
cancer and leukaemia) are highly invasive (12, 21). Therefore, in order to improve patient 
outcome a clear understanding of metastasis and its main mediators is critical (420). 
 
Metastasis is a precise biological process consisting of several successive stages and requires 
the collaboration of several signalling pathways and molecular components (150). Metastasis 
commences through the invasion of the tumour to the surrounding extracellular matrix 
(ECM) and basement membrane (BM). Then, the detached tumour mass enters the 
circulation, evades the immune response and adheres to the vascular endothelial cells most 
likely through adhesion molecules. Finally, distant metastasis occurs when this mass 
extravasates and implants in a remote site (421-422). Although the mechanisms behind local 
invasion have been extensively studied, the stages of distant metastasis, particularly 
extravasation and their mechanisms are poorly understood (154-156, 423).  
 
The accumulating research is suggesting that inflammation is more likely to act in favour of 
tumour initiation and metastasis (215). The extravasation of leukocytes in inflammation is 
well researched, and the different stages they follow have been identified (232). The process 
follows the main theme that cancer does not utilise novel mechanisms, but rather uses the 
existing biologic process in its favour.  Both cancer and inflammation requires specific 
components, namely adhesion of migrating cells to the vascular endothelium through their 
adhesion molecules, activation of these adhesion molecules, and proteolytic action of matrix 
metalloproteinase (MMP) (156). The adherence of leukocytes to endothelial cells is a 
prerequisite for the inflammatory reaction. This adherence occurs mainly through a group of 
adhesion molecules and their receptors on both types of cells (155).  
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The striking similarity which exists between the outflux of tumour mass in the circulation and 
that of inflammatory exudates in wound healing points to the possibility that the same 
mediators might be utilised for both purposes (155). In this aspect, SP is a primary regulator 
of neurogenic inflammation, acting mainly as a trigger for vasodilatation, plasma protein 
extravasation and leukocyte adhesion to vascular endothelial cells (324-333, 424). SP has 
been proposed as a model that can explain the inflammation-tumour relationship (352), 
therefore, the link between the role of Substance P and the extravasation of tumour cells into 
the circulation represents an attractive opportunity for unravelling the metastatic mechanisms. 
Aims  
The aims of the study included, firstly, performance of a systematic review to assess the 
association of the expression/inhibition of inflammatory mediators with the 
promotion/inhibition specific metastatic stages in clinical and experimental animal studies. 
Despite advances in the diagnostic molecular techniques, early detection of metastasis is still 
cumbersome (129). In addition, the emerging data describe a strong relationship between 
inflammation and cancer but these data remain of little value as they have not been translated 
for clinical use. Therefore, investigating the prognostic role of inflammatory mediators in 
OSCC has the potential to establish a preliminary inflammatory mediator panel that can be 
used for accurate and reliable prediction of patients with a high risk of metastasis. 
The second aim was to investigate the role of SP in the adhesion of OSCC as well as Jurkat 
cells to the HUVEC endothelial cells. Adhesion of tumour cells to endothelial cells represents 
a milestone event in the extravasation process (204-205). The interaction of the endothelium 
with the neoplastic cells determines the physical point of cell exit and hence can explain 
specific organ metastasis (33). In addition, this adhesion is of vital importance to the survival 
of the tumour cell as it provides anchorage and, therefore, it can prevent cell death and 
induces proliferation (425).  
Thirdly, we planned to investigate the effect of SP on the expression of adhesion molecules in 
OSCC as well as Jurkat cells. The steps of the adhesion process are mediated through a group 
of adhesion molecules on the migrating cells and their binding receptors on the endothelial 
cells (230, 426). Two large families of molecules – the selectins and integrins – are involved 
in the adhesive interaction which takes place in extravasation (233). The binding of these 
adhesion molecules to their receptors not only controls the adhesion but can inflict 
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morphological and functional changes to the cells involved in the adhesion and therefore 
represent a potential therapeutic opportunity for oncology research.  
The fourth aim was to investigate the effect of SP on the release of MMP-2 in OSCC as well 
as Jurkat cells. MMP-2 are constantly expressed at the invasive front of the tumour, which 
indicates a strong correlation with invasion and metastasis (297-298). It is believed that 
MMPs can also regulate the pre-metastatic niche and play a key role in the angiogenesis 
(298-299). Other aspects of MMP in inflammation have not been thoroughly researched, such 
as the contribution of MMP in the extravasation of leukocytes, despite a role having been 
established for these enzymes in establishing a chemo-attractant gradient for immune cells 
which facilitates migration (303-306). Another aspect that has not been fully investigated is 
the relation of the inflammatory mediator’s effect on these molecules and the relationship 
between MMPs and integrin adhesion molecules. 
Principal Findings 
I: The review identified nine inflammatory mediators associated with metastasis. The 16 
articles reported lymph node metastasis and one article reported both LN and DM. Four 
articles were clearly associated with stages of metastatic cascade and five studies were 
validated with in-vivo studies. The inflammatory mediators identified were CXCR4 (six 
studies), CXCL12 (SDF-1), CCR7, IL-6 (two studies each), IL-18, CCL20 (MIP-3), CXCL1 
(GRO-1), CCL3, and CXCR2 (one study each). 
 
This review systematically summarises the evidence of the prognostic role of inflammatory 
mediators in predicting metastasis/metastatic stages in OSCC. Additionally, it compares the 
available evidence from the clinical and experimental animal settings. The review is an effort 
to bridge the gap that was identified between the theoretical knowledge and the clinical 
implementation. The main aim of the review was to establish the key role of inflammation in 
metastasis progression as well as identifying the tumour-specific inflammatory markers that 
can be of potential to be used for diagnostic/prognostic purposes.  
 
CXCR4 is a polypeptide GPCR that binds to its conical ligand CXCL12 and is responsible 
for a variety of physiological processes, e.g. lymphocyte homing, development, and 
vascularisation (46). It has been shown to be highly expressed by numerous types of tumours 
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with a significant correlation with metastasis (367). Several mechanisms have been proposed 
to explain its role in metastasis, mainly as a chemotactic factor which is expressed by tumour 
cells migrating towards an increasing CXCL12 gradient in the lymph nodes (368, 373). In 
addition, CXCR4 is responsible for the induction of the EMT phenotype as well as MMP2/9 
expression as suggested by Albert and Lee et al. (371, 372). The CXCR4/SDF-1 axis 
activates the ERK/AKT/SRC family of kinases and is a major haempoetic homing factor for 
multipotent stem cells (372-374). However, the included articles (n=7 for clinical, n= 3 
experimental) for CXCR4 and CXCL12 did not report the role of those chemokines as stem 
cell niches and their role in metastasis. We proposed that CXCR4 is up-regulated in tumour 
cells due to a hypoxic environment, and these cell populations marking a new stem cell niche 
acquire EMT, invasive phenotype and mitogenic signalling which gives this niche growth 
and migratory advantage and will be selected to migrate towards gradient of CXCL12 
displayed by lymph nodes. These results suggest a strong role for CXCR4/CXCL12 for 
prognosis and predicting lymph node metastasis in OSCC.  
 
 
CCR7 is a trans-membrane receptor that exerts its action by binding to its ligands CCL21/19 
and it is expressed by many immune cells for homing and directional movement of these cells 
(376). CCR7 has been reported to be associated with lymph node metastasis in several 
tumours (377). Similarly, Xia and Shang et al. describe a significant association of this 
receptor with LNM and LVD with no distant metastasis (378-379). Moreover, Adenoid 
cystocarcinoma, which commonly migrates through a haematogenous pathway, did not 
migrate to gradient concentration of CCL21. The studies suggested an adhesion between 
CCR7 and lymph node cells explaining the LNM tendency.  
 
The IL-6 cytokine can exert either an inflammatory response through autocrine signalling to 
its IL-6R receptor, or an anti-inflammatory effect through a paracrine signal via GP130 
protein (380). Recent studies showed that IL-6 can activate several downstream pathways and 
is correlated with several types of cancer (381). Due to the complex network activated by IL-
6, it is difficult to pinpoint its role in metastatic process. However, Shinriki et al. showed a 
significant correlation with IL-6 and LNM as well as a correlation with VEGF-C and 
lymphogenesis, suggesting a direct effect for IL-6 in the process of metastasis (382). Wang et 
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al. was the only study to report an association of the inflammatory mediator with distant 
metastasis, though it did not report specific organ preference (383). More interestingly, the 
relationship was a negative correlation between IL-6 mRNA and the presence of either LNM 
or DM. These conflicting results need further validation to pinpoint the actual role of IL-6. 
 
The review showed that the research efforts provided an overwhelming amount of 
information about the involvement of inflammatory mediators in OSCC as well as other 
cancers (the rest of the systematic review identified other mediators in another 20 most 
common cancers which will be published in a series). However, the lack of follow up clinical 
trials to supplement the experimental studies has led to a clear gap between the experimental 
knowledge and the clinical translation into reliable bedside markers for prognostic or 
diagnostic value. Furthermore, the current understanding of metastasis and its mediators and 
stages still in early phase, in fact, the critical metastatic stages such as extravasation could not 
be detected at all in any clinical studies and this reflects a lack of proper experimental tools. It 
was clear from the review that it is also more likely that a panel of mediators, rather than a 
single one, orchestrates the metastatic cascade. Also, the systematic review revealed the 
inadequacy of the current research tools to investigate metastasis where the animal models 
represent expensive and time-consuming methods. The disadvantages include the lack of 
biologic simulation due to the difference between the patient and the host species. Due to 
these differences, inoculating such animals with tumours from human subject causes rejection 
of tumours by the immune system of the host. Using the knockout models does not fully 
represent the proper microenvironment response. All these factors results in the lag we see 
clinically in the understanding of the metastatic process. This in turn reflects the urgent need 
to develop in-vitro models that are more reproducible and precisely presenting the actual 
metastatic process and its dynamics in the specific patient tissue environment to gain 
potential information. 
 
These three inflammatory mediators, after validation, can be adapted to develop a reliable 
method to accurately predict the risk of metastasis in high-risk patients. The information 
provided, as well as the advancement of new techniques such as microfluidic metastasis 
platforms, can be integrated to yield a reproducible metastatic model that can successfully 
replace the current experimental model based on a patient sample. 
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II: Our results showed that SP and TNF-α increased the adhesion of Jurkat cells in a time-
course treatment with a peak adhesion increase at 3-4 hours. SP and TNF-α increased the 
adhesion of H157, CAL27 and DOK cells to HUVEC endothelial cells in a time-course 
treatment with a peak adhesion at 3 hours. It has been demonstrated that SP is expressed by 
several tumours and several roles have been proposed for its action in tumour growth and 
progression (343-347). Our study describes a new role for SP in stimulating early onset 
adhesion of tumour-endothelial adhesion.  
These results agree with data showing a similar action for SP in neutrophil adhesion (331). 
Moreover, they explain an array of previous studies reporting SP/NK-1R complex expression 
in the peritumoural vessels in several tumours (349, 352, 412). Stucki et al. reported a static 
quantitative adhesion assay of leukaemic cells to endothelial cells at 0-24 hours, where they 
found that the significant increase in adhesion occurred by three times at 3 hours up to 24 
hours (360). The authors suggested a similar mechanism for leukaemic cells to produce 
inflammatory stimulating factors that can accumulate more tumour cell adhesion to the 
endothelium. Reviewing the literature, we found that very few studies have reported a 48-72 
hours adhesion effect, except for inflammation studies. The study also showed a significant 
inhibitory action of the NK-1R antagonist on the adhesion levels stimulated by SP and in 
some cases with TNF-α (though it remains to be investigated) which provides further 
evidence of the key role of SP in tumour-endothelial adhesion. 
 
We found that treating endothelial cells with either stimulating factor or inhibitor produces 
more potent levels of adhesion which: 1) may explain the organ-specific metastasis of 
cancers; and 2) highlight the active interaction of tumour-endothelial cell during adhesion. 
Moreover, our data showed that inhibition of adhesion levels achieved using cycloheximide – 
which blocks translation of messenger RNA on the cytosolic 80S ribosomes but does not 
inhibit the organelle protein synthesis – did not achieve higher levels such as the one inflicted 
with monoclonal antibodies. This might suggest that tumour cells highly express adhesion 
molecules as well as inflammatory receptors. 
Previous research has shown that SP is a potent mitogenic factor (356). Our results while 
proposing a new role for SP, it can be integrated with all the previous research to highlight SP 
as a model for the role of inflammation in metastasis. This can be viewed as SP, as an 
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inflammatory mediator, is utilised by tumour to increase its growth and proliferation. In 
doing so, SP works under selective pressure to induce a mutant phenotype selected for its 
invasive and migratory abilities. These new mutant phenotypes have the capacity to follow a 
concentration gradient and establishing metastasis. It is logical to consider that a cancer cell 
with multiple genetic aberrations and high mutation levels can acquire a mutated phenotype 
that allows these cells to mimic an acute adhesion onset similar to that of inflammatory 
reaction. 
III: Our data showed in Jurkat cells, CAL27, and BICR22, SP 1 mcg or TNF-α 100 ng 
treatment has increased both CD 11 (not significant) and CD 49 (significant) but not CD15s 
expression in 1-48 hour timescale treatment, as indicated by the FACS analysis. Moreover, 
anti-human monoclonal antibodies to VCAM or ICAM significantly inhibited adhesion levels 
to below the untreated baseline levels. The NK-1R antagonist was only effective in inhibiting 
adhesion molecule expression in Jurkat and CAL27. No other effect was noted in the other 
OSCC cell lines.  
Previous studies have reported the effect of several inflammatory mediators on the adhesion 
molecules and, in turn, on the tumour-endothelial adhesion and metastasis (411). As we 
hypothesised that adhesion molecules are the main requirement of the adhesion process, the 
adhesion molecule expression followed a predicted pattern which increased from no 
expression in the normal oral keratinocytes to the lymph node positive cell line H157 and 
declined in the metastases for the three adhesion molecules. The precancer cell line DOK had 
an elevated expression profile which agrees with previous studies, suggesting an early 
invasive/metastatic phenotype early in the tumour cycle.  
Although SP treatment increased a specific adhesion molecule in each cell line as observed 
by FACS, the VLA-4 (α4β1 integrin) pathway appears to be the main molecule affected by 
the SP treatment and may mediate the enhanced cancer-endothelial cell adhesion in this 
study. This is in line with previous reports that showed the importance of VLA-4 in adhesion 
and metastasis, both in-vitro and in-vivo (416-418). Thus, these results provided preliminary 
evidence for the adhesion of oral cancer cells to endothelial cells, suggesting a role for VLA-
4 in this adhesion. 
Collectively, these data show that the α4 integrin expressed by cancer cells contributes to 
tumorigenesis and may also facilitate metastasis to regional lymph nodes by promoting stable 
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adhesion of tumour cells to the lymphatic vasculature. It has been suggested that cancer cell-
endothelial adhesion is thought to be regulated by the mechanical arrest of the cancer cells 
(202-203). The current study reveals an active role of adhesion molecules and/or ligands to 
adhesion molecules on the surface of cancer cells and endothelial cells induced by 
inflammatory mediators.  
Two findings reported in the study are of important significance: First, DOK (dysplastic cell 
line) showed high adhesion value to HUVEC endothelial cells as well as expressing high 
level of the adhesion molecules. Oral keratinocyte does not express adhesion molecules such 
as VLA-4 (integrin) except for the very basal cells attaching to the basement membrane. 
Instead, they demonstrate the expression of cytokeratin filament which anchors to the 
cadherins transmembrane proteins to form desmosomes junctions. These junctions are 
particularly important in the oral epithelium to withstand frictional pressures. The expression 
of integrin adhesion molecules is limited to the basal cells to bind to the laminin (a 
component of the basement membrane). The expression of integrin has been linked to 
motility and its expression by the precancer clones indicates that those early clones are 
selected for its invasive abilities. This has important implication to support the model that 
metastasis is a separate disease and its evolution commences early in the tumour cycle.  This 
can reflect the emergence of new approaches for metastasis prevention and development of 
anti-metastatic vaccines targeting high-risk patient groups.   
The second remark is that the endothelial-treated group with either SP or NK-1R inhibitor 
had more significant values of adhesion stimulation or adhesion suppression than the tumour-
treated group in most cases. We suggest that this may be explained in the context of organ-
specific metastasis. This might suggest the production of specific factors by the endothelium 
of the distant site which attract specific tumours (might be of similar embryogenic origin). 
Although this theory (142) has been proposed long time ago, a complete understanding of the 
factors and its relation remains to be investigated.  However, this highlights the important of 
endothelium as an active participant in the process and that any metastatic therapy should not 
ignore the role of the endothelium of the distant site. 
 
IV: Our results did not prove any significant effect for SP on the release of MMP-2 in either 
Jurkat cells or OSCC cell lines. This was against the predicted pattern in which we 
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hypothesised that SP would trigger up-regulation of MMP enzymes after adhesion to 
facilitate the further transmigration of tumour cells through the endothelium. Previous studies 
had supported this prediction (405-407) A small sample size, another effective MMP member 
e.g. MMP-9, or simply a tissue specific factor, might explain these results. SP treatment in 
the Jurkat cell line for 1 hour significantly increased the MMP-2 expression, while on the 
other side, 3-hour treatment of BICR22 significantly decreased this expression. Those results 
remain unexplained and warrant a further research for validation. Finally, as predicted, the 
expression of basal level MMP-2 increased in OSCC proportional to the malignant potential 
with a peak at BICR22 with the exception of DOK cells, which remarkably, showed a higher 
MMP-2 expression. This provides more evidence of early metastatic subpopulations in the 
tumour life cycle.  
In summary, metastasis represents a clinical challenge to researchers and oncologist. Little 
improvements are gained with in cancer patients once the tumour has spread to other organs. 
Despite decades of research and clinical trials, the results are not yet promising. This lag is 
mainly attributed to unclear understanding of the actual dynamics of this process. Another 
reason is medical paradigm that is directing the oncology research considering only treating 
metastasis after its commencement (which is a medical ultimate goal). The formidable 
challenge of cancer necessitates new way of thinking. One of the most important changes to 
the current way of looking at cancer and metastasis is to start thinking of metastasis as an 
“early separate disease” which can be prevented. However, this requires changing the timing 
of intervention to as early stage as patients with pre-cancer lesions. Another aspect is the 
understanding that tumours utilise the same pathways and mechanisms of the normal 
physiologic functions which, if properly understood and implemented, would be a safer and 
successful alternative in treatment and diagnostic settings. One of these important pathways 
that is deployed by cancer is inflammatory mediators which continue to emerge as potent 
driver of cancer spread and progression. Investigating these mediators and their role in 
tumour progression will yield potential targets that can be implemented for new anti-
metastatic therapy. 
Significance 
Metastasis is the prime cause of fatality in 90% of cancer patients. The incidence of 
metastasis significantly reduces the prognostic outcome. More than half of neoplasms will 
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have disseminated lesions at the time of primary diagnosis, which render these cases with 
very poor survival rates. The high risk of cancer metastasis mandates aggressive therapeutic 
modalities in an attempt to prevent their occurrence. However, even with the most advanced 
treatments, no or little improvements have been achieved in the outcome of the most 
advanced stage cancers.   
The resulting model represents a novel approach in cancer treatment where the main target is 
prevention of metastasis incidence. This paradigm shift has powerful potential in the 
development of effective anti-metastatic therapies through interfering with the metastatic 
cycle. The data resulting from the systematic review as well as the experimental findings can 
be integrated for future implementation in two main categories.  
First, as the systematic review shows that the animal experiments are expensive and time-
consuming, the problem can be overcome with the establishment of 3D microfluidic devices 
that can mimic the biological system, with representation of almost all the involved 
physiologic factors implicated in the cancer dissemination process. These devices are 
facilitated by advances in nanotechnology as well as imaging techniques. A miniature 
microfluidic device designed with a sample of patient tissue, including the blood vessels and 
expected destination of metastasis, can be an effective tool in early diagnosis of the potential 
for metastasis through measuring the effect and expression of various inflammatory factors 
that can predispose to cancer spread. The tool is significant in respect of ultimate 
personalised diagnosis of the particular patient in terms of his own immune response and 
tumour microenvironment. 
Second, the implementation of such diagnostic tools will reveal the obscure inflammatory 
mediator network and, therefore, accumulation and better understanding of such information 
can pave the way for implementation of “Metastasis Early Prevention and Detection” 
programs. These programs could cause a shift in the scientific paradigm for metastasis 
management as a separate entity parallel with the primary tumour, but not strictly the same 
disease. These programs will specially target high-risk group patients in particular as well as 
precancer, recently diagnosed (before the initiation of treatment), high-risk of genetic 
susceptibility and patients who have successfully completed their treatment for primary 
tumours. This will include identifying personalised mediators in those patients and placing 
them on those vaccines for metastasis prevention for a period of time that can be determined 
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through clinical trials. This will greatly reduce the risk of metastasis in those patients and thus 
improve the overall survival of those patients.  
Future research 
The research results provide a starting point to pursue an investigation in the role of 
inflammatory mediators in the metastatic progression of tumours through intervening with 
the adhesion with the endothelium. The preliminary data shows the feasibility of validating 
those results through animal models and clinical trials. The confirmation of these results will 
require the validation with dynamic vascular systems (such as in animals or artificial dynamic 
vascular devices) to represent the actual physiologic blood circulation. This will enable the 
visualisation and the proper quantification of the effect of such mediators on the adhesion of 
tumour cells and the subsequent metastasis. Once these results have been validated and 
confirmed through these animal experiments, research then can proceed in three directions: 
I- Follow up with clinical trials where these mediators can be used in the intervention for 
high-risk patient groups outlined above as metastatic vaccine to prevent the occurrence of 
metastasis in those patients.  
II- implementation of these inflammatory mediators resulted from the systematic review to 
develop a reliable experimental/prognostic tool which integrate the patient own tissue in a 
miniature devices that can be used to predict the possibility of metastatic progression in the 
patient with high degree of accuracy and examine the specific mediators responsible for this 
progression. 
III- Investigating other tumour types and identifying the specific inflammatory mediator 
responsible for progressing each tumour type as well as investigating the relation of the 
circulating tumour cells with cancer stem/initiating cells. 
Conclusion 
The systematic review identified nine inflammatory mediators associated with metastasis 
from the clinical and experimental studies which can be further validated for a diagnostic 
panel implementation for the early detection of metastasis. Our results showed that SP and 
TNF-α increased the adhesion of Jurkat cells in a time-course treatment with a peak adhesion 
increase at 3-4 hours. Similarly, SP and TNF-α have increased the adhesion of H157, CAL27 
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and DOK cells to HUVEC endothelial cells in a time-course treatment with a peak adhesion 
at 3 hours. Our data showed in Jurkat cells, CAL27, and BICR22, SP 1mcg or TNF-α  100ng 
treatment has increased both CD11 (not significant) and CD49 (significant) but  not CD15s 
expression in 1-48 hour timescale treatment, as indicated by the FACS analysis. Moreover, 
anti-human monoclonal antibodies to VCAM or ICAM significantly inhibited the adhesion 
levels to below untreated baseline levels. The NK-1R antagonist was only effective in 
inhibiting adhesion molecule expression in Jurkat and CAL27. Our results did not prove any 
significant effect for SP on the release of MMP-2 in either Jurkat cells or OSCC cell lines. 
The study results highlights two main concepts; first, the quest for search of alternative 
targets via biologic body mechanisms, in particular inflammation promise potential therapies. 
Second, metastasis should be investigated as a separate disease entity rather than a end result 
of the cancerous process, and it might commence as early as the tumour itself. With this two 
concepts in mind, a new role for substance P has been described. This inflammatory mediator 
can be used in the intervention/prevention of metastasis.  
The results of the study can be integrated to provide a model for early prediction as well as 
prevention of metastatic spread which can be implemented in high-risk group cancer patients. 
This will advance our knowledge about the metastatic process as well as giving advantage to 
the clinicians. Additionally, it can help as a guide to investigating other tumours, searching 
for similar panels that can be of high value as they would be more tumour specific.  Finally, it 
provides a rationale as well as an evidence for the implementation of “metastasis early 
prevention” programs. 
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Appendix 
Appendix 1 
Guidelines for classifications of neck dissections (Robbins, K T. 2001) 
CONCEPTUAL GUIDELINES FOR NECK DISSECTION 
CLASSIFICATION 
1. Radical neck dissection is considered to be the standard basic procedure 
for cervical lymphadenopathy. All other procedures represent one or more 
alterations of this procedure. 
2. When the alteration involves preservation of one or more nonlymphatic 
structures routinely removed in the radical neck dissection, the procedure is 
termed modified radical neck dissection. 
3. When the alteration involves preservation of one or more lymph node 
groups routinely removed in the radical neck dissection, the procedure is 
termed selective neck dissection. 
 
4. When the alteration involves removal of additional lymph node groups 
or non-lymphatic structures not typically removed in the radical neck 
dissection, the procedure is termed an extended radical neck dissection. 
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Appendix 2 
Query Terms and Results on PubMed 
Search Query Items found 
#118 Search (neurokinin) AND metastasis 2263 
#115 Search (interleukin) AND metastasis 4236 
#114 Search (chemokine) AND metastasis 3070 
#113 Search ("inflammatory cytokines") AND metastasis 315 
#112 Search (("expression of  neurokinin") AND metastasis) AND prognosis 1 
#111 Search (("expression of  neurokinin") AND cancer) AND prognosis 6 
#110 Search ("expression of neurokinin") AND metastatic stages 2 
#109 Search ("expression of neurokinin") AND metastasis 13 
#108 Search (neurokinin) AND Metastasis formation at secondary site 2 
#107 Search (neurokinin) AND tumour Extravasation 10 
#106 Search (neurokinin) AND tumour angiogenesis 16 
#105 Search(neurokinin) AND epithelial-mesenchymal transition 0 
#104 Search (neurokinin) AND tumour invasion 15 
#103 Search (neurokinin) AND metastatic stages 4 
#102 Search (neurokinin) AND metastatic cascade 1 
#101 Search neurokinin and tumor progression ("neurokinin a"[MeSH Terms] OR 
"neurokinin a"[All Fields] OR "neurokinin"[All Fields]) AND ("tumour"[All 
Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR 
"tumor"[All Fields]) AND ("disease progression"[MeSH Terms] OR 
("disease"[All Fields] AND "progression"[All Fields]) OR "disease 
progression"[All Fields] OR "progression"[All Fields]) 
33 
#100 Search "expression of neuropeptide" 1434 
#99 Search neuropeptide 8249 
#70 Search (((((expression of(interleukin) AND metastasis) AND prognosis))) 385 
#69 Search ((((expression of(interleukin) AND cancer) AND prognosis)) 1675 
#68 Search (expression of interleukin) AND metastasis 1855 
#67 Search (expression of interleukin) AND metastatic stages 95 
#66 Search (interleukin) AND Metastasis formation at secondary site 84 
#65 Search (interleukin) AND tumour Extravasation 261 
#64 Search (interleukin) AND tumour angiogenesis 2579 
#63 Search (interleukin) AND epithelial-mesenchymal transition 345 
#62 Search (interleukin) AND tumour invasion 1778 
#61 Search (interleukin) AND metastatic stages 282 
#60 Search (interleukin) AND metastatic cascade 153 
#59 Search (interleukin) AND #1 801 
#58 Search expression of interleukin 109839 
#57 Search interleukin 276059 
#56 Search (((expression of chemokine) AND metastasis) AND prognosis) 507 
#55 Search (((expression of chemokine) AND cancer) AND prognosis) 1106 
#54 Search (expression of chemokine) AND metastatic stages (("gene 68 
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expression"[MeSH Terms] OR ("gene"[All Fields] AND "expression"[All 
Fields]) OR "gene expression"[All Fields] OR "expression"[All Fields]) AND 
("chemokines"[MeSH Terms] OR "chemokines"[All Fields] OR 
"chemokine"[All Fields])) AND (("secondary"[Subheading] OR 
"secondary"[All Fields] OR "metastatic"[All Fields]) AND stages[All Fields]) 
#53 Search (chemokine) AND Metastasis formation at secondary site 100 
#52 Search (chemokine) AND tumour Extravasation ("chemokines"[MeSH 
Terms] OR "chemokines"[All Fields] OR "chemokine"[All Fields]) AND 
(("tumour"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All 
Fields] OR "tumor"[All Fields]) AND Extravasation[All Fields]) 
157 
#51 Search (chemokine) AND tumour angiogenesis ("chemokines"[MeSH Terms] 
OR "chemokines"[All Fields] OR "chemokine"[All Fields]) AND 
(("tumour"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All 
Fields] OR "tumor"[All Fields]) AND ("Angiogenesis"[Journal] OR 
"angiogenesis"[All Fields])) 
1988 
#50 Search (chemokine) AND epithelial-mesenchymal transition 
("chemokines"[MeSH Terms] OR "chemokines"[All Fields] OR 
"chemokine"[All Fields]) AND ("epithelial-mesenchymal transition"[MeSH 
Terms] OR ("epithelial-mesenchymal"[All Fields] AND "transition"[All 
Fields]) OR "epithelial-mesenchymal transition"[All Fields] OR 
("epithelial"[All Fields] AND "mesenchymal"[All Fields] AND 
"transition"[All Fields]) OR "epithelial-mesenchymal transition"[All Fields]) 
253 
#49 Search (chemokine) AND tumour invasion 1602 
#48 Search (chemokine) AND metastatic stages ("chemokines"[MeSH Terms] OR 
"chemokines"[All Fields] OR "chemokine"[All Fields]) AND 
(("secondary"[Subheading] OR "secondary"[All Fields] OR "metastatic"[All 
Fields]) AND stages[All Fields] 
129 
#47 Search (chemokine) AND #2 87 
#46 Search (chemokine) AND #1 3152 
#45 Search expression of chemokine 41487 
#44 Search chemokine 84418 
#43 Search (((expression of cytokines) AND metastasis) AND prognosis)(("gene 
expression"[MeSH Terms] OR ("gene"[All Fields] AND "expression"[All 
Fields]) OR "gene expression"[All Fields] OR "expression"[All Fields]) AND 
("cytokines"[MeSH Terms] OR "cytokines"[All Fields])) AND ("neoplasm 
metastasis"[MeSH Terms] OR ("neoplasm"[All Fields] AND "metastasis"[All 
Fields]) OR "neoplasm metastasis"[All Fields] OR "metastasis"[All Fields]) 
AND ("prognosis"[MeSH Terms] OR "prognosis"[All Fields]) 
1414 
#42 Search (((((expression of cytokines) AND cancer)) AND cancer) AND 
prognosis) (("gene expression"[MeSH Terms] OR ("gene"[All Fields] AND 
"expression"[All Fields]) OR "gene expression"[All Fields] OR 
"expression"[All Fields]) AND ("cytokines"[MeSH Terms] OR 
"cytokines"[All Fields])) AND ("neoplasms"[MeSH Terms] OR 
"neoplasms"[All Fields] OR "cancer"[All Fields]) AND ("neoplasms"[MeSH 
Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields]) AND 
("prognosis"[MeSH Terms] OR "prognosis"[All Fields]) 
4704 
#41 Search ((expression of cytokines) AND cancer) (("gene expression"[MeSH 51915 
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Terms] OR ("gene"[All Fields] AND "expression"[All Fields]) OR "gene 
expression"[All Fields] OR "expression"[All Fields]) AND 
("cytokines"[MeSH Terms] OR "cytokines"[All Fields])) AND 
("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All 
Fields]) 
#40 Search "expression of cytokines" 234020 
#39 Search (("inflammatory cytokines") AND tumour progression) "inflammatory 
cytokines"[All Fields] AND (("tumour"[All Fields] OR "neoplasms"[MeSH 
Terms] OR "neoplasms"[All Fields] OR "tumor"[All Fields]) AND ("disease 
progression"[MeSH Terms] OR ("disease"[All Fields] AND "progression"[All 
Fields]) OR "disease progression"[All Fields] OR "progression"[All Fields])) 
1024 
#38 Search (("inflammatory cytokines") AND metastatic cascade) "inflammatory 
cytokines"[All Fields] AND (("secondary"[Subheading] OR "secondary"[All 
Fields] OR "metastatic"[All Fields]) AND cascade[All Fields]) 
47 
#37 Search (("inflammatory cytokines") AND metastatic stages)"inflammatory 
cytokines"[All Fields] AND (("secondary"[Subheading] OR "secondary"[All 
Fields] OR "metastatic"[All Fields]) AND stages[All Fields]) 
38 
#36 Search (("inflammatory cytokines") AND tumour invasion) "inflammatory 
cytokines"[All Fields] AND (("tumour"[All Fields] OR "neoplasms"[MeSH 
Terms] OR "neoplasms"[All Fields] OR "tumor"[All Fields]) AND 
invasion[All Fields]) 
246 
#35 Search (("inflammatory cytokines") AND epithelial-mesenchymal transition) 
"inflammatory cytokines"[All Fields] AND ("epithelial-mesenchymal 
transition"[MeSH Terms] OR ("epithelial-mesenchymal"[All Fields] AND 
"transition"[All Fields]) OR "epithelial-mesenchymal transition"[All Fields] 
OR ("epithelial"[All Fields] AND "mesenchymal"[All Fields] AND 
"transition"[All Fields]) OR "epithelial-mesenchymal transition"[All Fields]) 
75 
#34 Search (("inflammatory cytokines") AND tumour angiogenesis) 
"inflammatory cytokines"[All Fields] AND (("tumour"[All Fields] OR 
"neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "tumor"[All 
Fields]) AND ("Angiogenesis"[Journal] OR "angiogenesis"[All Fields])) 
313 
#33 Search (("inflammatory cytokines") AND tumour Extravasation) 
"inflammatory cytokines"[All Fields] AND (("tumour"[All Fields] OR 
"neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "tumor"[All 
Fields]) AND Extravasation[All Fields]) 
38 
#32 Search (("inflammatory cytokines") AND Metastasis formation at secondary 
site) "inflammatory cytokines"[All Fields] AND (("neoplasm 
metastasis"[MeSH Terms] OR ("neoplasm"[All Fields] AND "metastasis"[All 
Fields]) OR "neoplasm metastasis"[All Fields] OR "metastasis"[All Fields]) 
AND ("metabolism"[MeSH Terms] OR "metabolism"[All Fields] OR 
"formation"[All Fields]) AND ("secondary"[Subheading] OR "secondary"[All 
Fields] OR "neoplasm metastasis"[MeSH Terms] OR ("neoplasm"[All Fields] 
AND "metastasis"[All Fields]) OR "neoplasm metastasis"[All Fields]) AND 
site[All Fields]) 
5 
#31 Search "inflammatory cytokines" 32637 
#30 Search (((("inflammatory mediators") AND expression)) AND metastatic 
stages) ("inflammatory mediators"[All Fields] AND ("gene 
4 
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expression"[MeSH Terms] OR ("gene"[All Fields] AND "expression"[All 
Fields]) OR "gene expression"[All Fields] OR "expression"[All Fields])) AND 
(("secondary"[Subheading] OR "secondary"[All Fields] OR "metastatic"[All 
Fields]) AND stages[All Fields]) 
#29 Search (((("inflammatory mediators") AND expression)) AND metastasis) 
("inflammatory mediators"[All Fields] AND ("gene expression"[MeSH 
Terms] OR ("gene"[All Fields] AND "expression"[All Fields]) OR "gene 
expression"[All Fields] OR "expression"[All Fields])) AND ("neoplasm 
metastasis"[MeSH Terms] OR ("neoplasm"[All Fields] AND "metastasis"[All 
Fields]) OR "neoplasm metastasis"[All Fields] OR "metastasis"[All Fields]) 
61 
#28 Search ((((("inflammatory mediators") AND expression)) AND metastasis) 
AND "metastatic stages") Schema: all 
0 
#27 Search ((((("inflammatory mediators") AND expression)) AND metastasis) 
AND "metastatic stages") 
0 
#26 Search (("inflammatory mediators") AND tumour progression) "inflammatory 
mediators"[All Fields] AND (("tumour"[All Fields] OR "neoplasms"[MeSH 
Terms] OR "neoplasms"[All Fields] OR "tumor"[All Fields]) AND ("disease 
progression"[MeSH Terms] OR ("disease"[All Fields] AND "progression"[All 
Fields]) OR "disease progression"[All Fields] OR "progression"[All Fields])) 
466 
#25 Search (("inflammatory mediators") AND metastatic cascade) "inflammatory 
mediators"[All Fields] AND (("secondary"[Subheading] OR "secondary"[All 
Fields] OR "metastatic"[All Fields]) AND cascade[All Fields]) 
30 
#24 Search (("inflammatory mediators") AND metastatic stages) "inflammatory 
mediators"[All Fields] AND (("secondary"[Subheading] OR "secondary"[All 
Fields] OR "metastatic"[All Fields]) AND stages[All Fields]) 
15 
#23 Search (("inflammatory mediators") AND tumour invasion) "inflammatory 
mediators"[All Fields] AND (("tumour"[All Fields] OR "neoplasms"[MeSH 
Terms] OR "neoplasms"[All Fields] OR "tumor"[All Fields]) AND 
invasion[All Fields]) 
99 
#22 Search (("inflammatory mediators") AND epithelial-mesenchymal transition) 
"inflammatory mediators"[All Fields] AND ("epithelial-mesenchymal 
transition"[MeSH Terms] OR ("epithelial-mesenchymal"[All Fields] AND 
"transition"[All Fields]) OR "epithelial-mesenchymal transition"[All Fields] 
OR ("epithelial"[All Fields] AND "mesenchymal"[All Fields] AND 
"transition"[All Fields]) OR "epithelial-mesenchymal transition"[All Fields]) 
24 
#21 Search (("inflammatory mediators") AND tumour angiogenesis) 
"inflammatory mediators"[All Fields] AND (("tumour"[All Fields] OR 
"neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "tumor"[All 
Fields]) AND ("Angiogenesis"[Journal] OR "angiogenesis"[All Fields])) 
142 
#20 Search (("inflammatory mediators") AND tumour Extravasation) 
"inflammatory mediators"[All Fields] AND (("tumour"[All Fields] OR 
"neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "tumor"[All 
Fields]) AND Extravasation[All Fields]) 
24 
#19 Search (("inflammatory mediators") AND Metastasis formation at secondary 
site) "inflammatory mediators"[All Fields] AND (("neoplasm 
metastasis"[MeSH Terms] OR ("neoplasm"[All Fields] AND "metastasis"[All 
Fields]) OR "neoplasm metastasis"[All Fields] OR "metastasis"[All Fields]) 
2 
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AND ("metabolism"[MeSH Terms] OR "metabolism"[All Fields] OR 
"formation"[All Fields]) AND ("secondary"[Subheading] OR "secondary"[All 
Fields] OR "neoplasm metastasis"[MeSH Terms] OR ("neoplasm"[All Fields] 
AND "metastasis"[All Fields]) OR "neoplasm metastasis"[All Fields]) AND 
site[All Fields]) 
#18 Search (((("inflammatory mediators"))) AND expression) AND metastasis 
"inflammatory mediators"[All Fields] AND ("gene expression"[MeSH Terms] 
OR ("gene"[All Fields] AND "expression"[All Fields]) OR "gene 
expression"[All Fields] OR "expression"[All Fields]) AND ("neoplasm 
metastasis"[MeSH Terms] OR ("neoplasm"[All Fields] AND "metastasis"[All 
Fields]) OR "neoplasm metastasis"[All Fields] OR "metastasis"[All Fields]) 
61 
#17 Search ((((("inflammatory mediators"))) AND expression) AND cancer) AND 
prognosis "inflammatory mediators"[All Fields] AND ("gene 
expression"[MeSH Terms] OR ("gene"[All Fields] AND "expression"[All 
Fields]) OR "gene expression"[All Fields] OR "expression"[All Fields]) AND 
("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All 
Fields]) AND ("prognosis"[MeSH Terms] OR "prognosis"[All Fields]) 
34 
#16 Search (((("inflammatory mediators"))) AND expression) AND cancer 
("inflammatory mediators"[All Fields] AND ("gene expression"[MeSH 
Terms] OR ("gene"[All Fields] AND "expression"[All Fields]) OR "gene 
expression"[All Fields] OR "expression"[All Fields])) AND 
("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All 
Fields]) 
613 
#15 Search ((("inflammatory mediators"))) AND expression 6846 
#14 Search ((("inflammatory mediator"))) AND metastasis "inflammatory 
mediator"[All Fields] AND ("neoplasm metastasis"[MeSH Terms] OR 
("neoplasm"[All Fields] AND "metastasis"[All Fields]) OR "neoplasm 
metastasis"[All Fields] OR "metastasis"[All Fields]) 
20 
#13 Search ((("inflammatory mediator"))) AND cancer "inflammatory 
mediator"[All Fields] AND ("neoplasms"[MeSH Terms] OR "neoplasms"[All 
Fields] OR "cancer"[All Fields]) 
246 
#12 Search metastasis 276521 
#11 Search (("inflammatory mediator")) AND cancer "inflammatory mediator"[All 
Fields] AND ("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR 
"cancer"[All Fields]) 
246 
#10 Search cancer 3229556 
#9 Search "inflammatory mediators" 18150 
#8 Search Metastasis formation at secondary site 2405 
#7 Search tumour Extravasation 3082 
#6 Search tumour angiogenesis 45654 
#5 Search epithelial-mesenchymal transition 12471 
#4 Search tumour invasion 84361 
#3 Search metastatic stages ("secondary"[Subheading] OR "secondary"[All 
Fields] OR "metastatic"[All Fields]) AND cascade[All Fields] 
16368 
#2 Search metastatic cascade("secondary"[Subheading] OR "secondary"[All 
Fields] OR "metastatic"[All Fields]) AND cascade[All Fields] 
3467 
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#1 Search tumour progression ("tumour"[All Fields] OR "neoplasms"[MeSH 
Terms] OR "neoplasms"[All Fields] OR "tumor"[All Fields]) AND ("disease 
progression"[MeSH Terms] OR ("disease"[All Fields] AND "progression"[All 
Fields]) OR "disease progression"[All Fields] OR "progression"[All Fields]). 
186639 
 Search (inflam*) AND metastasis 8141 
 Search (inflam*) AND metastas* 9912 
 Search inflammation 513890 
 Search (inflam*) AND cancer 97238 
 Search metastasis 278648 
 Search metastas* 346994 
 Search metastas 4 
 Search cancer 3248111 
 Search inflam* 775265 
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Appendix 3 
Scoring Checklist Items for Experimental Studies 
Title 
Provide as accurate and concise a 
description of the content of the article as 
possible 
0 
1   
2 
Ethical statement 
Indicate the nature of the ethical review 
permissions, relevant licences and national 
or institutional guidelines for the care and 
use of animals, that cover the research. 
0 
1 
 
Study design 
The number of experimental and control 
groups 
0 
1 
 
Any steps taken to minimise the effects of 
subjective bias when allocating animals to 
treatment (e.g. randomisation procedure) 
and when assessing results (e.g. if done, 
describe who was blinded and when 
0 
1 
 
The experimental unit (e.g. a single animal, 
group or cage of animals 
0 
1  
 
Experimental procedures  
For each experiment and each 
experimental group, including controls, 
provide precise details of all procedures 
carried out. For example: 
0. No 1.yes 
0 
1 
 
Experimental animals 8  
For each experimental group, provides 
information about medical condition and 
(mean) age. Provide further relevant 
information such as the source of animals, 
international strain nomenclature, genetic 
modification status (e.g. knockout or 
transgenic), genotype, health/immune 
status, drug or test naïve, previous 
procedures method of tumour inoculation, 
types of animals used (SCID, transgenic, 
knockdown, etc.), method of carcinogenic 
induction, type of tumour, etc.  
0. No 1.yes 
0 
1  
 
Sample size 9    
 a. Specify the total number of 
animals used in each experiment, and the 
0 
1 
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number of animals in each experimental 
group. 
0. No 1.yes  
 
 
b. Explain how the number of animals was 
arrived at. Provide details of any sample 
size calculation used. 
0. No 1.yes 
 
0 
1 
 
Indicate the number of independent 
replications of each experiment, if 
relevant. 
0. No 1.yes 
0 
1 
 
Experimental outcomes 12  
Clearly define the primary and secondary 
experimental outcomes assessed (e.g. cell 
death, molecular markers, behavioural 
changes). 
0. No 1.yes 
0 
1  
 
Statistical methods 13    
Provide details of the statistical methods 
used for each analysis. 
0 
1 
 
Baseline data 14    
 Provide clear information of  
a- Any pre-experiment measurements.  
 
0 
1 
 
Measurement of inflammatory mediator/s 
expression (in carcinogenesis induced) 
0 
1 
 
The role of the mediator in inducing 
specific metastatic stage 
0 
1 
 
The producing cell of origin for the 
mediator 
 
0 
1 
 
The downstream pathway for the mediator 
to achieve its action 
0 
1 
The method of inhibition   0 
1 
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Appendix 4 
REMARK modified score checklist for the Clinical studies 
Introduction  
1. State the marker examined, the study 
objectives and any prespecified hypotheses.  
0-1 
Materials and Methods  
Patients  
2. Describe the characteristics (e.g. disease 
stage or comorbidities) of the study 
patients, including their source and 
inclusion and exclusion criteria. (0,1) 
0-1 
  
Specimen characteristics  
4. Describe type of biological material used 
(including control samples), and methods 
of preservation and storage. (0,1) 
0-1 
Assay methods  
5. Specify the assay method used and 
provide (or reference) a detailed protocol, 
including specific reagents or kits used, 
quality control procedures, reproducibility 
assessments, quantitation methods and 
scoring and reporting protocols. Specify 
whether and how assays were performed 
blinded to the study end point. (0,1) 
 
0-1 
Study design  
6. State the method of case selection, 
including whether prospective or 
retrospective and whether stratification or 
matching (e.g. by stage of disease or age) 
was employed. Specify the time period 
from which cases were taken, the end of 
the follow-up period, and the median 
follow-up time. (0,1) 
0-1 
  
  
  
Statistical analysis methods  
10. Specify all statistical methods, 
including details of any variable selection 
procedures and other model-building 
0-1 
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issues, how model assumptions were 
verified, and how missing data were 
handled. (0,1) 
  
Results  
Data  
12. Describe the flow of patients through 
the study, including the number of patients 
included in each stage of the analysis (a 
diagram may be helpful) and reasons for 
dropout. Specifically, both overall and for 
each subgroup extensively examined report 
the numbers of patients and the number of 
events. (0,1) 
0-1 
13. Report distributions of basic 
demographic characteristics (at least age 
and sex), standard (disease-specific) 
prognostic variables, and tumour marker, 
including numbers of missing values. (0,1) 
0-1 
Analysis and presentation  
14. Show the relation of the marker to 
standard prognostic variables. (0,5) 
 
A. correlation with LN 0-1 
B. correlation with DM 0-1 
C. correlation with other prognostic factor 0-1 
D. correlation with staging 0-1 
E. correlation with metastatic stage (vessel 
density or invasion) 
0-1 
F. validation with in-vivo experiment 0-1 
15. Present univariate analyses showing the 
relation between the marker and outcome, 
with the estimated effect (e.g. hazard ratio 
and survival probability). Preferably 
provide similar analyses for all other 
variables being analysed. (0,1) 
0-1 
16. For key multivariable analyses, report 
estimated effects (e.g. hazard ratio) with 
confidence intervals for the marker and, at 
least for the final model, all other variables 
in the model. (0,1) 
0-1 
 
